

APPROVED DRUG PRODUCTS


With Therapeutic Equivalence Evaluations



The "Orange Book"

FDA data supplied by DrugPatentWatch.com

**CUMULATIVE
SUPPLEMENT 05
May 2010**



**APPROVED
DRUG PRODUCTS**

**WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS**

30th EDITION

**Department of Health and Human Services
Food and Drug Administration
Center for Drug Evaluation and Research
Office of Generic Drugs**

2010

Prepared By
Office of Generic Drugs
Center for Drug Evaluation and Research
Food and Drug Administration

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

30th EDITION

Cumulative Supplement 05

May 2010

CONTENTS

	<i>PAGE</i>
1.0 INTRODUCTION	iii
1.1 How to use the Cumulative Supplement	iii
1.2 Cumulative Supplement Content.....	iv
1.3 Applicant Name Changes.....	v
1.4 Availability of the Edition	vi
1.5 Report of Counts for the Prescription Drug Product List	vii
1.6 Cumulative Supplement Legend	vii
DRUG PRODUCT LISTS	
Prescription Drug Product List	1-1
OTC Drug Product List	2-1
Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research List.....	3-1
Orphan Product Designations and Approvals List	4-1
Drug Products Which Must Demonstrate in vivo Bioavailability Only if Product Fails to Achieve Adequate Dissolution	5-1
PATENT AND EXCLUSIVITY INFORMATION ADDENDUM	
A. Patent and Exclusivity Lists	A-1
B. Patent and Exclusivity Terms	B-1

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

30th EDITION

**CUMULATIVE SUPPLEMENT 05
May 2010**

1.0 INTRODUCTION

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 30th Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations; over-the-counter (OTC) drug products that require approved applications as a condition of marketing; drug products with approval under Section 505 of the Act administered by the Center for Biologics Evaluation and Research; and products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to mark to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement. Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision.

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case, the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, are for exportation, are for military use, or have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of the 30th Edition List will then be added to the "Discontinued Drug Product List" appearing in the 31th Edition. The current Edition Section 2., How To Use The Drug Product Lists, describes the layout and usage of the List.

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >A>. The Patent and Exclusivity List new additions are indicated by the symbol >A> to the left of Patent Number or Exclusivity Code. The >A> symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >D> (DELETE) to the left of the line. The information line with the >D> symbol is dropped in subsequent Cumulative Supplements for that item.

The Patent and Exclusivity List is arranged in alphabetical order by active ingredient name(s) and trade name. The trade name will follow the active ingredient name separated by a dash symbol. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Drug substance and drug product patents are indicated as such with DS or DP in the Patent codes column. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms, Section B, in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations. Refer to Section 1.3 for internet access to the most current list of Patent and Exclusivity terms.

1.2 CUMULATIVE SUPPLEMENT CONTENT

Since February 2005, we have been providing daily Electronic Orange Book (EOB) product information for new generic drug approvals. Daily generic updates provide the consumer with the current list of approved generic products which is important for substitution purposes. Previously, a first-time-generic product approved early in the month would not be published in the Cumulative Supplement (CS) for several weeks.

The CS monthly update publish goal is by the end of the following month's second work week (e.g., November's supplement will be updated by the end of the second full work week in December).

Currently, the monthly PDF CS includes:

- Generic product ANDA (Abbreviated New Drug Approval) approvals as of the date of publication.
- All product changes received and processed as of the date of publication.
 - Refer to CS Section 1.8 Cumulative Supplement Legend for types of changes
 - Discontinued products will be processed as of the date of publication. There will be circumstances where a product is discontinued in one month, however, it will be reported in a different month's CS. For example, the Orange Book Staff received a letter November 7 that the product has been discontinued from manufacturing and marketing. The Orange Book subsequently publishes the October CS on November 14. The product will show in the October CS that it is discontinued even though the date of discontinuance is the day that the Orange Book Staff receives notification (November 7).
- New Drug Application (NDA) approvals (20,000 and 50,000 series) appear in the CS month they were approved.

- Patent information, also updated daily in the EOB, is current to the date of publication.
- Exclusivity information is updated monthly and current to the date of publication.

Every effort is made to ensure the Cumulative Supplement is current and accurate. Applicant holders are requested to inform the FDA Orange Book Staff (OBS) of any changes or corrections. The OBS can be contacted by email at drugproducts@fda.hhs.gov. Send Changes by FAX: 240-276-8974; mail to:

FDA/CDER Orange Book Staff
Office of Generic Drugs, HFD-610
7500 Standish Place
Rockville, MD 20855-2773

1.3 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively, to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section. The Electronic Orange Book Query, updated monthly, will contain the most current applicant holder name.

<u>FORMER APPLICANT NAME</u> <u>(FORMER ABBREVIATED NAME)</u>	<u>NEW APPLICANT NAME</u> <u>(NEW ABBREVIATED NAME)</u>
ASCENT PEDIATRICS INC (ASCENT PEDS)	SHIONOGI PHARMA INC (SHIONOGI PHARMA)
GOLDLINE LABORATORIES INC (GOLDLINE)	IVAX PHARMACEUTICALS INC SUB TEVA PHARMACEUTICALS USA (IVAX SUB TEVA PHARMS)
HLR TECHNOLOGY (HLR)	HOFFMANN LA ROCHE INC (HOFFMANN LA ROCHE)
IVAX PHARMACEUTICALS INC (IVAX PHARMS)	IVAX PHARMACEUTICALS INC SUB TEVA PHARMACEUTICALS USA (IVAX SUB TEVA PHARMS)
MEDICIS PHARMACEUTICAL CORP (MEDICIS)	SHIONOGI PHARMA INC (SHIONOGI PHARMA)
MINRAD INC (MINRAD)	PIRAMAL CRITICAL CARE INC (PIRAMAL CRITICAL)

PROCTER AND GAMBLE CO (PROCTER AND GAMBLE)	WARNER CHILCOTT CO LLC (WARNER CHILCOTT)
PROCTER AND GAMBLE CO PHARMACEUTICALS INC SUB PROCTER AND GAMBLE CO (PROCTER AND GAMBLE)	WARNER CHILCOTT CO LLC (WARNER CHILCOTT)
SCIELE PHARMA INC (SCIELE PHARMA INC)	SHIONOGI PHARMA INC (SHIONOGI PHARMA)
TEVA PHARMACEUTICALS USA (TEVA PHARMS)	IVAX PHARMACEUTICALS INC SUB TEVA PHARMACEUTICALS USA (IVAX SUB TEVA PHARMS)
ZENITH GOLDLINE LABORATORIES INC (ZENITH GOLDLINE)	IVAX PHARMACEUTICALS INC SUB TEVA PHARMACEUTICALS USA (IVAX SUB TEVA PHARMS)
ZENITH GOLDLINE PHARMACEUTICALS (ZENITH GOLDLINE)	IVAX PHARMACEUTICALS INC SUB TEVA PHARMACEUTICALS USA (IVAX SUB TEVA PHARMS)
ZENITH GOLDLINE PHARMACEUTICALS INC (ZENITH GOLDLINE)	IVAX PHARMACEUTICALS INC SUB TEVA PHARMACEUTICALS USA (IVAX SUB TEVA PHARMS)

1.4 AVAILABILITY OF THE EDITION

Since 1997, the Electronic Orange Book Query (EOBQ) <http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm>, has been available on the internet and has become the updated-every-month Orange Book. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder, applicant number or patent number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product.

Commencing with the 25th edition, the Annual Edition and monthly Cumulative Supplements have been provided in downloadable Portable Document Format (PDF) at the EOB home page by clicking on Publications. The PDF annual and cumulative supplements duplicate previous paper versions. Over time, there will be an archive for the annuals and each year's December Cumulative Supplement.

The downloaded Annual Edition and Cumulative Supplements are also available in a paper version (Approved Drug Products with Therapeutic Equivalence Evaluations, ADP) from the U.S. Government Printing Office: <http://bookstore.gpo.gov>; toll free 866-512-1800.

There are historical lists of Orange Book cumulative supplement product monthly changes at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm086229.htm>. There are ASCII text files of the Orange Book drug product, patent, and exclusivity data at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm129689.htm>. The drug product text files are provided in eobzip.zip format. The files are updated concurrently with the monthly cumulative supplements. The annual Orange Book Edition Appendices A, B, and C in PDF format are updated quarterly.

Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List, <http://www.fda.gov/opacom/morechoices/fdaforms/default.html>.

The current listing of the Orphan Product Designations and Approvals is available at <http://www.fda.gov/orphan/designat/list.htm>.

1.5 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (Dec 2008) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST COUNTS CUMULATIVE BY QUARTER

<u>CATEGORIES COUNTED</u>	<u>DEC 2009</u>	<u>MAR 2010</u>	<u>JUN 2010</u>	<u>SEPT 2010</u>	<u>DEC 2010</u>
DRUG PRODUCTS LISTED	13065	13216			
SINGLE SOURCE	2460	2474			
	(18.8%)	(18.7%)			
MULTISOURCE	10516	10653			
	(80.5%)	(80.6%)			
THERAPEUTICALLY	10367	10502			
EQUIVALENT	(79.3%)	(79.5%)			
NOT THERAPEUTICALLY	149	151			
EQUIVALENT	(1.1%)	(1.1%)			
EXCEPTIONS ¹	89	89			
	(0.7%)	(0.7%)			
NEW MOLECULAR ENTITIES					
APPROVED	3	5			
NUMBER OF APPLICANTS	718	727			

¹Amino acid-containing products of varying composition (see Introduction, page xx of the List).

1.6 CUMULATIVE SUPPLEMENT LEGEND

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route and then by trade name.

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, applicant holder, strength(s), New Drug Application number, product number, and approval date. The application number preceded by "N" is a New Drug Application (NDA or innovator). The application number preceded by an "A" is an Abbreviated New Drug Application (ANDA or generic). The last two columns describe the action. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form; route(s), new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be preceded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >A>. All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

NEWA	New drug product approval usually in the supplement month.
CAHN	Applicant holder firm name has changed.
CAIN	Change. There has been a change in the Ingredient(s) name. All products will be deleted under the old name and all products will be added under the changed ingredient(s) name.
CDFR	Change. Dosage Form; Route of Administration.
CFTG	Change. A first time generic for the innovator product. A TE Code is added.
CMFD	Change. The product is moved from the Discontinued Section due to a change in marketing status.
CMS1	Change. Miscellaneous addition to list.
CMS2	Change. Miscellaneous deletion from list.
CPOT	Change. Potency amount/unit.
CRLD	Change. Reference Listed Drug.
CTEC	Change. Therapeutic Equivalence Code.
CTNA	Change. Trade Name.
DISC	Discontinued. The Rx or OTC listed product is not being marketed and will be moved to the discontinued section in the next edition.

PRESCRIPTION DRUG PRODUCT LIST - 30TH EDITION

RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 5 - May 2010

1-1

>D> ACETAMINOPHEN; ASPIRIN; CODEINE PHOSPHATE
 >D> CAPSULE; ORAL
 >D> ACETAMINOPHEN, ASPIRIN, AND CODEINE PHOSPHATE
 >D> + MIKART 150MG;180MG;30MG A081096 001 Oct 26, 1990 May DISC
 >A> @ 150MG;180MG;30MG A081096 001 Oct 26, 1990 May DISC

ACETAMINOPHEN; BUTALBITAL

TABLET; ORAL
 BUTAPAP
 AA MIKART 325MG;50MG A089987 001 Oct 26, 1992 Feb CTEC
 PHRENILIN
 AA + VALEANT 325MG;50MG A087811 001 Jun 19, 1985 Feb CTEC

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

CAPSULE; ORAL
 BUTALBITAL, ACETAMINOPHEN AND CAFFEINE
 + NEXGEN PHARMA 300MG;50MG;40MG A040885 001 Nov 16, 2009 Feb CRLD
 AA WEST WARD 500MG;50MG;40MG A040261 001 Oct 28, 1998 Feb CTEC
 ESGIC-PLUS
 AA + MIKART 500MG;50MG;40MG A040085 001 Mar 28, 1996 Feb CTEC
 TABLET; ORAL
 BUTALBITAL, ACETAMINOPHEN AND CAFFEINE
 AA CONCORD LABS NJ 325MG;50MG;40MG A040864 001 Dec 01, 2008 Feb CTEC
 AA 500MG;50MG;40MG A040883 001 Dec 23, 2008 Feb CTEC
 AA MALLINCKRODT 325MG;50MG;40MG A087804 001 Jan 24, 1985 Feb CTEC
 AA MIKART 325MG;50MG;40MG A089175 001 Jan 21, 1987 Feb CTEC
 AA VINTAGE PHARMS 325MG;50MG;40MG A040511 001 Aug 27, 2003 Feb CTEC
 AA 500MG;50MG;40MG A040513 001 Aug 25, 2003 Feb CTEC
 AA WATSON LABS 500MG;50MG;40MG A040267 001 Jul 30, 1998 Feb CTEC
 AA WEST WARD 325MG;50MG;40MG A089718 001 Jun 12, 1995 Feb CTEC
 AA 500MG;50MG;40MG A040336 001 Aug 18, 1999 Feb CTEC
 ESGIC-PLUS
 AA + MIKART 500MG;50MG;40MG A089451 001 May 23, 1988 Feb CTEC
 FIORICET
 AA + WATSON PHARMS 325MG;50MG;40MG A088616 001 Nov 09, 1984 Feb CTEC

ACETAMINOPHEN; HYDROCODONE BITARTRATE

SOLUTION; ORAL
 HYDROCODONE BITARTRATE AND ACETAMINOPHEN
 + MIKART 300MG/15ML;10MG/15ML A040881 001 Feb 25, 2010 Feb NEWA
 TABLET; ORAL
 HYDROCODONE BITARTRATE AND ACETAMINOPHEN
 >A> MIKART 325MG;2.5MG A040846 001 Jun 09, 2010 May NEWA
 >A> 650MG;5MG A040849 001 Jun 09, 2010 May NEWA

ACETAMINOPHEN; PENTAZOCINE HYDROCHLORIDE

TABLET; ORAL
 ACETAMINOPHEN AND PENTAZOCINE HYDROCHLORIDE
 AB + WATSON LABS 650MG;EQ 25MG BASE A074699 001 Mar 24, 2000 Feb CRLD
 TALACEN
 @ SANOFI AVENTIS US 650MG;EQ 25MG BASE N018458 001 Sep 23, 1982 Feb DISC

ACITRETIN

CAPSULE; ORAL

SORIATANE

	STIEFEL LABS INC	17.5MG		N019821 003	Aug 06, 2009	Jan	NEWA
		22.5MG		N019821 004	Aug 06, 2009	Jan	NEWA

ACYCLOVIR

CAPSULE; ORAL

ACYCLOVIR

	@ IVAX SUB TEVA PHARMS	200MG		A074674 001	Apr 22, 1997	Apr	DISC
AB	MYLAN	200MG		A074727 001	Apr 22, 1997	Mar	CMFD

TABLET; ORAL

ACYCLOVIR

	@ IVAX SUB TEVA PHARMS	400MG		A074836 001	Apr 22, 1997	Apr	DISC
	@	800MG		A074836 002	Apr 22, 1997	Apr	DISC
AB	MYLAN	400MG		A075211 001	Sep 28, 1998	Mar	CMFD
AB		800MG		A075211 002	Sep 28, 1998	Mar	CMFD

ADAPALENE

GEL; TOPICAL

>A>	ADAPALENE						
>A>	AB	PLIVA HRVATSKA DOO	0.1%	A090962 001	Jun 02, 2010	May	NEWA
		DIFFERIN					
>D>	+	GALDERMA LABS LP	0.1%	N020380 001	May 31, 1996	May	CFTG
>A>	AB	+	0.1%	N020380 001	May 31, 1996	May	CFTG

LOTION; TOPICAL

DIFFERIN

	+	GALDERMA R AND D	0.1%	N022502 001	Mar 17, 2010	Mar	NEWA
--	---	------------------	------	-------------	--------------	-----	------

ALBUTEROL SULFATE

SOLUTION; INHALATION

ALBUTEROL SULFATE

AN	APOTEX INC	EQ 0.021% BASE		A078623 001	Apr 05, 2010	Mar	NEWA
AN		EQ 0.042% BASE		A078623 002	Apr 05, 2010	Mar	NEWA
AN	NEPHRON	EQ 0.021% BASE		A076355 002	Mar 31, 2010	Mar	NEWA

SYRUP; ORAL

ALBUTEROL SULFATE

>A>	AA	AMNEAL PHARMS	EQ 2MG BASE/5ML	A079241 001	May 12, 2010	May	NEWA
-----	----	---------------	-----------------	-------------	--------------	-----	------

ALCLOMETASONE DIPROPIONATE

CREAM; TOPICAL

ACLOVATE

>D>	AB	+	GLAXOSMITHKLINE	0.05%	N018707 001	Dec 14, 1982	May	CAHN
>A>	AB	+	NYCOMED US	0.05%	N018707 001	Dec 14, 1982	May	CAHN

ALENDRONATE SODIUM

TABLET; ORAL

ALENDRONATE SODIUM

AB	CADISTA PHARMS	EQ 5MG BASE		A090557 001	Feb 18, 2010	Jan	NEWA
AB		EQ 10MG BASE		A090557 002	Feb 18, 2010	Jan	NEWA
AB		EQ 35MG BASE		A090557 003	Feb 18, 2010	Jan	NEWA
AB		EQ 70MG BASE		A090557 004	Feb 18, 2010	Jan	NEWA

ALPRAZOLAM

TABLET; ORAL

ALPRAZOLAM

>A>	AB	SUN PHARMA GLOBAL	0.25MG	A090082 001	Jun 17, 2010	May	NEWA
>A>	AB		0.5MG	A090082 002	Jun 17, 2010	May	NEWA
>A>	AB		1MG	A090082 003	Jun 17, 2010	May	NEWA
>A>	AB		2MG	A090082 004	Jun 17, 2010	May	NEWA

TABLET, EXTENDED RELEASE; ORAL

ALPRAZOLAM

>A>	AB	WATSON LABS FLORIDA	0.5MG	A077198 001	May 13, 2010	May	NEWA
>A>	AB		1MG	A077198 002	May 13, 2010	May	NEWA
>A>	AB		2MG	A077198 003	May 13, 2010	May	NEWA
>A>	AB		3MG	A077198 004	May 13, 2010	May	NEWA

TABLET, ORALLY DISINTEGRATING; ORAL

ALPRAZOLAM

AB		ACTAVIS ELIZABETH	0.25MG	A078561 001	Mar 16, 2010	Feb	NEWA
AB			0.5MG	A078561 002	Mar 16, 2010	Feb	NEWA
AB			1MG	A078561 003	Mar 16, 2010	Feb	NEWA
AB			2MG	A078561 004	Mar 16, 2010	Feb	NEWA

AMANTADINE HYDROCHLORIDE

TABLET; ORAL

AMANTADINE HYDROCHLORIDE

>D>	AB	USL PHARMA	100MG	A076186 001	Dec 16, 2002	May	CRLD
>A>	+		100MG	A076186 001	Dec 16, 2002	May	CRLD
>D>		SYMMETREL					
>D>	AB	+ ENDO PHARMS	100MG	N018101 001		May	DISC
>A>	@		100MG	N018101 001		May	DISC

AMLODIPINE BESYLATE

TABLET; ORAL

AMLODIPINE BESYLATE

AB		VINTAGE	EQ 2.5MG BASE	A078414 001	Apr 07, 2010	Mar	NEWA
AB			EQ 5MG BASE	A078414 002	Apr 07, 2010	Mar	NEWA
AB			EQ 10MG BASE	A078414 003	Apr 07, 2010	Mar	NEWA
AB		WORLD GEN	EQ 2.5MG BASE	A077516 001	Jul 11, 2007	Mar	CAHN
AB			EQ 5MG BASE	A077516 002	Jul 11, 2007	Mar	CAHN
AB			EQ 10MG BASE	A077516 003	Jul 11, 2007	Mar	CAHN

AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE

CAPSULE; ORAL

AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE

AB		DR REDDYS LABS INC	EQ 2.5MG BASE;10MG	A077183 001	Apr 15, 2010	Mar	NEWA
AB			EQ 5MG BASE;10MG	A077183 002	Apr 15, 2010	Mar	NEWA
AB			EQ 5MG BASE;20MG	A077183 003	Apr 15, 2010	Mar	NEWA
AB			EQ 10MG BASE;20MG	A077183 004	Apr 15, 2010	Mar	NEWA
AB		LUPIN PHARMS	EQ 2.5MG BASE;10MG	A078466 001	Feb 05, 2010	Jan	NEWA
AB			EQ 5MG BASE;10MG	A078466 002	Feb 05, 2010	Jan	NEWA
AB			EQ 5MG BASE;20MG	A078466 003	Feb 05, 2010	Jan	NEWA
AB			EQ 10MG BASE;20MG	A078466 004	Feb 05, 2010	Jan	NEWA
>A>	AB	MYLAN	EQ 2.5MG BASE;10MG	A077375 001	May 21, 2010	May	NEWA
>A>	AB		EQ 5MG BASE;10MG	A077375 002	May 21, 2010	May	NEWA
>A>	AB		EQ 5MG BASE;20MG	A077375 003	May 21, 2010	May	NEWA
>A>	AB		EQ 10MG BASE;20MG	A077375 004	May 21, 2010	May	NEWA

AMOXICILLIN

FOR SUSPENSION; ORAL

TRIMOX

@	APOTHECON	50MG/ML	A061886 001		Feb	DISC
@		125MG/5ML	A061886 002		Feb	DISC
@		125MG/5ML	A062885 001	Mar 08, 1988	Feb	DISC
@		250MG/5ML	A062885 002	Mar 08, 1988	Feb	DISC
@		250MG/5ML	A061886 003		Feb	DISC

AMOXICILLIN; CLAVULANATE POTASSIUM

FOR SUSPENSION; ORAL

AUGMENTIN '125'

AB	GLAXOSMITHKLINE	125MG/5ML;EQ 31.25MG BASE/5ML	N050575 001	Aug 06, 1984	Feb	CMFD
----	-----------------	-------------------------------	-------------	--------------	-----	------

AUGMENTIN '250'

AB	GLAXOSMITHKLINE	250MG/5ML;EQ 62.5MG BASE/5ML	N050575 002	Aug 06, 1984	Feb	CMFD
----	-----------------	------------------------------	-------------	--------------	-----	------

TABLET; ORAL

AUGMENTIN '250'

AB	GLAXOSMITHKLINE	250MG;EQ 125MG BASE	N050564 001	Aug 06, 1984	Feb	CMFD
----	-----------------	---------------------	-------------	--------------	-----	------

AUGMENTIN '500'

AB	GLAXOSMITHKLINE	500MG;EQ 125MG BASE	N050564 002	Aug 06, 1984	Feb	CMFD
----	-----------------	---------------------	-------------	--------------	-----	------

AUGMENTIN '875'

AB	GLAXOSMITHKLINE	875MG;EQ 125MG BASE	N050720 001	Feb 13, 1996	Feb	CMFD
----	-----------------	---------------------	-------------	--------------	-----	------

TABLET, EXTENDED RELEASE; ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

AB	SANDOZ	1GM;EQ 62.5MG BASE	A090227 001	Apr 21, 2010	Apr	NEWA
----	--------	--------------------	-------------	--------------	-----	------

AUGMENTIN XR

AB	GLAXOSMITHKLINE	1GM;EQ 62.5MG BASE	N050785 001	Sep 25, 2002	Feb	CMFD
----	-----------------	--------------------	-------------	--------------	-----	------

AMPHOTERICIN B

INJECTABLE, LIPID COMPLEX; INJECTION

ABELCET

+	SIGMA TAU	5MG/ML	N050724 001	Nov 20, 1995	Feb	CAHN
---	-----------	--------	-------------	--------------	-----	------

AMPICILLIN SODIUM; SULBACTAM SODIUM

INJECTABLE; INJECTION

AMPICILLIN AND SULBACTAM

AP	BIONICHE PHARMA	EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL	A065316 001	Jun 29, 2007	Mar	CAHN
----	-----------------	--	-------------	--------------	-----	------

AP		EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL	A065316 002	Jun 29, 2007	Mar	CAHN
----	--	-----------------------------------	-------------	--------------	-----	------

APOMORPHINE HYDROCHLORIDE

INJECTABLE; SUBCUTANEOUS

APOKYN

>A>	@	IPSEN BIOPHARM LTD	20MG/2ML (10MG/ML)	N021264 001	Apr 20, 2004	May	CAHN
-----	---	--------------------	--------------------	-------------	--------------	-----	------

>A>	+		30MG/3ML (10MG/ML)	N021264 002	Apr 20, 2004	May	CAHN
-----	---	--	--------------------	-------------	--------------	-----	------

>D>	+	IPSEN LTD	30MG/3ML (10MG/ML)	N021264 002	Apr 20, 2004	May	CAHN
-----	---	-----------	--------------------	-------------	--------------	-----	------

>D>	@		20MG/2ML (10MG/ML)	N021264 001	Apr 20, 2004	May	CAHN
-----	---	--	--------------------	-------------	--------------	-----	------

ARMODAFINIL

TABLET; ORAL

NUVIGIL

@	CEPHALON	100MG	N021875 002	Mar 26, 2009	Feb	DISC
---	----------	-------	-------------	--------------	-----	------

@		200MG	N021875 005	Mar 26, 2009	Feb	DISC
---	--	-------	-------------	--------------	-----	------

ARTEMETHER; LUMEFANTRINE

TABLET; ORAL

COARTEM

	+	NOVARTIS	20MG;120MG	N022268 001	Apr 07, 2009	Mar	CRLD
--	---	----------	------------	-------------	--------------	-----	------

ARTICAINE HYDROCHLORIDE; EPINEPHRINE BITARTRATE

INJECTABLE; INJECTION

ARTICAINE HYDROCHLORIDE WITH EPINEPHRINE

PIERREL

4%;EQ 0.009MG BASE/1.8ML (EQ
0.005MG BASE/ML)

N022466 001 Feb 26, 2010 Feb NEWA

	+		4%;EQ 0.018MG BASE/1.8ML (EQ 0.01MG BASE/ML)	N022466 002	Feb 26, 2010	Feb	NEWA
--	---	--	---	-------------	--------------	-----	------

ASPIRIN; BUTALBITAL; CAFFEINE

CAPSULE; ORAL

FIORINAL

AA	+	WATSON PHARMS	325MG;50MG;40MG	N017534 005	Apr 16, 1986	Feb	CTEC
----	---	---------------	-----------------	-------------	--------------	-----	------

LANORINAL

AA		LANNETT	325MG;50MG;40MG	A086996 002	Oct 11, 1985	Feb	CTEC
----	--	---------	-----------------	-------------	--------------	-----	------

TABLET; ORAL

BUTALBITAL, ASPIRIN AND CAFFEINE

AA		ACTAVIS ELIZABETH	325MG;50MG;40MG	A086710 002	Aug 23, 1983	Feb	CTEC
----	--	-------------------	-----------------	-------------	--------------	-----	------

AA	+	WEST WARD	325MG;50MG;40MG	A086162 002	Feb 16, 1984	Feb	CTEC
----	---	-----------	-----------------	-------------	--------------	-----	------

ASPIRIN; METHOCARBAMOL

TABLET; ORAL

METHOCARBAMOL AND ASPIRIN

@ IVAX SUB TEVA PHARMS 325MG;400MG

A087211 001 Dec 22, 1982 Apr DISC

	+	STEVENS J	325MG;400MG	A081145 001	Jan 31, 1995	Apr	CRLD
--	---	-----------	-------------	-------------	--------------	-----	------

ASPIRIN; OXYCODONE HYDROCHLORIDE; OXYCODONE TEREPHTHALATE

TABLET; ORAL

OXYCODONE AND ASPIRIN

>D>	AA		WATSON LABS	325MG;4.5MG;0.38MG	A040255 001	Feb 27, 1998	May	CRLD
-----	----	--	-------------	--------------------	-------------	--------------	-----	------

>A>				325MG;4.5MG;0.38MG	A040255 001	Feb 27, 1998	May	CRLD
-----	--	--	--	--------------------	-------------	--------------	-----	------

>D> PERCODAN

>D>	AA	+	ENDO PHARMS	325MG;4.5MG;0.38MG	N007337 006		May	DISC
-----	----	---	-------------	--------------------	-------------	--	-----	------

>A>			@	325MG;4.5MG;0.38MG	N007337 006		May	DISC
-----	--	--	---	--------------------	-------------	--	-----	------

ATOVAQUONE; PROGUANIL HYDROCHLORIDE

TABLET; ORAL

MALARONE PEDIATRIC

GLAXOSMITHKLINE

62.5MG;25MG

N021078 002 Jul 14, 2000 Apr CRLD

AZELASTINE HYDROCHLORIDE

SPRAY, METERED; NASAL

ASTELIN

AB	+	MEDA PHARMS	EQ 0.125MG BASE/SPRAY	N020114 001	Nov 01, 1996	Jan	CTEC
----	---	-------------	-----------------------	-------------	--------------	-----	------

AZELASTINE HYDROCHLORIDE

AB		APOTEX INC	EQ 0.125MG BASE/SPRAY	A077954 001	Apr 30, 2009	Jan	CMFD
----	--	------------	-----------------------	-------------	--------------	-----	------

AZITHROMYCIN

INJECTABLE; INJECTION

AZITHROMYCIN

>D>	AP		GENERAMEDIX	EQ 500MG BASE/VIAL	A065501 001	Nov 09, 2009	May	CAHN
-----	----	--	-------------	--------------------	-------------	--------------	-----	------

INJECTABLE; INJECTION

AZITHROMYCIN

AP	GENERAMEDIX	EQ 500MG BASE/VIAL	A065501 001	Nov 09, 2009	Mar	CAHN
>A>	GLAND PHARMA LTD	EQ 500MG BASE/VIAL	A065501 001	Nov 09, 2009	May	CAHN
AP		EQ 500MG BASE/VIAL	A065501 001	Nov 09, 2009	Feb	CAHN

AZTREONAM

FOR SOLUTION; INHALATION

CAYSTON

+	GILEAD	75MG/VIAL	N050814 001	Feb 22, 2010	Feb	NEWA
---	--------	-----------	-------------	--------------	-----	------

BACITRACIN

INJECTABLE; INJECTION

BACITRACIN

>A>	AP	SAGENT PHARMS	50,000 UNITS/VIAL	A090211 001	May 11, 2010	May	NEWA
-----	----	---------------	-------------------	-------------	--------------	-----	------

BACLOFEN

TABLET; ORAL

BACLOFEN

AB	MATRIX LABS LTD	10MG	A090334 001	Feb 18, 2010	Jan	NEWA
AB		20MG	A090334 002	Feb 18, 2010	Jan	NEWA

TABLET, ORALLY DISINTEGRATING; ORAL

KEMSTRO

@	SCHWARZ PHARMA	10MG	N021589 001	Oct 30, 2003	Jan	DISC
@		20MG	N021589 002	Oct 30, 2003	Jan	DISC

BECLOMETHASONE DIPROPIONATE

AEROSOL, METERED; INHALATION

QVAR 40

+	TEVA BRANDED PHARM	0.04MG/INH	N020911 002	Sep 15, 2000	Feb	CAHN
---	--------------------	------------	-------------	--------------	-----	------

QVAR 80

+	TEVA BRANDED PHARM	0.08MG/INH	N020911 001	Sep 15, 2000	Feb	CAHN
---	--------------------	------------	-------------	--------------	-----	------

BENZAEPRIIL HYDROCHLORIDE

TABLET; ORAL

BENZAEPRIIL HYDROCHLORIDE

AB	HUAHAI US INC	5MG	A076118 001	Feb 11, 2004	Mar	CAHN
AB		10MG	A076118 002	Feb 11, 2004	Mar	CAHN
AB		20MG	A076118 003	Feb 11, 2004	Mar	CAHN
AB		40MG	A076118 004	Feb 11, 2004	Mar	CAHN

BENZTROPINE MESYLATE

INJECTABLE; INJECTION

BENZTROPINE MESYLATE

AP	PHARMAFORCE	1MG/ML	A091152 001	Mar 29, 2010	Mar	NEWA
----	-------------	--------	-------------	--------------	-----	------

TABLET; ORAL

BENZTROPINE MESYLATE

AA	INVAGEN PHARMS	0.5MG	A090294 001	Mar 29, 2010	Mar	NEWA	
AA		1MG	A090294 002	Mar 29, 2010	Mar	NEWA	
AA		2MG	A090294 003	Mar 29, 2010	Mar	NEWA	
AA	+	LANNETT	0.5MG	A088877 001	Apr 11, 1985	Feb	CAHN
AA	+		1MG	A088894 001	Apr 11, 1985	Feb	CAHN
AA	+		2MG	A088895 001	Apr 11, 1985	Feb	CAHN

BETAMETHASONE ACETATE; BETAMETHASONE SODIUM PHOSPHATE

INJECTABLE; INJECTION

BETAMETHASONE ACETATE AND BETAMETHASONE SODIUM PHOSPHATE

AB	LUITPOLD	3MG/ML;EQ 3MG BASE/ML	A090747 001	Jul 31, 2009	Mar	CAHN
----	----------	-----------------------	-------------	--------------	-----	------

BETAXOLOL HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

BETAXOLOL HYDROCHLORIDE

AT	AKORN	EQ 0.5% BASE	A075386 001	Jun 30, 2000	Jan	CTNA
AT	NOVEX	EQ 0.5% BASE	A075446 001	Sep 28, 2000	Jan	CTNA
AT	WOCKHARDT	EQ 0.5% BASE	A078694 001	Nov 16, 2009	Jan	CAHN

TABLET; ORAL

BETAXOLOL HYDROCHLORIDE

>A>	AB	EPIC PHARMA	10MG	A075541 001	Oct 22, 1999	May	CAHN
>A>	AB	+	20MG	A075541 002	Oct 22, 1999	May	CAHN
>D>	AB	MIKAH PHARMA	10MG	A075541 001	Oct 22, 1999	May	CAHN
	AB		10MG	A075541 001	Oct 22, 1999	Feb	CAHN
>D>	AB	+	20MG	A075541 002	Oct 22, 1999	May	CAHN
	AB	+	20MG	A075541 002	Oct 22, 1999	Feb	CAHN

BETHANECHOL CHLORIDE

TABLET; ORAL

BETHANECHOL CHLORIDE

AA	EMCURE USA	5MG	A091256 001	May 04, 2010	Apr	NEWA
AA		10MG	A091256 002	May 04, 2010	Apr	NEWA
AA		25MG	A091256 003	May 04, 2010	Apr	NEWA
AA		50MG	A091256 004	May 04, 2010	Apr	NEWA

BICALUTAMIDE

TABLET; ORAL

BICALUTAMIDE

>A>	AB	FRESENIUS KABI ONCOL	50MG	A079045 001	May 13, 2010	May	NEWA
-----	----	----------------------	------	-------------	--------------	-----	------

BUPIVACAINE HYDROCHLORIDE; EPINEPHRINE

INJECTABLE; INJECTION

BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE

AP	HOSPIRA	0.5%;0.005MG/ML	A071170 001	Jun 16, 1988	Mar	CMFD
AP	+	0.5%;0.005MG/ML	A071168 001	Jun 16, 1988	Mar	CTEC

BUPRENORPHINE HYDROCHLORIDE

TABLET; SUBLINGUAL

BUPRENORPHINE HYDROCHLORIDE

AB	BARR	EQ 2MG BASE	A090360 001	May 07, 2010	Apr	NEWA
AB		EQ 8MG BASE	A090360 002	May 07, 2010	Apr	NEWA

BUPROPION HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

BUPROPION HYDROCHLORIDE

AB1	MYLAN	100MG	A090325 001	Apr 08, 2010	Mar	NEWA
AB2		150MG	A090941 001	May 03, 2010	Apr	NEWA
AB1		150MG	A090325 002	Apr 08, 2010	Mar	NEWA
AB1		200MG	A090325 003	Apr 08, 2010	Mar	NEWA
AB1	SUN PHARMA GLOBAL	100MG	A078866 001	Apr 06, 2010	Mar	NEWA
AB1		150MG	A078866 002	Apr 06, 2010	Mar	NEWA
AB1		200MG	A078866 003	Apr 06, 2010	Mar	NEWA

BUSPIRONE HYDROCHLORIDE

TABLET; ORAL					
BUSPAR					
	@ BRISTOL MYERS SQUIBB	10MG	N018731 002	Sep 29, 1986	Mar DISC
	@	15MG	N018731 003	Apr 22, 1996	Feb DISC
BUSPIRONE HYDROCHLORIDE					
AB	+ IVAX SUB TEVA PHARMS	15MG	A075385 003	Mar 01, 2002	Mar CRLD
AB	TEVA	30MG	A075022 004	Mar 25, 2004	Mar CRLD
AB	+	30MG	A075022 004	Mar 25, 2004	Feb CRLD

CABERGOLINE

TABLET; ORAL					
CABERGOLINE					
AB	IMPAX LABS INC	0.5MG	A077843 001	Jul 03, 2007	Mar CAHN

CAFFEINE CITRATE

SOLUTION; ORAL					
CAFFEINE CITRATE					
AA	PADDOCK LABS	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	A077304 001	Sep 21, 2006	Apr CAHN

CALCIPOTRIENE

OINTMENT; TOPICAL					
CALCIPOTRIENE					
	+ GLENMARK GENERICS	0.005%	A090633 001	Mar 24, 2010	Mar NEWA

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM CITRATE

SOLUTION; IRRIGATION					
BALANCED SALT					
AT	B BRAUN	0.48MG/ML;0.3MG/ML;0.75MG/ML;3.9MG/ML;6.4MG/ML;1.7MG/ML	A091387 001	Feb 03, 2010	Jan NEWA

CAPTOPRIL

TABLET; ORAL					
CAPTOPRIL					
AB	HUAHAI US INC	12.5MG	A074477 001	Feb 13, 1996	Apr CAHN
AB		25MG	A074477 002	Feb 13, 1996	Apr CAHN
AB		50MG	A074477 003	Feb 13, 1996	Apr CAHN
AB		100MG	A074477 004	Feb 13, 1996	Apr CAHN

CAPTOPRIL; HYDROCHLOROTHIAZIDE

TABLET; ORAL					
CAPTOPRIL AND HYDROCHLOROTHIAZIDE					
	@ IVAX SUB TEVA PHARMS	25MG;15MG	A075055 001	Jun 18, 1998	Apr DISC
	@	25MG;25MG	A075055 002	Jun 18, 1998	Apr DISC
	@	50MG;15MG	A075055 004	Jun 18, 1998	Apr DISC
	@	50MG;25MG	A075055 003	Jun 18, 1998	Apr DISC

CARBAMAZEPINE

TABLET; ORAL					
CARBAMAZEPINE					
	@ INWOOD LABS	200MG	A070231 001	Aug 14, 1986	Apr DISC

CARBIDOPA

TABLET; ORAL

LODOSYN

+	ATON	25MG	N017830 001		Apr	CAHN
---	------	------	-------------	--	-----	------

CARBIDOPA; LEVODOPA

TABLET, ORALLY DISINTEGRATING; ORAL

CARBIDOPA AND LEVODOPA

>A>	AB	IMPAX LABS	10MG;100MG	A090631 001	Jun 08, 2010	May	NEWA
>A>	AB		25MG;100MG	A090631 002	Jun 08, 2010	May	NEWA
>A>	AB		25MG;250MG	A090631 003	Jun 08, 2010	May	NEWA

CARBINOXAMINE MALEATE

SOLUTION; ORAL

CARBINOXAMINE MALEATE

AA		CYPRESS PHARM	4MG/5ML	A090418 001	May 04, 2010	Apr	NEWA
----	--	---------------	---------	-------------	--------------	-----	------

TABLET; ORAL

CARBINOXAMINE MALEATE

AA		INVAGEN PHARMS	4MG	A090435 001	Apr 15, 2010	Mar	NEWA
----	--	----------------	-----	-------------	--------------	-----	------

CARBOPLATIN

INJECTABLE; IV (INFUSION)

CARBOPLATIN

AP		BIONICHE PHARMA USA	50MG/5ML (10MG/ML)	A077998 001	Apr 24, 2007	Mar	CAHN
AP			150MG/15ML (10MG/ML)	A077998 002	Apr 24, 2007	Mar	CAHN
AP			450MG/45ML (10MG/ML)	A077998 003	Apr 24, 2007	Mar	CAHN

CARGLUMIC ACID

TABLET; ORAL

CARBAGLU

+	ORPHAN EUROPE	200MG	N022562 001	Mar 18, 2010	Mar	NEWA
---	---------------	-------	-------------	--------------	-----	------

CARVEDILOL PHOSPHATE

CAPSULE, EXTENDED RELEASE; ORAL

COREG CR

+	SB PHARMCO	40MG	N022012 003	Oct 20, 2006	Feb	CRLD
		80MG	N022012 004	Oct 20, 2006	Feb	CRLD

CEFACLOR

TABLET, EXTENDED RELEASE; ORAL

CEFACLOR

AB	+	WORLD GEN	EQ 500MG BASE	A065057 001	Jan 05, 2001	Mar	CAHN
----	---	-----------	---------------	-------------	--------------	-----	------

CEFADROXIL/CEFADROXIL HEMIHYDRATE

CAPSULE; ORAL

CEFADROXIL

AB	+	TEVA PHARMS	EQ 500MG BASE	A065282 001	Jan 20, 2006	Mar	CRLD
----	---	-------------	---------------	-------------	--------------	-----	------

FOR SUSPENSION; ORAL

CEFADROXIL

AB	+	LUPIN	EQ 500MG BASE/5ML	A065396 002	Feb 21, 2008	Jan	CRLD
----	---	-------	-------------------	-------------	--------------	-----	------

DURICEF

@	WARNER CHILCOTT	EQ 250MG BASE/5ML	N050527 003		Jan	DISC
---	-----------------	-------------------	-------------	--	-----	------

@		EQ 500MG BASE/5ML	N050527 001		Jan	DISC
---	--	-------------------	-------------	--	-----	------

CEFAZOLIN SODIUM

INJECTABLE; INJECTION

CEFAZOLIN SODIUM

>D>	@ HANFORD GC	EQ 500MG BASE/VIAL	A063216 001	Dec 27, 1991	May	CAHN
>D>	@	EQ 500MG BASE/VIAL	A063214 001	Dec 27, 1991	May	CAHN
>D>	AP	EQ 1GM BASE/VIAL	A063207 001	Dec 27, 1991	May	CAHN
>D>	AP	EQ 1GM BASE/VIAL	A063208 001	Dec 27, 1991	May	CAHN
>D>	AP	EQ 10GM BASE/VIAL	A063209 001	Dec 27, 1991	May	CAHN
>A>	@ STERI PHARMA	EQ 500MG BASE/VIAL	A063214 001	Dec 27, 1991	May	CAHN
>A>	@	EQ 500MG BASE/VIAL	A063216 001	Dec 27, 1991	May	CAHN
>A>	AP	EQ 1GM BASE/VIAL	A063208 001	Dec 27, 1991	May	CAHN
>A>	AP	EQ 1GM BASE/VIAL	A063207 001	Dec 27, 1991	May	CAHN
>A>	AP	EQ 10GM BASE/VIAL	A063209 001	Dec 27, 1991	May	CAHN

CEFEPIME HYDROCHLORIDE

>A>	INJECTABLE; INJECTION					
>A>	CEFEPIME AND DEXTROSE IN DUPLEX CONTAINER					
>A>	B BRAUN	EQ 1GM BASE/VIAL	N050821 001	May 06, 2010	May	NEWA
>A>		EQ 2GM BASE/VIAL	N050821 002	May 06, 2010	May	NEWA

CEFOTAXIME SODIUM

INJECTABLE; INJECTION

CEFOTAXIME SODIUM

AP	CEPHAZONE PHARMA	EQ 10GM BASE/VIAL	A065348 001	Jan 25, 2010	Jan	NEWA
----	------------------	-------------------	-------------	--------------	-----	------

CEFOXITIN SODIUM

INJECTABLE; INJECTION

CEFOXITIN

>A>	AP	ACS DOBFAR	EQ 10GM BASE/VIAL	A065415 001	May 19, 2010	May	NEWA
	AP	HIKMA FARMACEUTICA	EQ 1GM BASE/VIAL	A065238 001	Mar 12, 2010	Feb	NEWA
	AP		EQ 2GM BASE/VIAL	A065238 002	Mar 12, 2010	Feb	NEWA
	AP		EQ 10GM BASE/VIAL	A065239 001	Mar 02, 2010	Feb	NEWA

CEFPROZIL

FOR SUSPENSION; ORAL

CEFPROZIL

AB	+	LUPIN	250MG/5ML	A065261 002	Dec 19, 2005	Feb	CTEC
----	---	-------	-----------	-------------	--------------	-----	------

TABLET; ORAL

CEFPROZIL

AB	+	LUPIN	500MG	A065276 002	Dec 08, 2005	Feb	CRLD
----	---	-------	-------	-------------	--------------	-----	------

CEFTAZIDIME

INJECTABLE; INJECTION

CEFTAZIDIME

>A>	AP	AUROBINDO PHARMA	500MG/VIAL	A065481 001	May 28, 2010	May	NEWA
>A>	AP		1GM/VIAL	A065481 002	May 28, 2010	May	NEWA
>A>	AP		2GM/VIAL	A065481 003	May 28, 2010	May	NEWA
>A>	AP		6GM/VIAL	A065482 001	May 28, 2010	May	NEWA

CEFTIBUTEN DIHYDRATE

CAPSULE; ORAL

CEDAX

>A>	+	PERNIX THERAP	EQ 400MG BASE	N050685 002	Dec 20, 1995	May	CAHN
>D>	+	SHIONOGI PHARMA	EQ 400MG BASE	N050685 002	Dec 20, 1995	May	CAHN

FOR SUSPENSION; ORAL

CEDAX

>A>	+	PERNIX THERAP	EQ 90MG BASE/5ML	N050686 001	Dec 20, 1995	May	CAHN
>A>	@		EQ 180MG BASE/5ML	N050686 002	Dec 20, 1995	May	CAHN
>D>	+	SHIONOGI PHARMA	EQ 90MG BASE/5ML	N050686 001	Dec 20, 1995	May	CAHN
>D>	@		EQ 180MG BASE/5ML	N050686 002	Dec 20, 1995	May	CAHN

CEFTRIAZONE SODIUM

INJECTABLE; IM-IV

CEFTRIAZONE

>D>	AP	HANFORD GC	EQ 1GM BASE/VIAL	A065268 001	Feb 28, 2007	May	CAHN
>D>	AP		EQ 2GM BASE/VIAL	A065268 002	Feb 28, 2007	May	CAHN
>A>	AP	STERI PHARMA	EQ 1GM BASE/VIAL	A065268 001	Feb 28, 2007	May	CAHN
>A>	AP		EQ 2GM BASE/VIAL	A065268 002	Feb 28, 2007	May	CAHN

INJECTABLE; INJECTION

CEFTRIAZONE

>D>	AP	HANFORD GC	EQ 10GM BASE/VIAL	A065269 001	Feb 28, 2007	May	CAHN
>A>	AP	STERI PHARMA	EQ 10GM BASE/VIAL	A065269 001	Feb 28, 2007	May	CAHN

CEFUROXIME AXETIL

TABLET; ORAL

CEFUROXIME AXETIL

>A>	AB	ALKEM	EQ 250MG BASE	A065496 001	Jun 07, 2010	May	NEWA
>A>	AB		EQ 500MG BASE	A065496 002	Jun 07, 2010	May	NEWA

CEFUROXIME SODIUM

INJECTABLE; IM-IV

CEFUROXIME SODIUM

>D>	AB	HANFORD GC	EQ 750MG BASE/VIAL	A064125 001	May 30, 1997	May	CAHN
>A>	AB	STERI PHARMA	EQ 750MG BASE/VIAL	A064125 001	May 30, 1997	May	CAHN

INJECTABLE; INJECTION

CEFUROXIME SODIUM

>D>	AP	HANFORD GC	EQ 1.5GM BASE/VIAL	A064125 002	May 30, 1997	May	CAHN
>D>	AP		EQ 7.5GM BASE/VIAL	A064124 001	May 30, 1997	May	CAHN
>A>	AP	STERI PHARMA	EQ 1.5GM BASE/VIAL	A064125 002	May 30, 1997	May	CAHN
>A>	AP		EQ 7.5GM BASE/VIAL	A064124 001	May 30, 1997	May	CAHN

CEPHALEXIN

CAPSULE; ORAL

CEPHALEXIN

@	IVAX SUB TEVA PHARMS	EQ 250MG BASE	A061969 001			Apr	DISC
@		EQ 500MG BASE	A061969 002			Apr	DISC

CETIRIZINE HYDROCHLORIDE

SYRUP; ORAL

CETIRIZINE HYDROCHLORIDE

AA	ACTAVIS MID ATLANTIC	5MG/5ML	A078617 001	Feb 02, 2010	Jan	NEWA
----	----------------------	---------	-------------	--------------	-----	------

CHLOROQUINE PHOSPHATE

TABLET; ORAL

CHLOROQUINE PHOSPHATE

>A>	AA	IPCA LABS LTD	EQ 150MG BASE	A090610 001	Dec 03, 2009	May	CAHN
	AA		EQ 300MG BASE	A090249 001	Dec 03, 2009	Apr	CAHN
>D>	AA	OHM LABS	EQ 150MG BASE	A090610 001	Dec 03, 2009	May	CAHN

CHLORZOXAZONE

TABLET; ORAL

CHLORZOXAZONE

>A>	MIKART	375MG	A040861 001	Jun 01, 2010	May	NEWA
>A>		750MG	A040861 002	Jun 01, 2010	May	NEWA

CICLOPIROX

SHAMPOO; TOPICAL

CICLOPIROX

>A>	AT	NYCOMED US	1%	A090146 001	May 25, 2010	May	NEWA
	AT	PERRIGO	1%	A078594 001	Feb 16, 2010	Jan	NEWA

SOLUTION; TOPICAL

CICLOPIROX

	AT	VERSAPHARM	8%	A078975 001	Feb 17, 2010	Jan	NEWA
--	----	------------	----	-------------	--------------	-----	------

CILOSTAZOL

TABLET; ORAL

CILOSTAZOL

	@	IVAX SUB TEVA PHARMS	100MG	A077020 002	Mar 01, 2005	Apr	DISC
--	---	----------------------	-------	-------------	--------------	-----	------

CIPROFLOXACIN HYDROCHLORIDE

TABLET; ORAL

CIPRO

	AB	+	BAYER HLTHCARE	EQ 500MG BASE	N019537 003	Oct 22, 1987	Feb	CRLD
	AB			EQ 750MG BASE	N019537 004	Oct 22, 1987	Feb	CRLD

CITALOPRAM HYDROBROMIDE

TABLET; ORAL

CITALOPRAM HYDROBROMIDE

>D>		@	AMNEAL PHARMS	EQ 10MG BASE	A077045 003	Apr 29, 2005	May	CMFD
>D>		@		EQ 20MG BASE	A077045 002	Apr 29, 2005	May	CMFD
>D>		@		EQ 40MG BASE	A077045 001	Apr 29, 2005	May	CMFD
>A>	AB		EPIC PHARMA	EQ 10MG BASE	A077045 003	Apr 29, 2005	May	CMFD
>A>	AB			EQ 20MG BASE	A077045 002	Apr 29, 2005	May	CMFD
>A>	AB			EQ 40MG BASE	A077045 001	Apr 29, 2005	May	CMFD

CLARITHROMYCIN

TABLET; ORAL

CLARITHROMYCIN

	@	IVAX SUB TEVA PHARMS	250MG	A065137 001	May 31, 2005	Apr	DISC
	@		500MG	A065137 002	May 31, 2005	Apr	DISC

CLINDAMYCIN PHOSPHATE

AEROSOL, FOAM; TOPICAL

CLINDAMYCIN PHOSPHATE

	AT		COBREK PHARMS	1%	A090785 001	Mar 31, 2010	Mar	NEWA
--	----	--	---------------	----	-------------	--------------	-----	------

EVOCLIN

	AT	+	STIEFEL LABS INC	1%	N050801 001	Oct 22, 2004	Mar	CFTG
--	----	---	------------------	----	-------------	--------------	-----	------

CREAM; VAGINAL

CLINDAMYCIN PHOSPHATE

	AB		NYCOMED US	EQ 2% BASE	A065139 001	Dec 27, 2004	Mar	CAHN
--	----	--	------------	------------	-------------	--------------	-----	------

SOLUTION; TOPICAL

CLINDAMYCIN PHOSPHATE

>A>	AT		VERSAPHARM	EQ 1% BASE	A065513 001	Jun 17, 2010	May	NEWA
-----	----	--	------------	------------	-------------	--------------	-----	------

CLOBETASOL PROPIONATE

OINTMENT; TOPICAL

CLOBETASOL PROPIONATE

AB	NYCOMED US	0.05%	A074407 001	Feb 23, 1996	Mar	CAHN
----	------------	-------	-------------	--------------	-----	------

CLONIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

DURACLON

AP	BIONICHE PHARMA USA	1 MG/10 ML (0.1 MG/ML)	N020615 001	Oct 02, 1996	Mar	CAHN
----	---------------------	------------------------	-------------	--------------	-----	------

AP	+	5 MG/10 ML (0.5 MG/ML)	N020615 002	Apr 27, 1999	Mar	CAHN
----	---	------------------------	-------------	--------------	-----	------

TABLET; ORAL

CLONIDINE HYDROCHLORIDE

>D>	@ AMNEAL PHARMS NY	0.1MG	A071252 001	Oct 01, 1986	May	CAHN
-----	--------------------	-------	-------------	--------------	-----	------

>D>	@	0.2MG	A071253 001	Oct 01, 1986	May	CAHN
-----	---	-------	-------------	--------------	-----	------

>D>	@	0.3MG	A071254 001	Oct 01, 1986	May	CAHN
-----	---	-------	-------------	--------------	-----	------

>A>	@ INTERPHARM	0.1MG	A071252 001	Oct 01, 1986	May	CAHN
-----	--------------	-------	-------------	--------------	-----	------

>A>	@	0.2MG	A071253 001	Oct 01, 1986	May	CAHN
-----	---	-------	-------------	--------------	-----	------

>A>	@	0.3MG	A071254 001	Oct 01, 1986	May	CAHN
-----	---	-------	-------------	--------------	-----	------

CODEINE PHOSPHATE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE

AA	SUN PHARM INDS INC	10MG/5ML;6.25MG/5ML	A090180 001	Mar 17, 2010	Mar	NEWA
----	--------------------	---------------------	-------------	--------------	-----	------

COLCHICINE; PROBENECID

TABLET; ORAL

PROBENECID AND COLCHICINE

@	IVAX SUB TEVA PHARMS	0.5MG;500MG	A083734 001		Apr	DISC
---	----------------------	-------------	-------------	--	-----	------

COSYNTROPIN

INJECTABLE; INJECTION

COSYNTROPIN

AP	BIONICHE PHARMA	0.25MG/VIAL	A090574 001	Dec 17, 2009	Mar	CAHN
----	-----------------	-------------	-------------	--------------	-----	------

CROMOLYN SODIUM

CONCENTRATE; ORAL

CROMOLYN SODIUM

@	GENERA PHARMS	100MG/5ML	A090954 001	Dec 18, 2009	Apr	DISC
---	---------------	-----------	-------------	--------------	-----	------

GASTROCROM

+	AZUR PHARMA	100MG/5ML	N020479 001	Feb 29, 1996	Apr	CTEC
---	-------------	-----------	-------------	--------------	-----	------

CYANOCOBALAMIN

SPRAY, METERED; NASAL

CALOMIST

@	FLEMING	25MCG/SPRAY	N022102 001	Jul 27, 2007	Jan	DISC
---	---------	-------------	-------------	--------------	-----	------

CYCLOPHOSPHAMIDE

INJECTABLE; INJECTION

CYTOXAN

AP	+	BAXTER HLTHCARE	500MG/VIAL	N012142 003		Feb	CMFD
----	---	-----------------	------------	-------------	--	-----	------

AP	+		1GM/VIAL	N012142 004	Aug 30, 1982	Feb	CMFD
----	---	--	----------	-------------	--------------	-----	------

AP	+		2GM/VIAL	N012142 005	Aug 30, 1982	Feb	CMFD
----	---	--	----------	-------------	--------------	-----	------

LYOPHILIZED CYTOXAN

@	BAXTER HLTHCARE	100MG/VIAL	N012142 006	Dec 05, 1985	Feb	DISC
---	-----------------	------------	-------------	--------------	-----	------

@		200MG/VIAL	N012142 007	Dec 10, 1985	Feb	DISC
---	--	------------	-------------	--------------	-----	------

INJECTABLE; INJECTIONLYOPHILIZED CYTOXAN

@	BAXTER HLTHCARE	500MG/VIAL	N012142 008	Jan 04, 1984	Feb	DISC
@		1GM/VIAL	N012142 010	Sep 24, 1985	Feb	DISC
@		2GM/VIAL	N012142 009	Dec 10, 1984	Feb	DISC

CYPROHEPTADINE HYDROCHLORIDE

TABLET; ORAL

CYPROHEPTADINE HYDROCHLORIDE

>D>	AA	PLIVA	4MG	A088205 001	Jul 26, 1983	May	DISC
>A>		@	4MG	A088205 001	Jul 26, 1983	May	DISC

CYTARABINE

INJECTABLE; INJECTION

CYTARABINE

AP	+	HOSPIRA	20MG/ML	A071868 001	Jun 04, 1990	Apr	CRLD
AP	+		20MG/ML	A072168 001	Aug 31, 1990	Mar	CRLD

DACTINOMYCIN

INJECTABLE; INJECTION

COSMEGEN

AP	+	LUNDBECK INC	0.5MG/VIAL	N050682 001		Mar	CFTG
----	---	--------------	------------	-------------	--	-----	------

DACTINOMYCIN

AP		BEDFORD	0.5MG/VIAL	A090304 001	Mar 16, 2010	Mar	NEWA
----	--	---------	------------	-------------	--------------	-----	------

DALFAMPRIDINE

TABLET, EXTENDED RELEASE; ORAL

AMPYRA

+	ACORDA	10MG	N022250 001	Jan 22, 2010	Jan	NEWA
---	--------	------	-------------	--------------	-----	------

DARUNAVIR ETHANOLATE

TABLET; ORAL

PREZISTA

>D>		CENTOCOR ORTHO	EQ 75MG BASE	N021976 004	Dec 18, 2008	May	CAHN
>D>			EQ 150MG BASE	N021976 005	Dec 18, 2008	May	CAHN
>D>			EQ 300MG BASE	N021976 001	Jun 23, 2006	May	CAHN
>D>			EQ 400MG BASE	N021976 003	Oct 21, 2008	May	CAHN
>D>	+		EQ 600MG BASE	N021976 002	Feb 25, 2008	May	CAHN
>A>		TIBOTEC	EQ 75MG BASE	N021976 004	Dec 18, 2008	May	CAHN
>A>			EQ 150MG BASE	N021976 005	Dec 18, 2008	May	CAHN
>A>			EQ 300MG BASE	N021976 001	Jun 23, 2006	May	CAHN
>A>			EQ 400MG BASE	N021976 003	Oct 21, 2008	May	CAHN
>A>	+		EQ 600MG BASE	N021976 002	Feb 25, 2008	May	CAHN

DES Loratadine

TABLET; ORAL

CLARINEX

AB	+	SCHERING PLOUGH	5MG	N021165 001	Dec 21, 2001	Jan	CFTG
----	---	-----------------	-----	-------------	--------------	-----	------

DES Loratadine

AB		ORCHID HLTHCARE	5MG	A078357 001	Feb 19, 2010	Jan	NEWA
----	--	-----------------	-----	-------------	--------------	-----	------

Desmopressin Acetate

SPRAY, METERED; NASAL

STIMATE (NEEDS NO REFRIGERATION)

@	CSL BEHRING	1.5MG/SPRAY	N020355 002	Oct 24, 2007	Jan	DISC
---	-------------	-------------	-------------	--------------	-----	------

DESOGESTREL; ETHINYL ESTRADIOL

TABLET; ORAL-28

MIRCETTE

AB	+	TEVA WOMENS	0.15MG,N/A;0.02MG,0.01MG	N020713 001	Apr 22, 1998	Apr	CAHN
----	---	-------------	--------------------------	-------------	--------------	-----	------

DEXLANSOPRAZOLE

CAPSULE, DELAYED RELEASE; ORAL

DEXILANT

		TAKEDA PHARMS	30MG	N022287 001	Jan 30, 2009	Mar	CTNA
	+		60MG	N022287 002	Jan 30, 2009	Mar	CTNA

DEXMEDETOMIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

PRECEDEX

	+	HOSPIRA	EQ 100MCG BASE/ML (EQ100MCG BASE/ML)	N021038 001	Dec 17, 1999	Jan	CAIN
--	---	---------	---	-------------	--------------	-----	------

DIATRIZOATE SODIUM

FOR SOLUTION; ORAL, RECTAL

HYPAQUE

>D>		GE HEALTHCARE	100%	N011386 001		May	DISC
>A>		@	100%	N011386 001		May	DISC

DIAZOXIDE

CAPSULE; ORAL

PROGLYCEM

	@	TEVA BRANDED PHARM	50MG	N017425 001		Feb	CAHN
	@		100MG	N017425 002		Feb	CAHN

DICLOFENAC POTASSIUM

FOR SOLUTION; ORAL

CAMBIA

	+	NAUTILUS NEUROSCIENC	50MG	N022165 001	Jun 17, 2009	Mar	CAHN
--	---	----------------------	------	-------------	--------------	-----	------

TABLET; ORAL

DICLOFENAC POTASSIUM

	@	SANDOZ	50MG	A075582 001	Feb 23, 2001	Jan	DISC
	@	WATSON LABS	50MG	A075152 001	Nov 27, 1998	Apr	DISC

DICLOFENAC SODIUM

SOLUTION; TOPICAL

PENNSAID

>A>	+	MALLINCKRODT	1.5%	N020947 001	Nov 04, 2009	May	CAHN
>D>	+	NUVO RES	1.5%	N020947 001	Nov 04, 2009	May	CAHN

TABLET, DELAYED RELEASE; ORAL

DICLOFENAC SODIUM

	@	NOSTRUM LABS	50MG	A074986 001	Feb 26, 1999	Apr	DISC
	@		75MG	A074986 002	Feb 26, 1999	Apr	DISC

DIDANOSINE

CAPSULE, DELAYED REL PELLETS; ORAL

DIDANOSINE

AB		MATRIX LABS LTD	125MG	A090788 001	Apr 08, 2010	Mar	NEWA
AB			200MG	A090788 002	Apr 08, 2010	Mar	NEWA
AB			250MG	A090788 003	Apr 08, 2010	Mar	NEWA
AB			400MG	A090788 004	Apr 08, 2010	Mar	NEWA

>A> DIENOGEST; ESTRADIOL VALERATE

>A> TABLET; ORAL-28

>A> NATAZIA

>A> BAYER HLTHCARE N/A, 2MG, 3MG, N/A, N/A; 3MG, 2MG, 2MG, 1 N022252 001 May 06, 2010 May NEWA
MG, N/ADIFLORASONE DIACETATE

CREAM; TOPICAL

DIFLORASONE DIACETATE

AB1 + ALTANA 0.05% A075187 001 Mar 30, 1998 Mar CRLD

PSORCON

@ SANOFI AVENTIS US 0.05% N020205 001 Nov 20, 1992 Feb DISC

DILTIAZEM HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

CARDIZEM LA

AB BIOVAIL LABS INTL 120MG N021392 001 Feb 06, 2003 Feb CFTG

AB 180MG N021392 002 Feb 06, 2003 Feb CFTG

AB 240MG N021392 003 Feb 06, 2003 Feb CFTG

AB 300MG N021392 004 Feb 06, 2003 Feb CFTG

AB 360MG N021392 005 Feb 06, 2003 Feb CFTG

AB + 420MG N021392 006 Feb 06, 2003 Feb CFTG

DILTIAZEM HYDROCHLORIDE

AB WATSON LABS FLORIDA 120MG A077686 006 Mar 15, 2010 Feb NEWA

AB 180MG A077686 005 Mar 15, 2010 Feb NEWA

AB 240MG A077686 004 Mar 15, 2010 Feb NEWA

AB 300MG A077686 003 Mar 15, 2010 Feb NEWA

AB 360MG A077686 002 Mar 15, 2010 Feb NEWA

AB 420MG A077686 001 Mar 15, 2010 Feb NEWA

DISOPYRAMIDE PHOSPHATE

CAPSULE; ORAL

DISOPYRAMIDE PHOSPHATE

>D> @ AMNEAL PHARMS NY EQ 100MG BASE A071190 001 Jan 15, 1987 May CAHN

>D> @ EQ 150MG BASE A071191 001 Jan 15, 1987 May CAHN

>A> @ INTERPHARM EQ 100MG BASE A071190 001 Jan 15, 1987 May CAHN

>A> @ EQ 150MG BASE A071191 001 Jan 15, 1987 May CAHN

DOXAZOSIN MESYLATE

TABLET; ORAL

DOXAZOSIN MESYLATE

@ IVAX SUB TEVA PHARMS EQ 1MG BASE A075453 001 Oct 18, 2000 Apr DISC

@ EQ 2MG BASE A075453 002 Oct 18, 2000 Apr DISC

@ EQ 4MG BASE A075453 003 Oct 18, 2000 Apr DISC

@ EQ 8MG BASE A075453 004 Oct 18, 2000 Apr DISC

DOXEPIN HYDROCHLORIDE

TABLET; ORAL

SILENOR

SOMAXON EQ 3MG BASE N022036 001 Mar 17, 2010 Mar NEWA

+ EQ 6MG BASE N022036 002 Mar 17, 2010 Mar NEWA

DOXYCYCLINE HYCLATE

CAPSULE; ORAL

DOXYCYCLINE HYCLATE

>D>	@	AMNEAL PHARMS NY	EQ 50MG BASE	A062763 001	Sep 02, 1988	May	CAHN
>D>	@		EQ 100MG BASE	A062763 002	Sep 02, 1988	May	CAHN
>A>	@	INTERPHARM	EQ 50MG BASE	A062763 001	Sep 02, 1988	May	CAHN
>A>	@		EQ 100MG BASE	A062763 002	Sep 02, 1988	May	CAHN

TABLET; ORAL

DOXYCYCLINE HYCLATE

>D>	@	AMNEAL PHARMS NY	EQ 100MG BASE	A062764 001	Sep 02, 1988	May	CAHN
>A>	@	INTERPHARM	EQ 100MG BASE	A062764 001	Sep 02, 1988	May	CAHN
	@	LARKEN LABS	EQ 20MG BASE	A065287 001	Feb 28, 2006	Apr	CAHN

DRONABINOL

CAPSULE; ORAL

MARINOL

>A>	AB	ABBOTT PRODS	2.5MG	N018651 001	May 31, 1985	May	CAHN
>A>	AB	+	5MG	N018651 002	May 31, 1985	May	CAHN
>A>	AB		10MG	N018651 003	May 31, 1985	May	CAHN
>D>	AB	UNIMED	2.5MG	N018651 001	May 31, 1985	May	CAHN
>D>	AB	+	5MG	N018651 002	May 31, 1985	May	CAHN
>D>	AB		10MG	N018651 003	May 31, 1985	May	CAHN

ELTROMBOPAG OLAMINE

TABLET; ORAL

PROMACTA

GLAXOSMITHKLINE

EQ 75MG ACID

N022291 003 Sep 08, 2009 Mar NEWA

ENALAPRIL MALEATE

TABLET; ORAL

ENALAPRIL MALEATE

AB	MYLAN		2.5MG	A075472 001	Aug 22, 2000	Apr	CAHN
AB			5MG	A075472 002	Aug 22, 2000	Apr	CAHN
AB			10MG	A075472 003	Aug 22, 2000	Apr	CAHN
AB			20MG	A075472 004	Aug 22, 2000	Apr	CAHN

ENALAPRIL MALEATE; FELODIPINE

TABLET, EXTENDED RELEASE; ORAL

LEXXEL

@ ASTRAZENECA

5MG;5MG

N020668 001 Dec 27, 1996 Mar DISC

EPINEPHRINE

INJECTABLE; IM-SC

ADRENACLICK

BX	+	SHIONOGI PHARMA	EQ 0.15MG /DELIVERY	N020800 003	Nov 25, 2009	Apr	CTEC
	+		EQ 0.15MG /DELIVERY	N020800 003	Nov 25, 2009	Mar	NEWA
BX	+		EQ 0.3MG /DELIVERY	N020800 004	Nov 25, 2009	Apr	CTEC
	+		EQ 0.3MG /DELIVERY	N020800 004	Nov 25, 2009	Mar	NEWA

EPIPEN

BX	+	MERIDIAN MEDCL TECHN	0.3MG/DELIVERY	N019430 001	Dec 22, 1987	Apr	CDFR
----	---	----------------------	----------------	-------------	--------------	-----	------

EPIPEN JR.

BX	+	MERIDIAN MEDCL TECHN	0.15MG/DELIVERY	N019430 002	Dec 22, 1987	Apr	CDFR
----	---	----------------------	-----------------	-------------	--------------	-----	------

TWINJECT 0.15

BX	+	SHIONOGI PHARMA	EQ 0.15MG /DELIVERY	N020800 002	May 28, 2004	Apr	CTEC
	+		EQ 0.15MG /DELIVERY	N020800 002	May 28, 2004	Jan	CAHN

INJECTABLE; IM-SC

TWINJECT 0.3

BX	+	SHIONOGI PHARMA	EQ 0.3MG /DELIVERY	N020800 001	May 30, 2003	Apr	CTEC
	+		EQ 0.3MG /DELIVERY	N020800 001	May 30, 2003	Jan	CAHN

EPIRUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

EPIRUBICIN HYDROCHLORIDE

AP		BIONICHE PHARMA USA	50MG/25ML (2MG/ML)	A065371 001	Nov 28, 2007	Mar	CAHN
AP			200MG/100ML (2MG/ML)	A065371 002	Nov 28, 2007	Mar	CAHN
AP		X GEN PHARMS	50MG/25ML (2MG/ML)	A090075 001	Mar 25, 2010	Mar	NEWA
AP			200MG/100ML (2MG/ML)	A090075 002	Mar 25, 2010	Mar	NEWA

ERYTHROMYCIN

OINTMENT; OPHTHALMIC

ERYTHROMYCIN

AT		AKORN	0.5%	A064030 001	Jul 18, 1996	Apr	CMFD
----	--	-------	------	-------------	--------------	-----	------

SWAB; TOPICAL

ERYTHROMYCIN

>A>	AT	VERSAPHARM	2%	A090215 001	May 12, 2010	May	NEWA
-----	----	------------	----	-------------	--------------	-----	------

ESOMEPRAZOLE MAGNESIUM; NAPROXEN

TABLET, DELAYED RELEASE; ORAL

VIMOVO

POZEN

			EQ 20MG BASE;375MG	N022511 002	Apr 30, 2010	Apr	NEWA
	+		EQ 20MG BASE;500MG	N022511 001	Apr 30, 2010	Apr	NEWA

ESTRADIOL VALERATE

INJECTABLE; INJECTION

ESTRADIOL VALERATE

AO		PHARMAFORCE	20MG/ML	A090920 001	Jan 19, 2010	Jan	NEWA
AO			40MG/ML	A090920 002	Jan 19, 2010	Jan	NEWA

ESTRADIOL; NORETHINDRONE ACETATE

TABLET; ORAL

ESTRADIOL AND NORETHINDRONE ACETATE

>A>	AB	BARR	1MG;0.5MG	A079193 001	May 11, 2010	May	NEWA
-----	----	------	-----------	-------------	--------------	-----	------

ESTROGENS, CONJUGATED SYNTHETIC A

TABLET; ORAL

CENESTIN

TEVA WOMENS

			0.3MG	N020992 001	Jun 21, 2002	Apr	CAHN
			0.45MG	N020992 005	Feb 05, 2004	Apr	CAHN
			0.625MG	N020992 002	Mar 24, 1999	Apr	CAHN
			0.9MG	N020992 003	Mar 24, 1999	Apr	CAHN
	+		1.25MG	N020992 004	Mar 13, 2000	Apr	CAHN

ESTROGENS, CONJUGATED SYNTHETIC B

TABLET; ORAL

ENJUVIA

TEVA WOMENS

			0.3MG	N021443 001	Dec 20, 2004	Apr	CAHN
			0.45MG	N021443 002	Dec 20, 2004	Apr	CAHN
			0.625MG	N021443 003	May 10, 2004	Apr	CAHN
			0.9MG	N021443 005	Apr 27, 2007	Apr	CAHN
	+		1.25MG	N021443 004	May 10, 2004	Apr	CAHN

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET; ORAL-21

NORETHINDRONE AND ETHINYL ESTRADIOL

WATSON LABS 0.035MG;0.4MG A078379 001 Feb 23, 2010 Feb NEWA

TABLET; ORAL-28

NORETHINDRONE AND ETHINYL ESTRADIOL

AB WATSON LABS 0.035MG,0.035MG,0.035MG;0.5MG,0.7 5MG,1MG A076393 001 Feb 04, 2010 Jan NEWA

AB 0.035MG;0.4MG A078323 001 Feb 04, 2010 Jan NEWA

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

TABLET; ORAL

NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE

AB WATSON LABS 0.02MG;1MG A078267 001 Sep 01, 2009 Jan CDFR

TABLET; ORAL-28

NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL

AB WATSON LABS 0.02MG,0.03MG,0.035MG;1MG,1MG,1MG A076629 001 Mar 18, 2010 Mar NEWA

NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE

AB VINTAGE 0.02MG;1MG A077077 001 May 20, 2005 Feb CAHN

AB 0.03MG;1.5MG A077075 001 Apr 28, 2005 Feb CAHN

ETHINYL ESTRADIOL; NORGESTIMATE

TABLET; ORAL-28

PREVIFEM

AB VINTAGE 0.035MG;0.25MG A076334 001 Jan 09, 2004 Feb CAHN

TRI-PREVIFEM

AB VINTAGE 0.035MG,0.035MG,0.035MG;0.18MG,0. 215MG,0.25MG A076335 001 Mar 26, 2004 Feb CAHN

ETHIODIZED OIL

OIL; INTRALYMPHATIC, INTRAUTERINE

ETHIODOL

>A> GUERBET 99% N009190 001 May CAHN

>D> SAVAGE LABS 99% N009190 001 May CAHN

EVEROLIMUS

TABLET; ORAL

ZORTRESS

NOVARTIS 0.25MG N021560 001 Apr 20, 2010 Apr NEWA

0.5MG N021560 002 Apr 20, 2010 Apr NEWA

+ 0.75MG N021560 003 Apr 20, 2010 Apr NEWA

FAMOTIDINE

FOR SUSPENSION; ORAL

FAMOTIDINE

>A> AB NAVINTA LLC 40MG/5ML A091020 001 May 27, 2010 May NEWA

PEPCID

>D> + SALIX PHARMS 40MG/5ML N019527 001 Feb 02, 1987 May CFTG

>A> AB + 40MG/5ML N019527 001 Feb 02, 1987 May CFTG

INJECTABLE; INJECTION

FAMOTIDINE

AP + BAXTER HLTHCARE 10MG/ML A075488 001 Apr 16, 2001 Feb CRLD

AP + 10MG/ML A075799 001 Apr 30, 2002 Feb CRLD

FAMOTIDINE PRESERVATIVE FREE

AP + BAXTER HLTHCARE 10MG/ML A075789 001 Apr 30, 2002 Feb CRLD

INJECTABLE; INJECTION

		FAMOTIDINE PRESERVATIVE FREE							
AP	+	BAXTER HLTHCARE	10MG/ML	A075486	001	Apr 16, 2001	Feb	CRLD	
		FAMOTIDINE PRESERVATIVE FREE IN PLASTIC CONTAINER							
AP	+	BAXTER HLTHCARE	0.4MG/ML	A075591	001	May 10, 2001	Feb	CRLD	
		TABLET, ORALLY DISINTEGRATING; ORAL							
		FLUXID							
		@ SCHWARZ PHARMA	20MG	N021712	001	Sep 24, 2004	Jan	DISC	
		@	40MG	N021712	002	Sep 24, 2004	Jan	DISC	

FENOFIBRATE

CAPSULE; ORAL

ANTARA (MICRONIZED)

		LUPIN ATLANTIS	43MG	N021695	001	Nov 30, 2004	Jan	CAHN	
		@	87MG	N021695	002	Nov 30, 2004	Jan	CAHN	
	+		130MG	N021695	003	Nov 30, 2004	Jan	CAHN	

TABLET; ORAL

FENOGLIDE

		SHIONOGI PHARMA	40MG	N022118	001	Aug 10, 2007	Jan	CAHN	
	+		120MG	N022118	002	Aug 10, 2007	Jan	CAHN	

FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

ALLEGRA D 24 HOUR

AB	+	SANOFI AVENTIS US	180MG;240MG	N021704	001	Oct 19, 2004	Mar	CFTG	
		FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE							
AB		DR REDDYS LABS LTD	180MG;240MG	A079043	001	Mar 17, 2010	Mar	NEWA	

FINASTERIDE

TABLET; ORAL

FINASTERIDE

AB		ACCORD HLTHCARE INC	5MG	A090121	001	Feb 23, 2010	Feb	NEWA	
>A>	AB	HETERO DRUGS LTD	5MG	A090061	001	Jun 07, 2010	May	NEWA	

FLAVOXATE HYDROCHLORIDE

TABLET; ORAL

FLAVOXATE HYDROCHLORIDE

>A>	AB	EPIC PHARMA	100MG	A076835	001	Nov 30, 2005	May	CAHN	
>D>	AB	HAMPTON LAINE LLC	100MG	A076835	001	Nov 30, 2005	May	CAHN	

FLUCONAZOLE

INJECTABLE; INJECTION

FLUCONAZOLE IN SODIUM CHLORIDE 0.9%

		BEDFORD	100MG/50ML (2MG/ML)	A076087	002	Sep 26, 2008	Jan	CTNA	
>A>	AP	CLARIS LIFESCIENCES	200MG/100ML (2MG/ML)	A077947	001	May 26, 2010	May	NEWA	
>A>	AP		400MG/200ML (2MG/ML)	A077947	002	May 26, 2010	May	NEWA	
		FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER							
>A>	AP	CLARIS LIFESCIENCES	200MG/100ML (2MG/ML)	A077909	001	May 26, 2010	May	NEWA	
>A>	AP		400MG/200ML (2MG/ML)	A077909	002	May 26, 2010	May	NEWA	
		@ HOSPIRA	200MG/100ML (2MG/ML)	A076617	001	Jul 29, 2004	Feb	DISC	
		@	400MG/200ML (2MG/ML)	A076617	002	Jul 29, 2004	Feb	DISC	
		FLUCONAZOLE IN DEXTROSE 5% IN PLASTIC CONTAINER							
>A>	AP	CLARIS LIFESCIENCES	200MG/100ML (2MG/ML)	A077988	001	May 26, 2010	May	NEWA	
>A>	AP		400MG/200ML (2MG/ML)	A077988	002	May 26, 2010	May	NEWA	

FLUDEOXYGLUCOSE F-18

INJECTABLE; INTRAVENOUS

FLUDEOXYGLUCOSE F18

>A>	FEINSTEIN	20-300mCi/ML	N021870 002	Nov 21, 2008	May	NEWA
-----	-----------	--------------	-------------	--------------	-----	------

FLUNISOLIDE

AEROSOL, METERED; INHALATION

AEROSPAN HFA

	+ ACTON PHARMS	EQ 78MCG BASE/INH	N021247 001	Jan 27, 2006	Feb	CAHN
--	----------------	-------------------	-------------	--------------	-----	------

SPRAY, METERED; NASAL

NASAREL

AB	+ TEVA BRANDED PHARM	0.029MG/SPRAY	N020409 001	Mar 08, 1995	Feb	CAHN
----	----------------------	---------------	-------------	--------------	-----	------

FLUOROURACIL

CREAM; TOPICAL

FLUOROURACIL

AB	TARO	5%	A090368 001	Mar 05, 2010	Feb	NEWA
----	------	----	-------------	--------------	-----	------

INJECTABLE; INJECTION

FLUOROURACIL

AP	+ BIONICHE PHARMA	500MG/10ML (50MG/ML)	A040743 002	Apr 26, 2007	Mar	CAHN
----	-------------------	----------------------	-------------	--------------	-----	------

AP		1GM/20ML (50MG/ML)	A040743 001	Apr 26, 2007	Mar	CAHN
----	--	--------------------	-------------	--------------	-----	------

AP		2.5GM/50ML (50MG/ML)	A040798 002	Apr 26, 2007	Mar	CAHN
----	--	----------------------	-------------	--------------	-----	------

AP		5GM/100ML (50MG/ML)	A040798 001	Apr 26, 2007	Mar	CAHN
----	--	---------------------	-------------	--------------	-----	------

FLUOXETINE HYDROCHLORIDE

CAPSULE, DELAYED REL PELLETS; ORAL

FLUOXETINE HYDROCHLORIDE

AB	BARR	EQ 90MG BASE	A076237 001	Mar 24, 2010	Mar	NEWA
----	------	--------------	-------------	--------------	-----	------

AB	DR REDDYS LABS LTD	EQ 90MG BASE	A078572 001	Mar 22, 2010	Mar	NEWA
----	--------------------	--------------	-------------	--------------	-----	------

PROZAC WEEKLY

AB	+ LILLY	EQ 90MG BASE	N021235 001	Feb 26, 2001	Mar	CFTG
----	---------	--------------	-------------	--------------	-----	------

SOLUTION; ORAL

FLUOXETINE HYDROCHLORIDE

AA	LANNETT	EQ 20MG BASE/5ML	A076458 001	May 14, 2004	Feb	CAHN
----	---------	------------------	-------------	--------------	-----	------

FOLIC ACID

TABLET; ORAL

FOLIC ACID

AA	+ PHARMAX	1MG	A040625 001	Jul 21, 2005	Jan	CRLD
----	-----------	-----	-------------	--------------	-----	------

>A>	AA	VINTAGE	1MG	A040756 001	Jun 04, 2010	May	NEWA
-----	----	---------	-----	-------------	--------------	-----	------

AA	+ WATSON LABS	1MG	A080680 001		Jan	CMFD
----	---------------	-----	-------------	--	-----	------

FOMEPIZOLE

INJECTABLE; INJECTION

FOMEPIZOLE

AP	BIONICHE PHARMA USA	1.5GM/1.5ML (1GM/ML)	A079033 001	Apr 07, 2009	Mar	CAHN
----	---------------------	----------------------	-------------	--------------	-----	------

FORMOTEROL FUMARATE

SOLUTION; INHALATION

PERFORMIST

	+ DEY PHARMA	0.02MG/2ML	N022007 001	May 11, 2007	Apr	CAHN
--	--------------	------------	-------------	--------------	-----	------

FOSPHENYTOIN SODIUM

INJECTABLE; INJECTION
FOSPHENYTOIN SODIUM

>A>	AP	LUITPOLD	EQ 50MG PHENYTOIN NA/ML	A090099 001	May 13, 2010	May	NEWA
	AP	PHARMAFORCE	EQ 50MG PHENYTOIN NA/ML	A078277 001	Aug 06, 2007	Feb	CAHN
>A>	AP	STRIDES ARCOLAB	EQ 50MG PHENYTOIN NA/ML	A078736 001	Jun 08, 2010	May	NEWA

GABAPENTIN

CAPSULE; ORAL
GABAPENTIN

>D>	AB	SANDOZ	100MG	A075539 001	Apr 06, 2005	May	DISC
>A>		@	100MG	A075539 001	Apr 06, 2005	May	DISC
>D>	AB		300MG	A075539 002	Apr 06, 2005	May	DISC
>A>		@	300MG	A075539 002	Apr 06, 2005	May	DISC
>D>	AB		400MG	A075539 003	Apr 06, 2005	May	DISC
>A>		@	400MG	A075539 003	Apr 06, 2005	May	DISC

TABLET; ORAL
GABAPENTIN

>A>	AB	MATRIX LABS LTD	600MG	A090335 001	Jun 01, 2010	May	NEWA
>A>	AB		800MG	A090335 002	Jun 01, 2010	May	NEWA
>D>	AB	SANDOZ	600MG	A076877 001	Jul 06, 2006	May	DISC
>A>		@	600MG	A076877 001	Jul 06, 2006	May	DISC
>D>	AB		800MG	A076877 002	Jul 06, 2006	May	DISC
>A>		@	800MG	A076877 002	Jul 06, 2006	May	DISC

GADOVERSETAMIDE

INJECTABLE; INJECTION
OPTIMARK IN PLASTIC CONTAINER

	+	MALLINCKRODT	9927MG/30ML (330.9MG/ML)	N020976 001	Dec 08, 1999	Mar	CPOT
--	---	--------------	--------------------------	-------------	--------------	-----	------

GANCICLOVIR SODIUM

INJECTABLE; INJECTION
CYTOVENE

	+	ROCHE PALO	EQ 500MG BASE/VIAL	N019661 001	Jun 23, 1989	Mar	CMFD
		GANCICLOVIR SODIUM					
		@ BEDFORD	EQ 500MG BASE/VIAL	A076222 001	Jul 16, 2003	Mar	DISC

GATIFLOXACIN

SOLUTION/DROPS; OPHTHALMIC

>A>		ZYMAXID					
>A>	+	ALLERGAN	0.5%	N022548 001	May 18, 2010	May	NEWA

GEMFIBROZIL

TABLET; ORAL

GEMFIBROZIL

AB		DAVA PHARMS INC	600MG	A074270 001	Sep 27, 1993	Mar	CMFD
----	--	-----------------	-------	-------------	--------------	-----	------

GEMIFLOXACIN MESYLATE

TABLET; ORAL

FACTIVE

>A>	+	CORNERSTONE THERAP	EQ 320MG BASE	N021158 001	Apr 04, 2003	May	CAHN
>D>	+	OSCIENT	EQ 320MG BASE	N021158 001	Apr 04, 2003	May	CAHN

GLIMEPIRIDE

TABLET; ORAL

GLIMEPIRIDE

AB	WATSON LABS FLORIDA	1MG	A076995 001	Apr 27, 2010	Apr	NEWA
AB		2MG	A076995 002	Apr 27, 2010	Apr	NEWA
AB		4MG	A076995 003	Apr 27, 2010	Apr	NEWA

GLYBURIDE; METFORMIN HYDROCHLORIDE

TABLET; ORAL

GLYBURIDE AND METFORMIN HYDROCHLORIDE

@ TEVA

1.25MG;250MG

A076821 001 Jan 27, 2005 Jan DISC

@

2.5MG;500MG

A076821 002 Jan 27, 2005 Jan DISC

@

5MG;500MG

A076821 003 Jan 27, 2005 Jan DISC

GLYCOPYRROLATE

TABLET; ORAL

ROBINUL

AA	+ SHIONOGI PHARMA	1MG	N012827 001		Jan	CAHN
----	-------------------	-----	-------------	--	-----	------

ROBINUL FORTE

AA	+ SHIONOGI PHARMA	2MG	N012827 002		Jan	CAHN
----	-------------------	-----	-------------	--	-----	------

GRANISETRON HYDROCHLORIDE

INJECTABLE; INJECTION

GRANISETRON HYDROCHLORIDE

AP	SAGENT STRIDES	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	A091136 001	Apr 09, 2010	Mar	NEWA
----	----------------	-------------------------------------	-------------	--------------	-----	------

AP		EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A091136 002	Apr 09, 2010	Mar	NEWA
----	--	---------------------------------	-------------	--------------	-----	------

AP		EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A091137 002	Apr 09, 2010	Mar	NEWA
----	--	----------------------------------	-------------	--------------	-----	------

TABLET; ORAL

GRANISETRON HYDROCHLORIDE

>D>	AB	BARR	EQ 1MG BASE	A078221 001	Dec 31, 2007	May DISC
-----	----	------	-------------	-------------	--------------	----------

>A>		@	EQ 1MG BASE	A078221 001	Dec 31, 2007	May DISC
-----	--	---	-------------	-------------	--------------	----------

>A>	AB	TARO	EQ 1MG BASE	A090817 001	May 28, 2010	May NEWA
-----	----	------	-------------	-------------	--------------	----------

GRISEOFULVIN, MICROCRYSTALLINE

TABLET; ORAL

FULVICIN-U/F

@ ELORAC

250MG

A060569 002 Feb CAHN

@

500MG

A060569 001 Feb CAHN

GUANFACINE HYDROCHLORIDE

TABLET; ORAL

GUANFACINE HYDROCHLORIDE

AB	MIKAH PHARMA	EQ 1MG BASE	A074673 001	Feb 28, 1997	Feb	CAHN
----	--------------	-------------	-------------	--------------	-----	------

AB		EQ 2MG BASE	A074673 002	Feb 28, 1997	Feb	CAHN
----	--	-------------	-------------	--------------	-----	------

HALCINONIDE

SOLUTION; TOPICAL

HALOG

>D>		RANBAXY	0.1%	N017823 001		May DISC
-----	--	---------	------	-------------	--	----------

>A>		@	0.1%	N017823 001		May DISC
-----	--	---	------	-------------	--	----------

HALOPERIDOL LACTATE

INJECTABLE; INJECTION

HALDOL

@ ORTHO MCNEIL JANSSEN EQ 5MG BASE/ML

N015923 001

Feb DISC

HALOPERIDOL

AP + TEVA PARENTERAL EQ 5MG BASE/ML

A076035 001 Aug 29, 2001 Feb CRLD

HEPARIN SODIUM

INJECTABLE; INJECTION

>D> HEPARIN SODIUM PRESERVATIVE FREE

>D> + HOSPIRA 2,000 UNITS/ML

N005264 013 Apr 07, 1986 May DISC

>A> @ 2,000 UNITS/ML

N005264 013 Apr 07, 1986 May DISC

>D> + 2,500 UNITS/ML

N005264 014 Apr 07, 1986 May DISC

>A> @ 2,500 UNITS/ML

N005264 014 Apr 07, 1986 May DISC

>A> HEXAMINOLEVULINATE HYDROCHLORIDE

>A> FOR SOLUTION; INTRAVESICAL

>A> CYSVIEW KIT

>A> + PHOTOCURE ASA 100MG/VIAL

N022555 001 May 28, 2010 May NEWA

HYDRALAZINE HYDROCHLORIDE

TABLET; ORAL

HYDRALAZINE HYDROCHLORIDE

AA HERITAGE PHARMS INC 10MG

A086242 001 Feb 04, 2010 Jan NEWA

AA 100MG

A086242 004 Feb 04, 2010 Jan NEWA

AA ZYDUS PHARMS USA 10MG

A040858 001 Feb 26, 2010 Feb NEWA

AA 25MG

A040858 002 Feb 26, 2010 Feb NEWA

AA 50MG

A040858 003 Feb 26, 2010 Feb NEWA

AA 100MG

A040858 004 Feb 26, 2010 Feb NEWA

HYDROCHLOROTHIAZIDE

CAPSULE; ORAL

HYDROCHLOROTHIAZIDE

AB UNICHEM 12.5MG

A090510 001 Jan 19, 2010 Jan NEWA

HYDROCHLOROTHIAZIDE; LISINAPRIL

TABLET; ORAL

LISINAPRIL AND HYDROCHLOROTHIAZIDE

@ TEVA 12.5MG;10MG

A075869 001 Jul 01, 2002 Jan DISC

@ 12.5MG;20MG

A075869 002 Jul 01, 2002 Jan DISC

@ 25MG;20MG

A075869 003 Jul 01, 2002 Jan DISC

HYDROCHLOROTHIAZIDE; LOSARTAN POTASSIUM

TABLET; ORAL

HYZAAR

AB MERCK 12.5MG;50MG

N020387 001 Apr 28, 1995 Mar CFTG

AB 12.5MG;100MG

N020387 003 Oct 20, 2005 Mar CFTG

AB + 25MG;100MG

N020387 002 Nov 10, 1998 Mar CFTG

LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE

>A> AB LUPIN LTD 12.5MG;100MG

A078245 002 May 21, 2010 May NEWA

AB MYLAN 12.5MG;100MG

A091652 002 Apr 06, 2010 Mar NEWA

AB ROXANE 12.5MG;100MG

A077732 001 Apr 06, 2010 Mar NEWA

AB TEVA PHARMS 12.5MG;50MG

A077157 001 Apr 06, 2010 Mar NEWA

AB 12.5MG;100MG

A077157 002 Apr 06, 2010 Mar NEWA

AB 25MG;100MG

A077157 003 Apr 06, 2010 Mar NEWA

TABLET; ORAL

LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE

AB	TORRENT PHARMS	12.5MG;100MG	A090528 003	Apr 06, 2010	Mar	NEWA
----	----------------	--------------	-------------	--------------	-----	------

HYDROCHLOROTHIAZIDE; METOPROLOL TARTRATE

TABLET; ORAL

METOPROLOL TARTRATE AND HYDROCHLOROTHIAZIDE

AB	MYLAN	25MG;100MG	A076792 002	Aug 20, 2004	Apr	CRLD
AB	+	25MG;100MG	A076792 002	Aug 20, 2004	Jan	CRLD
		50MG;100MG	A076792 003	Aug 20, 2004	Jan	CTEC

HYDROCHLOROTHIAZIDE; MOEXIPRIL HYDROCHLORIDE

TABLET; ORAL

MOEXIPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

AB	GLENMARK PHARMS	12.5MG;7.5MG	A090718 001	Mar 17, 2010	Mar	NEWA
AB		12.5MG;15MG	A090718 002	Mar 17, 2010	Mar	NEWA
AB		25MG;15MG	A090718 003	Mar 17, 2010	Mar	NEWA

HYDROCORTISONE

CREAM; TOPICAL

HYDROCORTISONE

AT	+	FOUGERA	1%	A080693 003		Feb	CRLD
AT	+		2.5%	A089414 001	Dec 16, 1986	Feb	CRLD
		HYTONE					
		@ SANOFI AVENTIS US	1%	A080472 003		Feb	DISC
		@	2.5%	A080472 004		Feb	DISC

LOTION; TOPICAL

HYTONE

@ SANOFI AVENTIS US

@

			1%	A080473 003		Feb	DISC
			2.5%	A080473 004	Nov 30, 1982	Feb	DISC

HYDROMORPHONE HYDROCHLORIDE

INJECTABLE; INJECTION

HYDROMORPHONE HYDROCHLORIDE

AP	AKORN	10MG/ML	A078228 001	Apr 14, 2010	Apr	NEWA
AP		10MG/ML	A078261 001	Apr 14, 2010	Mar	NEWA
AP		10MG/ML	A078228 001	Apr 14, 2010	Mar	NEWA

TABLET, EXTENDED RELEASE; ORAL

EXALGO

MALLINCKRODT INC

		8MG	N021217 001	Mar 01, 2010	Mar	NEWA
		12MG	N021217 002	Mar 01, 2010	Mar	NEWA
	+	16MG	N021217 003	Mar 01, 2010	Mar	NEWA

HYDROXYZINE HYDROCHLORIDE

TABLET; ORAL

HYDROXYZINE HYDROCHLORIDE

>D>	AB	ANDAPHARM	10MG	A040804 001	Jun 30, 2008	May	CAHN
>D>	AB		25MG	A040804 002	Jun 30, 2008	May	CAHN
>D>	AB		50MG	A040804 003	Jun 30, 2008	May	CAHN
>A>	AB	HERITAGE PHARMS INC	10MG	A040804 001	Jun 30, 2008	May	CAHN
>A>	AB		25MG	A040804 002	Jun 30, 2008	May	CAHN
>A>	AB		50MG	A040804 003	Jun 30, 2008	May	CAHN
>A>	AB	MYLAN	10MG	A091176 001	Jun 07, 2010	May	NEWA
>A>	AB		25MG	A091176 002	Jun 07, 2010	May	NEWA
>A>	AB		50MG	A091176 003	Jun 07, 2010	May	NEWA

HYDROXYZINE PAMOATE

CAPSULE; ORAL

HYDROXYZINE PAMOATE

@	IVAX SUB TEVA PHARMS	EQ 25MG HCL	A087761	001	Mar 05, 1982	Apr	DISC
@		EQ 50MG HCL	A087760	001	Mar 05, 1982	Apr	DISC

IBUPROFEN

TABLET; ORAL

IBUPROFEN

AB	CONTRACT PHARMACAL	400MG	A071267	001	Oct 15, 1986	Jan	CAHN
AB		600MG	A071268	001	Oct 15, 1986	Jan	CAHN
AB		800MG	A072300	001	Jul 01, 1988	Jan	CAHN

IBUTILIDE FUMARATE

INJECTABLE; INJECTION

IBUTILIDE FUMARATE

AP	BIONICHE PHARMA USA	0.1MG/ML	A090924	001	Jan 11, 2010	Mar	CAHN
----	---------------------	----------	---------	-----	--------------	-----	------

IFOSFAMIDE

INJECTABLE; INJECTION

IFEX

AP	BAXTER HLTHCARE	1GM/VIAL	N019763	001	Dec 30, 1988	Feb	CMFD
AP		3GM/VIAL	N019763	002	Dec 30, 1988	Feb	CMFD

IFOSFAMIDE

AP	+	APP PHARMS	1GM/VIAL	A076078	001	May 28, 2002	Feb	CTEC
AP	+		1GM/VIAL	A076078	001	May 28, 2002	Feb	CTEC
	+		1GM/VIAL	A076078	001	May 28, 2002	Jan	CTEC
	+		1GM/VIAL	A076078	001	May 28, 2002	Jan	CTEC
AP			1GM/20ML (50MG/ML)	A090181	001	Sep 22, 2009	Jan	CPOT
AP	+		3GM/VIAL	A076078	002	May 28, 2002	Feb	CTEC
AP	+		3GM/VIAL	A076078	002	May 28, 2002	Feb	CTEC
	+		3GM/VIAL	A076078	002	May 28, 2002	Jan	CTEC
	+		3GM/VIAL	A076078	002	May 28, 2002	Jan	CTEC
AP			3GM/60ML (50MG/ML)	A090181	002	Sep 22, 2009	Jan	CPOT
AP	+	TEVA PARENTERAL	1GM/20ML (50MG/ML)	A076657	001	Apr 04, 2007	Jan	CTEC
AP	+		3GM/60ML (50MG/ML)	A076657	002	Apr 04, 2007	Jan	CTEC

IFOSFAMIDE; MESNA

INJECTABLE; INJECTION

IFEX/MESNEX KIT

@	BAXTER HLTHCARE	1GM/VIAL;100MG/ML	N019763	003	Oct 10, 1992	Feb	DISC
@		3GM/VIAL;100MG/ML	N019763	004	Oct 10, 1992	Feb	DISC

IMIPRAMINE HYDROCHLORIDE

TABLET; ORAL

IMIPRAMINE HYDROCHLORIDE

AB	LUPIN LTD	10MG	A090443	001	Mar 11, 2010	Feb	NEWA
AB		25MG	A090442	001	Mar 11, 2010	Feb	NEWA
AB		50MG	A090441	001	Mar 11, 2010	Feb	NEWA

IMIPRAMINE PAMOATE

CAPSULE; ORAL

IMIPRAMINE PAMOATE

AB	LUPIN LTD	EQ 75MG HCL	A090444	001	Apr 16, 2010	Apr	NEWA
AB		EQ 100MG HCL	A090444	002	Apr 16, 2010	Apr	NEWA

CAPSULE; ORALIMIPRAMINE PAMOATE

AB	LUPIN LTD	EQ 125MG HCL	A090444 003	Apr 16, 2010	Apr	NEWA
AB		EQ 150MG HCL	A090444 004	Apr 16, 2010	Apr	NEWA
AB	ROXANE	EQ 75MG HCL	A091099 001	Apr 16, 2010	Apr	NEWA
AB		EQ 100MG HCL	A091099 002	Apr 16, 2010	Apr	NEWA
AB		EQ 125MG HCL	A091099 003	Apr 16, 2010	Apr	NEWA
AB		EQ 150MG HCL	A091099 004	Apr 16, 2010	Apr	NEWA
<u>TOFRANIL-PM</u>						
AB	+ TYCO HLTHCARE	EQ 75MG HCL	N017090 001		Apr	CFTG
AB		EQ 100MG HCL	N017090 004		Apr	CFTG
AB		EQ 125MG HCL	N017090 003		Apr	CFTG
AB		EQ 150MG HCL	N017090 002		Apr	CFTG

IMIQUIMODCREAM; TOPICALALDARA

AB	+ GRACEWAY	5%	N020723 001	Feb 27, 1997	Feb	CFTG
<u>IMIQUIMOD</u>						
AB	NYCOMED US	5%	A078548 001	Feb 25, 2010	Feb	NEWA
<u>ZYCLARA</u>						
	+ GRACEWAY	3.75%	N022483 001	Mar 25, 2010	Mar	NEWA

INAMRINONE LACTATEINJECTABLE; INJECTIONAMRINONE LACTATE

	@ BAXTER HLTHCARE CORP	EQ 5MG BASE/ML	A075542 001	May 10, 2000	Feb	DISC
	+ BEDFORD	EQ 5MG BASE/ML	A075513 001	May 09, 2000	Feb	CTEC

INDOMETHACININJECTABLE; INJECTIONINDOMETHACIN

	+ APP PHARMS	EQ 1MG BASE/VIAL	N022536 001	Mar 17, 2010	Mar	NEWA
--	--------------	------------------	-------------	--------------	-----	------

IOVERSOLINJECTABLE; INJECTION

>D>	OPTIRAY 160					
>D>	+ MALLINCKRODT	34%	N019710 003	Dec 30, 1988	May	DISC
>A>	@	34%	N019710 003	Dec 30, 1988	May	DISC

IRINOTECAN HYDROCHLORIDEINJECTABLE; INJECTIONIRINOTECAN HYDROCHLORIDE

AP	DR REDDYS LABS LTD	40MG/2ML (20MG/ML)	A078953 001	Apr 15, 2010	Apr	NEWA
AP		100MG/5ML (20MG/ML)	A078953 002	Apr 15, 2010	Apr	NEWA
	@ SANDOZ	40MG/2ML (20MG/ML)	A077994 001	Feb 27, 2008	Mar	DISC
	@	100MG/5ML (20MG/ML)	A077994 002	Feb 27, 2008	Mar	DISC

ISOSORBIDE DINITRATETABLET, EXTENDED RELEASE; ORALISOSORBIDE DINITRATE

AB	+ CARACO	40MG	A040009 001	Dec 30, 1998	Mar	CAHN
----	----------	------	-------------	--------------	-----	------

ITRACONAZOLE

TABLET; ORAL

ITRACONAZOLE

	+	STIEFEL LABS INC	200MG		N022484 001	Apr 29, 2010	Apr	NEWA
--	---	------------------	-------	--	-------------	--------------	-----	------

KETOROLAC TROMETHAMINE

>A> SPRAY, METERED; NASAL

>A> SPRIX

>A>	+	ROXRO PHARMA INC	15.75MG/SPRAY		N022382 001	May 14, 2010	May	NEWA
-----	---	------------------	---------------	--	-------------	--------------	-----	------

LABETALOL HYDROCHLORIDE

INJECTABLE; INJECTION

LABETALOL HYDROCHLORIDE

AP		SAGENT STRIDES	5MG/ML		A079134 001	Feb 03, 2010	Jan	NEWA
----	--	----------------	--------	--	-------------	--------------	-----	------

TABLET; ORAL

TRANDATE

AB	+	PROMETHEUS LABS	200MG		N018716 002	Aug 01, 1984	Feb	CRLD
----	---	-----------------	-------	--	-------------	--------------	-----	------

@ 300MG

					N018716 003	Aug 01, 1984	Apr	DISC
--	--	--	--	--	-------------	--------------	-----	------

AB			300MG		N018716 003	Aug 01, 1984	Feb	CRLD
----	--	--	-------	--	-------------	--------------	-----	------

LACOSAMIDE

SOLUTION; ORAL

VIMPAT

	+	SCHWARZ BIOSCIENCES	10MG/ML		N022255 001	Apr 20, 2010	Apr	NEWA
--	---	---------------------	---------	--	-------------	--------------	-----	------

LAMOTRIGINE

TABLET; ORAL

LAMOTRIGINE

>A>	AB	LUPIN LTD	25MG		A078691 001	Jun 01, 2010	May	NEWA
-----	----	-----------	------	--	-------------	--------------	-----	------

>A>	AB		100MG		A078691 002	Jun 01, 2010	May	NEWA
-----	----	--	-------	--	-------------	--------------	-----	------

>A>	AB		150MG		A078691 003	Jun 01, 2010	May	NEWA
-----	----	--	-------	--	-------------	--------------	-----	------

>A>	AB		200MG		A078691 004	Jun 01, 2010	May	NEWA
-----	----	--	-------	--	-------------	--------------	-----	------

TABLET, EXTENDED RELEASE; ORAL

LAMICTAL XR

SMITHKLINE BEECHAM 300MG

					N022115 005	Apr 14, 2010	Apr	NEWA
--	--	--	--	--	-------------	--------------	-----	------

LANSOPRAZOLE

CAPSULE, DELAYED RELEASE; ORAL

LANSOPRAZOLE

AB		SANDOZ	15MG		A090331 001	Apr 23, 2010	Apr	NEWA
----	--	--------	------	--	-------------	--------------	-----	------

AB			30MG		A090331 002	Apr 23, 2010	Apr	NEWA
----	--	--	------	--	-------------	--------------	-----	------

LENALIDOMIDE

CAPSULE; ORAL

REVLIMID

	+	CELGENE	5MG		N021880 001	Dec 27, 2005	Jan	CRLD
--	---	---------	-----	--	-------------	--------------	-----	------

>D>			15MG		N021880 003	Jun 29, 2006	May	CRLD
-----	--	--	------	--	-------------	--------------	-----	------

>A>	+		15MG		N021880 003	Jun 29, 2006	May	CRLD
-----	---	--	------	--	-------------	--------------	-----	------

LEUPROLIDE ACETATE

INJECTABLE; INJECTION

LEUPROLIDE ACETATE

AP		OAKWOOD LABS	1MG/0.2ML		A074728 001	Aug 04, 1998	Apr	CAHN
----	--	--------------	-----------	--	-------------	--------------	-----	------

LEVETIRACETAM

INJECTABLE; IV (INFUSION)

KEPPRA

>D>	+	UCB INC	500MG/5ML (100MG/ML)	N021872 001	Jul 31, 2006	May	CFTG
>A>	AP	+	500MG/5ML (100MG/ML)	N021872 001	Jul 31, 2006	May	CFTG
<u>LEVETIRACETAM</u>							
>A>	AP	NEXUS PHARMS	500MG/5ML (100MG/ML)	A090813 001	May 26, 2010	May	NEWA
>A>	AP	SUN PHARM INDS LTD	500MG/5ML (100MG/ML)	A090754 001	Jun 16, 2010	May	NEWA

SOLUTION; ORAL

LEVETIRACETAM

AA		WOCKHARDT	100MG/ML	A090028 001	Mar 03, 2010	Feb	NEWA
----	--	-----------	----------	-------------	--------------	-----	------

TABLET; ORAL

LEVETIRACETAM

AB		TARO	250MG	A078960 004	Feb 01, 2010	Jan	NEWA
AB			500MG	A078960 003	Feb 01, 2010	Jan	NEWA
AB			750MG	A078960 002	Feb 01, 2010	Jan	NEWA
AB			1GM	A078960 001	Feb 01, 2010	Jan	NEWA

LEVONORGESTREL

TABLET; ORAL

LEVONORGESTREL

AB	+	WATSON LABS	0.75MG	A078665 001	Aug 28, 2009	Apr	CRLD
----	---	-------------	--------	-------------	--------------	-----	------

LEVOTHYROXINE SODIUM

CAPSULE; ORAL

TIROSINT

INST BIOCHIMIQUE

		0.013MG	N022121 001	Aug 01, 2007	Feb	CMFD
		0.025MG	N021924 002	Oct 13, 2006	Feb	CMFD
		0.05MG	N021924 003	Oct 13, 2006	Feb	CMFD
		0.075MG	N021924 004	Oct 13, 2006	Feb	CMFD
		0.088MG	N021924 010	Oct 02, 2009	Feb	NEWA
		0.1MG	N021924 005	Oct 13, 2006	Feb	CMFD
		0.112MG	N021924 008	Oct 02, 2009	Feb	NEWA
		0.125MG	N021924 006	Oct 13, 2006	Feb	CMFD
		0.137MG	N021924 009	Oct 02, 2009	Feb	NEWA
		0.15MG	N021924 007	Oct 13, 2006	Feb	CMFD

LIDOCAINE; PRILOCAINE

CREAM; TOPICAL

LIDOCAINE AND PRILOCAINE

AB		NYCOMED US	2.5%;2.5%	A076453 001	Aug 18, 2003	Mar	CAHN
----	--	------------	-----------	-------------	--------------	-----	------

LIRAGLUTIDE RECOMBINANT

SOLUTION; SUBCUTANEOUS

VICTOZA

+		NOVO NORDISK INC	18MG/3ML (6MG/ML)	N022341 001	Jan 25, 2010	Jan	NEWA
---	--	------------------	-------------------	-------------	--------------	-----	------

LISINAPRIL

TABLET; ORAL

LISINAPRIL

@ TEVA

		2.5MG	A075783 001	Jul 01, 2002	Jan	DISC
	@	5MG	A075783 002	Jul 01, 2002	Jan	DISC
	@	10MG	A075783 003	Jul 01, 2002	Jan	DISC
	@	20MG	A075783 004	Jul 01, 2002	Jan	DISC
	@	30MG	A075783 005	Jul 01, 2002	Jan	DISC

TABLET; ORAL
LISINOPRIL
@ TEVA

40MG

A075783 006 Jul 01, 2002 Jan DISC

LITHIUM CARBONATE

CAPSULE; ORAL
ESKALITH
@ NOVEN THERAP

300MG

N016860 001 Jan DISC

LORAZEPAM

CONCENTRATE; ORAL
LORAZEPAM

>A> AA

PHARM ASSOC

2MG/ML

A090260 001 Jun 15, 2010 May NEWA

LOSARTAN POTASSIUM

TABLET; ORAL
COZAAR

AB

MERCCK

25MG

N020386 001 Apr 14, 1995 Mar CFTG

AB

50MG

N020386 002 Apr 14, 1995 Mar CFTG

AB

+

100MG

N020386 003 Oct 13, 1998 Mar CFTG

LOSARTAN POTASSIUM

AB

TEVA

25MG

A076958 001 Apr 06, 2010 Mar NEWA

AB

50MG

A076958 002 Apr 06, 2010 Mar NEWA

AB

100MG

A076958 003 Apr 06, 2010 Mar NEWA

MECLIZINE HYDROCHLORIDE

TABLET; ORAL
ANTIVERT

AA

+

PFIZER

50MG

N010721 001 Jan 20, 1982 Jan CMFD

MECLIZINE HYDROCHLORIDE

>A> AA

CADISTA PHARMS

12.5MG

A040659 001 Jun 04, 2010 May NEWA

>A> AA

25MG

A040659 002 Jun 04, 2010 May NEWA

TABLET, CHEWABLE; ORAL

ANTIVERT

@ PFIZER

25MG

N010721 005 Jan DISC

MEFLOQUINE HYDROCHLORIDE

TABLET; ORAL
MEFLOQUINE HYDROCHLORIDE

AB

WEST WARD

250MG

A077699 001 Apr 21, 2010 Apr NEWA

MELPHALAN HYDROCHLORIDE

INJECTABLE; INJECTION
MELPHALAN HYDROCHLORIDE

AP

BIONICHE PHARMA USA

EQ 50MG BASE/VIAL

A090299 001 Oct 27, 2009 Mar CAHN

MEMANTINE HYDROCHLORIDE

TABLET; ORAL
MEMANTINE

@ SUN PHARM INDS (IN)

5MG

A090058 001 May 05, 2010 Apr DISC

@

10MG

A090058 002 May 05, 2010 Apr DISC

MEMANTINE HYDROCHLORIDE

@ DR REDDYS LABS LTD

5MG

A090048 001 Apr 14, 2010 Apr DISC

AB

5MG

A090048 001 Apr 14, 2010 Mar NEWA

@

10MG

A090048 002 Apr 14, 2010 Apr DISC

AB

10MG

A090048 002 Apr 14, 2010 Mar NEWA

TABLET; ORAL

METFORMIN HYDROCHLORIDE

	@ IPCA LABS LTD	1GM	A078422 003	Aug 06, 2007	Mar	DISC
	@ IVAX SUB TEVA PHARMS	500MG	A075975 001	Jan 24, 2002	Apr	DISC
		625MG	A075972 005	Jan 24, 2002	Apr	CTEC
	@	625MG	A075975 004	Jan 24, 2002	Apr	DISC
		750MG	A075972 004	Jan 24, 2002	Apr	CTEC
	@	750MG	A075975 005	Jan 24, 2002	Apr	DISC
	@	850MG	A075975 002	Jan 24, 2002	Apr	DISC
	@	1GM	A075975 003	Jan 24, 2002	Apr	DISC

TABLET, EXTENDED RELEASE; ORAL

METFORMIN HYDROCHLORIDE

	@ IVAX SUB TEVA PHARMS	500MG	A076545 001	Dec 01, 2003	Apr	DISC
AB	TORRENT PHARMS	750MG	A079226 001	Feb 18, 2010	Jan	NEWA

METHADONE HYDROCHLORIDE

INJECTABLE; INJECTION

DOLOPHINE HYDROCHLORIDE

	+ BIONICHE PHARMA	10MG/ML	N021624 001		Mar	CAHN
--	-------------------	---------	-------------	--	-----	------

METHAMPHETAMINE HYDROCHLORIDE

TABLET; ORAL

DESOXYN

AA	+ LUNDBECK INC	5MG	N005378 002		Apr	CTEC
----	----------------	-----	-------------	--	-----	------

METHAMPHETAMINE HYDROCHLORIDE

AA	COASTAL PHARMS	5MG	A091189 001	Apr 21, 2010	Apr	NEWA
----	----------------	-----	-------------	--------------	-----	------

METHENAMINE HIPPURATE

TABLET; ORAL

UREX

AB	CNTY LINE PHARMS	1GM	N016151 001		Feb	CAHN
----	------------------	-----	-------------	--	-----	------

METHOTREXATE SODIUM

INJECTABLE; INJECTION

METHOTREXATE SODIUM PRESERVATIVE FREE

AP	+ BIONICHE PHARMA	EQ 50MG BASE/2ML (EQ 25MG BASE/ML)	A040767 001	Apr 30, 2007	Mar	CAHN
----	-------------------	------------------------------------	-------------	--------------	-----	------

AP	+ BIONICHE PHARMA USA	EQ 250MG BASE/10ML (EQ 25MG BASE/ML)	A040768 001	Apr 30, 2007	Mar	CAHN
----	-----------------------	--------------------------------------	-------------	--------------	-----	------

AP	+	EQ 1GM BASE/40ML (EQ 25MG BASE/ML)	A040716 001	Apr 30, 2007	Mar	CAHN
----	---	------------------------------------	-------------	--------------	-----	------

METOCLOPRAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION

METOCLOPRAMIDE HYDROCHLORIDE

	@ HOSPIRA	EQ 5MG BASE/ML	A074147 001	Aug 02, 1996	Feb	DISC
--	-----------	----------------	-------------	--------------	-----	------

TABLET; ORAL

METOCLOPRAMIDE HYDROCHLORIDE

>D>	@ AMNEAL PHARMS NY	EQ 10MG BASE	A071213 001	Sep 24, 1986	May	CAHN
-----	--------------------	--------------	-------------	--------------	-----	------

>A>	@ INTERPHARM	EQ 10MG BASE	A071213 001	Sep 24, 1986	May	CAHN
-----	--------------	--------------	-------------	--------------	-----	------

	@ SANDOZ	EQ 10MG BASE	A074478 002	Oct 05, 1995	Jan	DISC
--	----------	--------------	-------------	--------------	-----	------

	@ WATSON LABS	EQ 10MG BASE	A070511 001	Jan 22, 1986	Jan	DISC
--	---------------	--------------	-------------	--------------	-----	------

METOPROLOL SUCCINATE

TABLET, EXTENDED RELEASE; ORAL

METOPROLOL SUCCINATE

AB	WATSON LABS FLORIDA	EQ 100MG TARTRATE	A077298 001	Apr 15, 2010	Apr	NEWA
----	---------------------	-------------------	-------------	--------------	-----	------

TABLET, EXTENDED RELEASE; ORAL

METOPROLOL SUCCINATE

AB	WATSON LABS FLORIDA	EQ 200MG TARTRATE	A077298 002	Apr 15, 2010	Apr	NEWA
----	---------------------	-------------------	-------------	--------------	-----	------

METOPROLOL TARTRATE

INJECTABLE; INJECTION

METOPROLOL TARTRATE

AP	SAGENT STRIDES	1MG/ML	A090317 001	Apr 19, 2010	Apr	NEWA
----	----------------	--------	-------------	--------------	-----	------

METRONIDAZOLE

TABLET; ORAL

METRONIDAZOLE

	@	IVAX SUB TEVA PHARMS	250MG	N018517 001		Apr	DISC
	@		500MG	N018517 002	May 05, 1982	Apr	DISC
>D>	@	PAR PHARM	500MG	A070039 001	Jan 29, 1985	May	CAHN
	@	WORLD GEN	250MG	A070040 001	Jan 29, 1985	Mar	CAHN
>A>	@		500MG	A070039 001	Jan 29, 1985	May	CAHN

TABLET, EXTENDED RELEASE; ORAL

FLAGYL ER

AB	+	GD SEARLE LLC	750MG	N020868 001	Nov 26, 1997	Apr	CFTG
----	---	---------------	-------	-------------	--------------	-----	------

METRONIDAZOLE

AB		ALEMBIC LTD	750MG	A090222 001	May 05, 2010	Apr	NEWA
----	--	-------------	-------	-------------	--------------	-----	------

MICONAZOLE

TABLET; BUCCAL

ORAVIG

	+	BIOALLIANCE PHARMA	50MG	N022404 001	Apr 16, 2010	Apr	NEWA
--	---	--------------------	------	-------------	--------------	-----	------

MILRINONE LACTATE

INJECTABLE; INJECTION

MILRINONE LACTATE IN DEXTROSE 5% IN PLASTIC CONTAINER

AP	+	BAXTER HLTHCARE	EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)	A075834 001	May 28, 2002	Feb	CTEC
----	---	-----------------	---------------------------------------	-------------	--------------	-----	------

AP	+		EQ 40MG BASE/200ML (EQ 0.2MG BASE/ML)	A075834 002	May 28, 2002	Feb	CRLD
----	---	--	---------------------------------------	-------------	--------------	-----	------

MILRINONE LACTATE IN PLASTIC CONTAINER

AP		HIKMA FARMACEUTICA	EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)	A090038 001	Jan 21, 2010	Jan	NEWA
----	--	--------------------	---------------------------------------	-------------	--------------	-----	------

AP			EQ 40MG BASE/200ML (EQ 0.2MG BASE/ML)	A090038 002	Jan 21, 2010	Jan	NEWA
----	--	--	---------------------------------------	-------------	--------------	-----	------

PRIMACOR IN DEXTROSE 5% IN PLASTIC CONTAINER

	@	SANOFI AVENTIS US	EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)	N020343 003	Aug 09, 1994	Feb	DISC
--	---	-------------------	---------------------------------------	-------------	--------------	-----	------

	@		EQ 40MG BASE/200ML (EQ 0.2MG BASE/ML)	N020343 004	Aug 09, 1994	Feb	DISC
--	---	--	---------------------------------------	-------------	--------------	-----	------

MITOXANTRONE HYDROCHLORIDE

INJECTABLE; INJECTION

MITOXANTRONE HYDROCHLORIDE

AP		BIONICHE PHARMA USA	EQ 20MG BASE/10ML (EQ 2MG BASE/ML)	A078980 001	Apr 13, 2009	Mar	CAHN
----	--	---------------------	------------------------------------	-------------	--------------	-----	------

AP			EQ 30MG BASE/15ML (EQ 2MG BASE/ML)	A078980 002	Apr 13, 2009	Mar	CAHN
----	--	--	------------------------------------	-------------	--------------	-----	------

MIVACURIUM CHLORIDE

INJECTABLE; INJECTION

MIVACURIUM CHLORIDE

>D>	+	EBEWE PARENTA	EQ 2MG BASE/ML	A078562 001	Apr 30, 2009	May	CAHN
-----	---	---------------	----------------	-------------	--------------	-----	------

>A>	+	PISGAH LABS	EQ 2MG BASE/ML	A078562 001	Apr 30, 2009	May	CAHN
-----	---	-------------	----------------	-------------	--------------	-----	------

MOEXIPRIL HYDROCHLORIDE

TABLET; ORAL

MOEXIPRIL HYDROCHLORIDE

AB	GLENMARK GENERICS	7.5MG	A090416 001	Mar 30, 2010	Mar	NEWA
AB		15MG	A090416 002	Mar 30, 2010	Mar	NEWA

>D> MOLINDONE HYDROCHLORIDE

>D> TABLET; ORAL

>D> MOBAN

>D>	ENDO PHARMS	5MG	N017111 004		May	DISC
>A>	@	5MG	N017111 004		May	DISC
>D>		10MG	N017111 005		May	DISC
>A>	@	10MG	N017111 005		May	DISC
>D>	+	25MG	N017111 006		May	DISC
>A>	@	25MG	N017111 006		May	DISC
>D>	+	50MG	N017111 007		May	DISC
>A>	@	50MG	N017111 007		May	DISC

MORPHINE SULFATE

SOLUTION; ORAL

MORPHINE SULFATE

ROXANE

		20MG/5ML	N022195 002	Mar 17, 2008	Jan	CRLD
+		100MG/5ML	N022195 003	Jan 25, 2010	Jan	NEWA

TABLET, EXTENDED RELEASE; ORAL

MORPHINE SULFATE

@ PURDUE PHARMA LP

@

@

@

@

		15MG	A074862 001	Jul 07, 1998	Feb	CAHN
		30MG	A074862 002	Jul 07, 1998	Feb	CAHN
		60MG	A074862 003	Jul 07, 1998	Feb	CAHN
		100MG	A074769 001	Jul 02, 1998	Feb	CAHN
		200MG	A074769 002	Jul 02, 1998	Feb	CAHN

MYCOPHENOLATE MOFETIL

CAPSULE; ORAL

MYCOPHENOLATE MOFETIL

>A>	AB	STRIDES ARCOLAB LTD	250MG	A090055 001	Jun 10, 2010	May	NEWA
-----	----	---------------------	-------	-------------	--------------	-----	------

TABLET; ORAL

MYCOPHENOLATE MOFETIL

>A>	AB	STRIDES ARCOLAB LTD	500MG	A090456 001	Jun 10, 2010	May	NEWA
-----	----	---------------------	-------	-------------	--------------	-----	------

NALIDIXIC ACID

TABLET; ORAL

NEGGRAM

@ SANOFI AVENTIS US

@

@

		250MG	N014214 002		Feb	DISC
		500MG	N014214 004		Feb	DISC
		1GM	N014214 005		Feb	DISC

NALOXONE HYDROCHLORIDE; PENTAZOCINE HYDROCHLORIDE

TABLET; ORAL

PENTAZOCINE AND NALOXONE HYDROCHLORIDES

AB	+	WATSON LABS	EQ 0.5MG BASE;EQ 50MG BASE	A074736 001	Jan 21, 1997	Feb	CRLD
----	---	-------------	----------------------------	-------------	--------------	-----	------

TALWIN NX

@ SANOFI AVENTIS US

			EQ 0.5MG BASE;EQ 50MG BASE	N018733 001	Dec 16, 1982	Feb	DISC
--	--	--	----------------------------	-------------	--------------	-----	------

NEFAZODONE HYDROCHLORIDE

TABLET; ORAL

NEFAZODONE HYDROCHLORIDE

@	IVAX SUB TEVA PHARMS	50MG	A075763 001	Sep 16, 2003	Apr	DISC
@		100MG	A075763 002	Sep 16, 2003	Apr	DISC
@		150MG	A075763 003	Sep 16, 2003	Apr	DISC
@		200MG	A075763 004	Sep 16, 2003	Apr	DISC
@		250MG	A075763 005	Sep 16, 2003	Apr	DISC

NEOMYCIN SULFATE

TABLET; ORAL

NEOMYCIN SULFATE

AA	OMAN PHARM PRODUCTS	500MG	A065468 001	Mar 29, 2010	Mar	NEWA
----	---------------------	-------	-------------	--------------	-----	------

NICARDIPINE HYDROCHLORIDE

INJECTABLE; INJECTION

NICARDIPINE HYDROCHLORIDE

AP	BIONICHE PHARMA USA	25MG/10ML (2.5MG/ML)	A090664 001	Nov 17, 2009	Mar	CAHN
----	---------------------	----------------------	-------------	--------------	-----	------

NIFEDIPINE

CAPSULE; ORAL

NIFEDIPINE

AB	INTERGEL PHARM	10MG	A072781 001	Jul 30, 1993	Mar	CAHN
----	----------------	------	-------------	--------------	-----	------

NISOLDIPINE

TABLET, EXTENDED RELEASE; ORAL

SULAR

+	SHIONOGI PHARMA	8.5MG	N020356 008	Jan 02, 2008	Jan	CAHN
@		10MG	N020356 001	Feb 02, 1995	Jan	CAHN
+		17MG	N020356 007	Jan 02, 2008	Jan	CAHN
@		20MG	N020356 002	Feb 02, 1995	Jan	CAHN
		25.5MG	N020356 006	Jan 02, 2008	Jan	CAHN
@		30MG	N020356 003	Feb 02, 1995	Jan	CAHN
+		34MG	N020356 005	Jan 02, 2008	Jan	CAHN
@		40MG	N020356 004	Feb 02, 1995	Jan	CAHN

NITROFURANTOIN

SUSPENSION; ORAL

FURADANTIN

+	SHIONOGI PHARMA	25MG/5ML	N009175 001		Jan	CAHN
---	-----------------	----------	-------------	--	-----	------

NITROGLYCERIN

AEROSOL; SUBLINGUAL

NITROLINGUAL

@	POHL BOSKAMP	0.4MG/SPRAY	N018705 001	Oct 31, 1985	Mar	CAHN
@	SHIONOGI PHARMA	0.4MG/SPRAY	N018705 001	Oct 31, 1985	Jan	CAHN

SPRAY, METERED; SUBLINGUAL

NITROLINGUAL PUMPSPRAY

+	POHL BOSKAMP	0.4MG/SPRAY	N018705 002	Jan 10, 1997	Mar	CAHN
+	SHIONOGI PHARMA	0.4MG/SPRAY	N018705 002	Jan 10, 1997	Jan	CAHN

NORETHINDRONE

TABLET; ORAL-28

HEATHER

AB1	GLENMARK GENERICS	0.35MG	A090454 001	Apr 23, 2010	Apr	NEWA
-----	-------------------	--------	-------------	--------------	-----	------

OFLOXACIN

TABLET; ORAL

OFLOXACIN

@	LARKEN LABS	200MG	A076093 001	Sep 02, 2003	Jan	CAHN
@		300MG	A076093 002	Sep 02, 2003	Jan	CAHN
@		400MG	A076093 003	Sep 02, 2003	Jan	CAHN

OMEPRAZOLE; SODIUM BICARBONATE

CAPSULE; ORAL

>A>		OMEPRAZOLE AND SODIUM BICARBONATE				
>A>	AB	PAR PHARM	20MG;1.1GM	A078966 001	May 25, 2010	May NEWA
>A>	AB		40MG;1.1GM	A078966 002	May 25, 2010	May NEWA
		ZEGERID				
>D>		SANTARUS	20MG;1.1GM	N021849 001	Feb 27, 2006	May CFTG
>A>	AB		20MG;1.1GM	N021849 001	Feb 27, 2006	May CFTG
>D>		+	40MG;1.1GM	N021849 002	Feb 27, 2006	May CFTG
>A>	AB	+	40MG;1.1GM	N021849 002	Feb 27, 2006	May CFTG

ONDANSETRON

TABLET, ORALLY DISINTEGRATING; ORAL

ONDANSETRON

AB	AUROBINDO PHARMA	4MG	A090469 001	Apr 12, 2010	Mar	NEWA
AB		8MG	A090469 002	Apr 12, 2010	Mar	NEWA

ONDANSETRON HYDROCHLORIDE

INJECTABLE; INJECTION

ONDANSETRON HYDROCHLORIDE

AP	EMCURE PHARMS	EQ 2MG BASE/ML	A090424 001	Apr 16, 2010	Apr	NEWA
AP	LANNETT	EQ 2MG BASE/ML	A090116 001	Apr 14, 2010	Mar	NEWA

ORPHENADRINE CITRATE

TABLET, EXTENDED RELEASE; ORAL

ORPHENADRINE CITRATE

AB	GAVIS PHARMS	100MG	A040284 001	Jun 19, 1998	Feb	CAHN
----	--------------	-------	-------------	--------------	-----	------

OXALIPLATIN

INJECTABLE; INJECTION

OXALIPLATIN

AP	+	HOSPIRA INC	50MG/VIAL	A078815 001	Sep 30, 2009	Jan CRLD
AP	+		100MG/VIAL	A078815 002	Sep 30, 2009	Jan CRLD

INJECTABLE; IV (INFUSION)

OXALIPLATIN

>A>	AP	APP PHARMS	50MG/VIAL	A078819 001	Jun 02, 2010	May NEWA
>A>	AP		100MG/VIAL	A078819 002	Jun 02, 2010	May NEWA
>A>	AP	FRESENIUS KABI ONCOL	50MG/10ML (5MG/ML)	A078811 001	Jun 10, 2010	May NEWA
>A>	AP		100MG/20ML (5MG/ML)	A078811 002	Jun 10, 2010	May NEWA
	AP	+	HOSPIRA INC	A078815 001	Sep 30, 2009	Apr CDFR
	AP	+		A078815 002	Sep 30, 2009	Apr CDFR

OXCARBAZEPINE

TABLET; ORAL

OXCARBAZEPINE

AB	CADISTA PHARMS	150MG	A090239 001	Jan 25, 2010	Jan	NEWA
AB		300MG	A090239 002	Jan 25, 2010	Jan	NEWA
AB		600MG	A090239 003	Jan 25, 2010	Jan	NEWA

OXYCODONE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

OXYCODONE HYDROCHLORIDE

@ MALLINCKRODT	10MG	A077822 001	Jul 24, 2008	Apr	DISC
@	20MG	A077822 002	Jul 24, 2008	Apr	DISC
@	40MG	A077822 003	Jul 24, 2008	Apr	DISC
@	80MG	A077822 004	Jul 24, 2008	Apr	DISC

OXYCONTIN

>A>	PURDUE PHARMA INC	10MG	N022272 001	Apr 05, 2010	May	NEWA
>A>		15MG	N022272 002	Apr 05, 2010	May	NEWA
>A>		20MG	N022272 003	Apr 05, 2010	May	NEWA
>A>		30MG	N022272 004	Apr 05, 2010	May	NEWA
>A>		40MG	N022272 005	Apr 05, 2010	May	NEWA
>A>		60MG	N022272 006	Apr 05, 2010	May	NEWA
>A>		80MG	N022272 007	Apr 05, 2010	May	NEWA
	PURDUE PHARMA LP	10MG	N020553 001	Dec 12, 1995	Apr	CTEC
		20MG	N020553 002	Dec 12, 1995	Apr	CTEC
	+	40MG	N020553 003	Dec 12, 1995	Apr	CTEC
		80MG	N020553 004	Jan 06, 1997	Apr	CTEC

OXYMORPHONE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

OPANA ER

>D>	ENDO PHARMS	5MG	N021610 001	Jun 22, 2006	May	CFTG
>A>	AB	5MG	N021610 001	Jun 22, 2006	May	CFTG
>D>		10MG	N021610 002	Jun 22, 2006	May	CFTG
>A>	AB	10MG	N021610 002	Jun 22, 2006	May	CFTG
>D>		20MG	N021610 003	Jun 22, 2006	May	CFTG
>A>	AB	20MG	N021610 003	Jun 22, 2006	May	CFTG
>D>	+	40MG	N021610 004	Jun 22, 2006	May	CFTG
>A>	AB	40MG	N021610 004	Jun 22, 2006	May	CFTG

OXYMORPHONE HYDROCHLORIDE

>A>	AB	IMPAX LABS	5MG	A079087 001	Jun 14, 2010	May	NEWA
>A>	AB		10MG	A079087 003	Jun 14, 2010	May	NEWA
>A>	AB		20MG	A079087 005	Jun 14, 2010	May	NEWA
>A>	AB		40MG	A079087 007	Jun 14, 2010	May	NEWA

PACLITAXEL

INJECTABLE; INJECTION

PACLITAXEL

@ PLIVA LACHEMA	6MG/ML	A077413 001	Mar 12, 2008	Apr	DISC
-----------------	--------	-------------	--------------	-----	------

PALIPERIDONE PALMITATE

SUSPENSION, EXTENDED RELEASE; INTRAMUSCULAR

INVEGA SUSTENNA

+	JOHNSON AND JOHNSON	234MG/1.5ML (156MG/ML)	N022264 005	Jul 31, 2009	Jan	CRLD
---	---------------------	------------------------	-------------	--------------	-----	------

PAMIDRONATE DISODIUM

INJECTABLE; INJECTION

PAMIDRONATE DISODIUM

AP	MN PHARMS	30MG/VIAL	A078300 001	Mar 10, 2009	Feb	CAHN
AP		90MG/VIAL	A078300 002	Mar 10, 2009	Feb	CAHN

PANCRELIPASE (AMYLASE;LIPASE;PROTEASE)

CAPSULE, DELAYED RELEASE; ORAL

CREON

	ABBOTT PRODS	30,000USP UNITS;6,000USP UNITS;19,000USP UNITS	N020725 001	Apr 30, 2009	Mar	CAHN
		60,000USP UNITS;12,000USP UNITS;38,000USP UNITS	N020725 002	Apr 30, 2009	Mar	CAHN
+		120,000USP UNITS;24,000USP UNITS;76,000USP UNITS	N020725 003	Apr 30, 2009	Mar	CAHN

PANCREAZE

	ORTHO MCNEIL JANSSEN	17,500USP/ UNITS;4,200USP/ UNITS;10,000USP/ UNITS	N022523 001	Apr 12, 2010	Apr	NEWA
		43,750USP/ UNITS;10,500USP/ UNITS;25,000USP/ UNITS	N022523 002	Apr 12, 2010	Apr	NEWA
		70,000USP/ UNITS;16,800USP/ UNITS;40,000USP/ UNITS	N022523 004	Apr 12, 2010	Apr	NEWA
+		61,000USP/ UNITS;21,000USP/ UNITS;37,000USP/ UNITS	N022523 003	Apr 12, 2010	Apr	NEWA

PEGADEMASE BOVINE

INJECTABLE; INJECTION

ADAGEN

+	SIGMA TAU	250 UNITS/ML	N019818 001	Mar 21, 1990	Feb	CAHN
---	-----------	--------------	-------------	--------------	-----	------

PERINDOPRIL ERBUMINE

TABLET; ORAL

ACEON

>A>	AB	ABBOTT PRODS	2MG	N020184 001	Dec 30, 1993	May	CAHN
>A>	AB		4MG	N020184 002	Dec 30, 1993	May	CAHN
>A>	AB	+	8MG	N020184 003	Dec 30, 1993	May	CAHN
>D>	AB	SOLVAY PHARMS	2MG	N020184 001	Dec 30, 1993	May	CAHN
>D>	AB		4MG	N020184 002	Dec 30, 1993	May	CAHN
>D>	AB	+	8MG	N020184 003	Dec 30, 1993	May	CAHN

PERINDOPRIL ERBUMINE

	AB	LUPIN LTD	2MG	A078263 001	Jan 27, 2010	Jan	NEWA
	AB		4MG	A078263 002	Jan 27, 2010	Jan	NEWA
	AB		8MG	A078263 003	Jan 27, 2010	Jan	NEWA

PHENDIMETRAZINE TARTRATE

CAPSULE, EXTENDED RELEASE; ORAL

BONTRIL

BC	VALEANT	105MG	A088021 001	Sep 21, 1982	Feb	CAHN
----	---------	-------	-------------	--------------	-----	------

PHENTERMINE HYDROCHLORIDE

CAPSULE; ORAL

PHENTERMINE HYDROCHLORIDE

AA	BARR	15MG	A090591 001	Mar 18, 2010	Mar	NEWA
AA		30MG	A090591 002	Mar 18, 2010	Mar	NEWA

POLIDOCANOL

SOLUTION; INTRAVENOUS

ASCLERA

	CHEMISCH FBRK KRSSLR	10MG/2ML (5MG/ML)	N021201 001	Mar 30, 2010	Mar	NEWA
+		20MG/2ML (10MG/ML)	N021201 002	Mar 30, 2010	Mar	NEWA

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

FOR SOLUTION; ORAL

LAX-LYTE WITH FLAVOR PACKS

AA	PADDOCK	420GM/BOT;1.48GM/BOT;5.72GM/BOT;1 1.2GM/BOT	A079232 001	Feb 25, 2010	Feb	NEWA
----	---------	--	-------------	--------------	-----	------

PEG-3350;POTASSIUM CHLORIDE;SODIUM BICARBONATE;SODIUM CHLORIDE

AA	MYLAN	420GM/BOT;1.48GM/BOT;5.72GM/BOT;1 1.2GM/BOT	A090409 001	Apr 02, 2010	Mar	NEWA
----	-------	--	-------------	--------------	-----	------

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE

FOR SOLUTION; ORAL

CLENZ-LYTE

>A>	AA	PADDOCK LABS	236GM/BOT;2.97GM/BOT;6.74GM/BOT;5 .86GM/BOT;22.74GM/BOT	A090769 001	Jun 07, 2010	May	NEWA
-----	----	--------------	--	-------------	--------------	-----	------

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE ANHYDROUS

FOR SOLUTION; ORAL

PEG 3350 AND ELECTROLYTES

AA	MYLAN	236GM;2.97GM;6.74GM;5.86GM;22.74G M	A090928 001	Jan 28, 2010	Jan	NEWA
----	-------	--	-------------	--------------	-----	------

POLYETHYLENE GLYCOL 3350 AND ELECTROLYTES

AA	PADDOCK LABS	240GM/BOT;2.98GM/BOT;6.72GM/BOT;5 .84GM/BOT;22.72GM/BOT	A090712 001	Feb 25, 2010	Feb	NEWA
----	--------------	--	-------------	--------------	-----	------

POTASSIUM CHLORIDE

TABLET, EXTENDED RELEASE; ORAL

KLOR-CON

BC	+	UPSHER SMITH	8MEQ	N019123 001	Apr 17, 1986	Apr	CTEC
----	---	--------------	------	-------------	--------------	-----	------

POTASSIUM CITRATE

TABLET, EXTENDED RELEASE; ORAL

UROCIT-K

		MISSION PHARMA	15MEQ	N019071 003	Dec 30, 2009	Feb	NEWA
--	--	----------------	-------	-------------	--------------	-----	------

PRAMIPEXOLE DIHYDROCHLORIDE

TABLET; ORAL

MIRAPEX

AB		BOEHRINGER INGELHEIM	0.75MG	N020667 007	Jul 30, 2007	Mar	CFTG
----	--	----------------------	--------	-------------	--------------	-----	------

PRAMIPEXOLE DIHYDROCHLORIDE

AB		MYLAN	0.75MG	A090764 001	Apr 09, 2010	Mar	NEWA
----	--	-------	--------	-------------	--------------	-----	------

TABLET, EXTENDED RELEASE; ORAL

MIRAPEX ER

		BOEHRINGER INGELHEIM	0.375MG	N022421 001	Feb 19, 2010	Feb	NEWA
--	--	----------------------	---------	-------------	--------------	-----	------

			0.75MG	N022421 002	Feb 19, 2010	Feb	NEWA
--	--	--	--------	-------------	--------------	-----	------

			1.5MG	N022421 003	Feb 19, 2010	Feb	NEWA
--	--	--	-------	-------------	--------------	-----	------

			3MG	N022421 004	Feb 19, 2010	Feb	NEWA
--	--	--	-----	-------------	--------------	-----	------

	+		4.5MG	N022421 005	Feb 19, 2010	Feb	NEWA
--	---	--	-------	-------------	--------------	-----	------

PRAVASTATIN SODIUM

TABLET; ORAL

PRAVASTATIN SODIUM

>A>	AB	MATRIX LABS LTD	10MG	A079187 001	May 27, 2010	May	NEWA
-----	----	-----------------	------	-------------	--------------	-----	------

>A>	AB		20MG	A079187 002	May 27, 2010	May	NEWA
-----	----	--	------	-------------	--------------	-----	------

>A>	AB		40MG	A079187 003	May 27, 2010	May	NEWA
-----	----	--	------	-------------	--------------	-----	------

>A>	AB		80MG	A079187 004	May 27, 2010	May	NEWA
-----	----	--	------	-------------	--------------	-----	------

PRAZOSIN HYDROCHLORIDE

CAPSULE; ORAL

PRAZOSIN HYDROCHLORIDE

@ WATSON LABS EQ 1MG BASE A072352 001 May 16, 1989 Jan DISC

@ EQ 2MG BASE A072333 001 May 16, 1989 Jan DISC

PREDNISOLONE

SYRUP; ORAL

PREDNISOLONE

@ IVAX SUB TEVA PHARMS 15MG/5ML A040287 001 May 28, 1999 Apr DISC

PREDNISONE

TABLET; ORAL

PREDNISONE

AB CONTRACT PHARMACAL 5MG A080209 001 Jan CAHN

PREGABALIN

SOLUTION; ORAL

LYRICA

+ PFIZER 20MG/ML N022488 001 Jan 04, 2010 Jan NEWA

PROCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

PROCAINE HYDROCHLORIDE

@ WATSON LABS 1% A080658 001 Jan DISC

PROCHLORPERAZINE MALEATE

TABLET; ORAL

PROCHLORPERAZINE MALEATE

@ DURAMED PHARMS BARR EQ 5MG BASE A040207 001 May 01, 1997 Jan DISC

@ EQ 10MG BASE A040207 002 May 01, 1997 Jan DISC

PROCOMP

AB CADISTA PHARMS EQ 5MG BASE A040268 001 Feb 27, 1998 Jan CTNA

AB EQ 10MG BASE A040268 002 Feb 27, 1998 Jan CTNA

PROPOXYPHENE HYDROCHLORIDE

CAPSULE; ORAL

PROPOXYPHENE HYDROCHLORIDE

@ PAR PHARM 65MG A080269 001 Jan DISC

PROPRANOLOL HYDROCHLORIDE

TABLET; ORAL

PROPRANOLOL HYDROCHLORIDE

>D> @ AMNEAL PHARMS NY 10MG A071368 001 May 05, 1987 May CAHN

>D> @ 20MG A071369 001 May 05, 1987 May CAHN

>D> @ 40MG A071370 001 May 05, 1987 May CAHN

>D> @ 80MG A071371 001 May 05, 1987 May CAHN

>A> @ INTERPHARM 10MG A071368 001 May 05, 1987 May CAHN

>A> @ 20MG A071369 001 May 05, 1987 May CAHN

>A> @ 40MG A071370 001 May 05, 1987 May CAHN

>A> @ 80MG A071371 001 May 05, 1987 May CAHN

PROTRIPTYLINE HYDROCHLORIDE

TABLET; ORAL

PROTRIPTYLINE HYDROCHLORIDE

AB	SIGMAPHARM LABS LLC	5MG	A090462 001	May 03, 2010	Apr	NEWA
AB		10MG	A090462 002	May 03, 2010	Apr	NEWA

QUINIDINE SULFATE

TABLET; ORAL

QUINIDINE SULFATE

@	CONTRACT PHARMACAL	200MG	A083808 001		Jan	CAHN
---	--------------------	-------	-------------	--	-----	------

RIFAXIMIN

TABLET; ORAL

XIFAXAN

	SALIX PHARMS	550MG	N021361 002	Mar 24, 2010	Mar	NEWA
--	--------------	-------	-------------	--------------	-----	------

RISPERIDONE

INJECTABLE; INTRAMUSCULAR

RISPERDAL CONSTA

+	ORTHO MCNEIL JANSSEN	25MG/VIAL	N021346 001	Oct 29, 2003	Jan	CRLD
		50MG/VIAL	N021346 003	Oct 29, 2003	Jan	CRLD

TABLET; ORAL

RISPERIDONE

@	SYNTHON PHARMS	0.25MG	A078187 001	Oct 22, 2009	Feb	DISC
@		0.5MG	A078187 002	Oct 22, 2009	Feb	DISC
@		1MG	A078187 003	Oct 22, 2009	Feb	DISC
@		2MG	A078187 004	Oct 22, 2009	Feb	DISC
@		3MG	A078187 005	Oct 22, 2009	Feb	DISC
@		4MG	A078187 006	Oct 22, 2009	Feb	DISC

TABLET, ORALLY DISINTEGRATING; ORAL

RISPERIDONE

>A>	AB	RATIOPHARM	0.25MG	A077784 001	Jun 08, 2010	May	NEWA
>A>	AB		0.5MG	A077784 002	Jun 08, 2010	May	NEWA
>A>	AB		1MG	A077784 003	Jun 08, 2010	May	NEWA
>A>	AB		2MG	A077784 004	Jun 08, 2010	May	NEWA
>A>	AB		3MG	A077784 005	Jun 08, 2010	May	NEWA
>A>	AB		4MG	A077784 006	Jun 08, 2010	May	NEWA

RITONAVIR

TABLET; ORAL

NORVIR

>A>	+	ABBOTT LABS	100MG	N022417 001	Feb 10, 2010	May	CTNA
>D>		RITONAVIR					
>D>	+	ABBOTT LABS	100MG	N022417 001	Feb 10, 2010	May	CTNA
	+		100MG	N022417 001	Feb 10, 2010	Feb	NEWA

RIVASTIGMINE TARTRATE

CAPSULE; ORAL

EXELON

AB	NOVARTIS	EQ 6MG BASE	N020823 006	Apr 21, 2000	Feb	CRLD
----	----------	-------------	-------------	--------------	-----	------

ROCURONIUM BROMIDE

INJECTABLE; INJECTION

ROCURONIUM BROMIDE

AP	BIONICHE PHARMA USA	50MG/5ML (10MG/ML)	A079199 001	Nov 26, 2008	Mar	CAHN
----	---------------------	--------------------	-------------	--------------	-----	------

INJECTABLE; INJECTION

ROCURONIUM BROMIDE

AP	BIONICHE PHARMA USA	100MG/10ML (10MG/ML)	A079199 002	Nov 26, 2008	Mar	CAHN
----	---------------------	----------------------	-------------	--------------	-----	------

ROPINIROLE HYDROCHLORIDE

TABLET; ORAL

ROPINIROLE HYDROCHLORIDE

AB	ALEMBIC LTD	EQ 0.25MG BASE	A090429 001	Mar 24, 2010	Mar	NEWA
AB		EQ 0.5MG BASE	A090429 002	Mar 24, 2010	Mar	NEWA
AB		EQ 1MG BASE	A090429 003	Mar 24, 2010	Mar	NEWA
AB		EQ 2MG BASE	A090429 004	Mar 24, 2010	Mar	NEWA
AB		EQ 3MG BASE	A090429 005	Mar 24, 2010	Mar	NEWA
AB		EQ 4MG BASE	A090429 006	Mar 24, 2010	Mar	NEWA
AB		EQ 5MG BASE	A090429 007	Mar 24, 2010	Mar	NEWA
AB	GLENMARK GENERICS	EQ 0.25MG BASE	A090135 001	Feb 25, 2010	Feb	NEWA
AB		EQ 0.5MG BASE	A090135 002	Feb 25, 2010	Feb	NEWA
AB		EQ 1MG BASE	A090135 003	Feb 25, 2010	Feb	NEWA
AB		EQ 2MG BASE	A090135 004	Feb 25, 2010	Feb	NEWA
AB		EQ 3MG BASE	A090135 005	Feb 25, 2010	Feb	NEWA
AB		EQ 4MG BASE	A090135 006	Feb 25, 2010	Feb	NEWA
AB		EQ 5MG BASE	A090135 007	Feb 25, 2010	Feb	NEWA

SELEGILINE HYDROCHLORIDE

TABLET; ORAL

SELEGILINE HYDROCHLORIDE

AB	MYLAN	5MG	A074866 001	Nov 26, 1997	Mar	CAHN
----	-------	-----	-------------	--------------	-----	------

SERTRALINE HYDROCHLORIDE

TABLET; ORAL

SERTRALINE HYDROCHLORIDE

>D>	AB	SANDOZ	EQ 25MG BASE	A077713 001	Feb 06, 2007	May	DISC
>A>		@	EQ 25MG BASE	A077713 001	Feb 06, 2007	May	DISC
>D>	AB		EQ 50MG BASE	A077713 002	Feb 06, 2007	May	DISC
>A>		@	EQ 50MG BASE	A077713 002	Feb 06, 2007	May	DISC
>D>	AB		EQ 100MG BASE	A077713 003	Feb 06, 2007	May	DISC
>A>		@	EQ 100MG BASE	A077713 003	Feb 06, 2007	May	DISC

SIMVASTATIN

TABLET; ORAL

SIMVASTATIN

>A>	AB	MATRIX LABS LTD	5MG	A090868 001	Jun 08, 2010	May	NEWA
>A>	AB		10MG	A090868 002	Jun 08, 2010	May	NEWA
>A>	AB		20MG	A090868 003	Jun 08, 2010	May	NEWA
>A>	AB		40MG	A090868 004	Jun 08, 2010	May	NEWA
>A>	AB		80MG	A090868 005	Jun 08, 2010	May	NEWA

SODIUM BICARBONATE

INJECTABLE; INJECTION

SODIUM BICARBONATE

+	HOSPIRA	0.9MEQ/ML	A077394 001	Nov 09, 2005	Feb	CRLD
---	---------	-----------	-------------	--------------	-----	------

SOMATROPIN RECOMBINANT

INJECTABLE; INJECTION

NORDITROPIN FLEXPRO

BX	NOVO NORDISK INC	5MG/1.5ML	N021148 008	Mar 01, 2010	Mar	NEWA
BX		10MG/1.5ML	N021148 009	Mar 01, 2010	Mar	NEWA

INJECTABLE; INJECTION
NORDITROPIN FLEXPRO
NOVO NORDISK INC

15MG/1.5ML

N021148 010 Mar 01, 2010 Mar NEWA

STAVUDINE

CAPSULE; ORAL
STAVUDINE

AB	MYLAN	15MG	A079069 001	Dec 29, 2008	Feb	CAHN
AB		20MG	A079069 002	Dec 29, 2008	Feb	CAHN
AB		30MG	A079069 003	Dec 29, 2008	Feb	CAHN
AB		40MG	A079069 004	Dec 29, 2008	Feb	CAHN

SUCRALFATE

TABLET; ORAL
SUCRALFATE

AB	NOSTRUM LABS	1GM	A074415 001	Jun 08, 1998	Mar	CAHN
----	--------------	-----	-------------	--------------	-----	------

SULFAMETHOXAZOLE; TRIMETHOPRIM

SUSPENSION; ORAL

SULFAMETHOXAZOLE AND TRIMETHOPRIM

>A>	AB	AUROBINDO PHARMA	200MG/5ML;40MG/5ML	A091348 001	Jun 08, 2010	May	NEWA	
>D>	AB	HI TECH PHARMA	200MG/5ML;40MG/5ML	A074650 001	Dec 29, 1997	May	CRLD	
>A>	AB	+	200MG/5ML;40MG/5ML	A074650 001	Dec 29, 1997	May	CRLD	
>D>	AB	+	TEVA PHARMS	200MG/5ML;40MG/5ML	A077612 001	Nov 13, 2006	May	DISC
>A>		@	200MG/5ML;40MG/5ML	A077612 001	Nov 13, 2006	May	DISC	

TABLET; ORAL

SULFAMETHOXAZOLE AND TRIMETHOPRIM

>D>		@	AMNEAL PHARMS NY	400MG;80MG	A071299 001	Oct 27, 1987	May	CAHN
>D>		@		800MG;160MG	A071300 001	Oct 27, 1987	May	CAHN
	AB		AUROBINDO PHARMA	400MG;80MG	A090624 001	Feb 16, 2010	Jan	NEWA
	AB			800MG;160MG	A090624 002	Feb 16, 2010	Jan	NEWA
>A>		@	INTERPHARM	400MG;80MG	A071299 001	Oct 27, 1987	May	CAHN
>A>		@		800MG;160MG	A071300 001	Oct 27, 1987	May	CAHN

SULFISOXAZOLE

TABLET; ORAL

SULFISOXAZOLE

@ IVAX SUB TEVA PHARMS 500MG

A080142 001 Apr DISC

SUMATRIPTAN SUCCINATE

INJECTABLE; SUBCUTANEOUS

SUMATRIPTAN SUCCINATE

>A>	AP	SAGENT STRIDES	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A090314 001	Jun 10, 2010	May	NEWA
-----	----	----------------	-------------------------------------	-------------	--------------	-----	------

TACROLIMUS

CAPSULE; ORAL

TACROLIMUS

>A>	AB	DR REDDYS LABS LTD	EQ 0.5MG BASE	A090509 001	May 12, 2010	May	NEWA
>A>	AB		EQ 1MG BASE	A090509 002	May 12, 2010	May	NEWA
>A>	AB		EQ 5MG BASE	A090509 003	May 12, 2010	May	NEWA

TAMSULOSIN HYDROCHLORIDE

CAPSULE; ORAL

FLOMAX

AB	+	BOEHRINGER INGELHEIM	0.4MG	N020579 001	Apr 15, 1997	Feb	CFTG
----	---	----------------------	-------	-------------	--------------	-----	------

CAPSULE; ORALTAMSULOSIN HYDROCHLORIDE

AB	IMPAX LABS	0.4MG	A090377 001	Mar 02, 2010	Feb	NEWA
AB	MYLAN	0.4MG	A090408 001	Apr 27, 2010	Apr	NEWA
AB	SANDOZ	0.4MG	A078015 001	Apr 27, 2010	Apr	NEWA
AB	SYNTHON PHARMS	0.4MG	A078801 001	Apr 27, 2010	Apr	NEWA
AB	TEVA PHARMS	0.4MG	A077630 001	Apr 27, 2010	Apr	NEWA
AB	WOCKHARDT	0.4MG	A078938 001	Apr 27, 2010	Apr	NEWA
AB	ZYDUS PHARMS USA INC	0.4MG	A078225 001	Apr 27, 2010	Apr	NEWA

TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATORSOLUTION; INJECTION, ORALTECHNELITE

+	LANTHEUS MEDCL	0.0083-2.7 CI/GENERATOR	N017771 001		Feb	CRLD
	ULTRA-TECHNEKOW FM					
+	MALLINCKRODT	0.25-3 CI/GENERATOR	N017243 002		Feb	CRLD

TEMAZEPAMCAPSULE; ORALTEMAZEPAM

>A>	AB	MYLAN	7.5MG	A070920 002	May 21, 2010	May	NEWA
-----	----	-------	-------	-------------	--------------	-----	------

TEMOZOLOMIDECAPSULE; ORALTEMODAR

AB	SCHERING	5MG	N021029 001	Aug 11, 1999	Feb	CFTG
AB		20MG	N021029 002	Aug 11, 1999	Feb	CFTG
AB		100MG	N021029 003	Aug 11, 1999	Feb	CFTG
AB		140MG	N021029 005	Oct 19, 2006	Feb	CFTG
AB		180MG	N021029 006	Oct 19, 2006	Feb	CFTG
AB	+	250MG	N021029 004	Aug 11, 1999	Feb	CFTG

TEMOZOLOMIDE

AB	BARR	5MG	A078879 001	Mar 01, 2010	Feb	NEWA
AB		20MG	A078879 002	Mar 01, 2010	Feb	NEWA
AB		100MG	A078879 003	Mar 01, 2010	Feb	NEWA
AB		140MG	A078879 005	Mar 01, 2010	Feb	NEWA
AB		180MG	A078879 006	Mar 01, 2010	Feb	NEWA
AB		250MG	A078879 004	Mar 01, 2010	Feb	NEWA

TERBINAFINE HYDROCHLORIDETABLET; ORALTERBINAFINE HYDROCHLORIDE

>A>	AB	BRECKENRIDGE PHARM	EQ 250MG BASE	A077714 001	Jun 04, 2010	May	NEWA
-----	----	--------------------	---------------	-------------	--------------	-----	------

TERCONAZOLECREAM; VAGINALTERCONAZOLE

BX	+	NYCOMED US	0.8%	N021735 001	Oct 01, 2004	Jan	CAHN
----	---	------------	------	-------------	--------------	-----	------

THEOPHYLLINEELIXIR; ORALELIXOPHYLLIN

+	CARACO	80MG/15ML	A085186 001		Mar	CAHN
---	--------	-----------	-------------	--	-----	------

TABLET, EXTENDED RELEASE; ORALTHEOCHRON

AB	CARACO	100MG	A088320 001	Feb 21, 1985	Mar	CAHN
----	--------	-------	-------------	--------------	-----	------

TABLET, EXTENDED RELEASE; ORAL

THEOCHRON

AB	CARACO	200MG	A088321 001	Feb 21, 1985	Mar	CAHN
AB		300MG	A087400 002	Jan 11, 1983	Mar	CAHN

TINZAPARIN SODIUM

INJECTABLE; INJECTION

INNOHEP

+	LEO PHARMA AS	20,000 IU/ML	N020484 001	Jul 14, 2000	Feb	CAHN
---	---------------	--------------	-------------	--------------	-----	------

TOLAZAMIDE

TABLET; ORAL

TOLAZAMIDE

>D>	@ AMNEAL PHARMS NY	250MG	A071270 001	Sep 23, 1986	May	CAHN
>D>	@	500MG	A071271 001	Sep 23, 1986	May	CAHN
>A>	@ INTERPHARM	250MG	A071270 001	Sep 23, 1986	May	CAHN
>A>	@	500MG	A071271 001	Sep 23, 1986	May	CAHN

TOLMETIN SODIUM

TABLET; ORAL

TOLMETIN SODIUM

@	IVAX SUB TEVA PHARMS	EQ 600MG BASE	A074399 001	Mar 28, 1996	Apr	DISC
---	----------------------	---------------	-------------	--------------	-----	------

TOPIRAMATE

TABLET; ORAL

TOPIRAMATE

@	PLIVA HRVATSKA DOO	25MG	A077905 001	Mar 30, 2009	Jan	DISC
@		50MG	A077905 002	Mar 30, 2009	Jan	DISC
@		100MG	A077905 003	Mar 30, 2009	Jan	DISC
@		200MG	A077905 004	Mar 30, 2009	Jan	DISC

TORSEMIDE

INJECTABLE; INJECTION

TORSEMIDE

AP	+	BEDFORD LABS	20MG/2ML (10MG/ML)	A078007 001	Jun 11, 2008	Apr	CTEC
AP	+		50MG/5ML (10MG/ML)	A078007 002	Jun 11, 2008	Apr	CTEC
AP		PHARMAFORCE	50MG/5ML (10MG/ML)	A090656 002	Apr 21, 2010	Apr	NEWA
AP			20MG/2ML (10MG/ML)	A090656 001	Apr 21, 2010	Apr	NEWA

TRAMADOL HYDROCHLORIDE

>A>	CAPSULE, EXTENDED RELEASE; ORAL						
>A>	TRAMADOL HYDROCHLORIDE						
>A>	+	CIPHER PHARMS INC	100MG	N022370 001	May 07, 2010	May	NEWA
>A>			200MG	N022370 002	May 07, 2010	May	NEWA
>A>			300MG	N022370 003	May 07, 2010	May	NEWA

TABLET; ORAL

TRAMADOL HYDROCHLORIDE

>A>	AB	NORTHSTAR HLTHCARE	50MG	A078935 001	May 26, 2010	May	NEWA
-----	----	--------------------	------	-------------	--------------	-----	------

TABLET, ORALLY DISINTEGRATING; ORAL

TRAMADOL HYDROCHLORIDE

+	VICTORY PHARMA	50MG	N021693 001	May 05, 2005	Mar	CMFD
---	----------------	------	-------------	--------------	-----	------

TRANDOLAPRIL

TABLET; ORAL

TRANDOLAPRIL

AB	EPIC PHARMA	1MG	A078508 003	Jun 18, 2008	Feb	CAHN
----	-------------	-----	-------------	--------------	-----	------

TABLET; ORAL

TRANDOLAPRIL

AB	EPIC PHARMA	2MG	A078508 001	Jun 18, 2008	Feb	CAHN
AB		4MG	A078508 002	Jun 18, 2008	Feb	CAHN

TRANDOLAPRIL; VERAPAMIL HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

TARKA

>D>	ABBOTT	2MG;180MG	N020591 001	Oct 22, 1996	May	CFTG
>A>	AB	2MG;180MG	N020591 001	Oct 22, 1996	May	CFTG
>D>		2MG;240MG	N020591 004	Oct 22, 1996	May	CFTG
>A>	AB	2MG;240MG	N020591 004	Oct 22, 1996	May	CFTG
	AB +	4MG;240MG	N020591 002	Oct 22, 1996	Apr	CFTG

TRANDOLAPRIL AND VERAPAMIL HYDROCHLORIDE

>A>	AB	GLENMARK GENERICS	2MG;180MG	A079135 001	May 26, 2010	May	NEWA
>A>	AB		2MG;240MG	A079135 002	May 26, 2010	May	NEWA
	AB		4MG;240MG	A079135 003	May 05, 2010	Apr	NEWA

TRANEXAMIC ACID

TABLET; ORAL

LYSTEDA

>A>	+	FERRING PHARMS AS	650MG	N022430 001	Nov 13, 2009	May	CAHN
>D>	+	XANODYNE PHARM	650MG	N022430 001	Nov 13, 2009	May	CAHN

TRAZODONE HYDROCHLORIDE

TABLET; ORAL

TRAZODONE HYDROCHLORIDE

AB	VINTAGE	50MG	A072192 001	Feb 02, 1989	Feb	CAHN
AB		100MG	A072193 001	Feb 02, 1989	Feb	CAHN

TABLET, EXTENDED RELEASE; ORAL

OLEPTRO

	LABOPHARM	150MG	N022411 001	Feb 02, 2010	Feb	NEWA
	+	300MG	N022411 002	Feb 02, 2010	Feb	NEWA

TRETINOIN

CAPSULE; ORAL

TRETINOIN

+	BARR	10MG	A077684 001	Jun 22, 2007	Feb	CRLD
---	------	------	-------------	--------------	-----	------

VESANOID

	@ ROCHE	10MG	N020438 001	Nov 22, 1995	Feb	DISC
--	---------	------	-------------	--------------	-----	------

CREAM; TOPICAL

TRETINOIN

+	TRIAx PHARMS LLC	0.0375%	A090098 001	Mar 22, 2010	Mar	NEWA
---	------------------	---------	-------------	--------------	-----	------

TRIPTORELIN PAMOATE

INJECTABLE; INTRAMUSCULAR

TRELSTAR

+	WATSON LABS	EQ 22.5MG BASE/VIAL	N022437 001	Mar 10, 2010	Mar	NEWA
---	-------------	---------------------	-------------	--------------	-----	------

UNOPROSTONE ISOPROPYL

SOLUTION/DROPS; OPHTHALMIC

RESCULA

	@ SUCAMPO PHARMS	0.15%	N021214 001	Aug 03, 2000	Jan	DISC
--	------------------	-------	-------------	--------------	-----	------

UREA, C-14

CAPSULE; ORAL

PYTEST

+ AVENT 1uCi N020617 001 May 09, 1997 Feb CAHN

PYTEST KIT

+ AVENT 1uCi N020617 002 May 09, 1997 Feb CAHN

URSODIOL

CAPSULE; ORAL

URSODIOL

>A> AB EPIC PHARMA 300MG A075517 001 Mar 14, 2000 May CAHN

>D> AB MIKAH PHARMA 300MG A075517 001 Mar 14, 2000 May CAHN

AB 300MG A075517 001 Mar 14, 2000 Feb CAHN

AB MYLAN 300MG A090530 001 Feb 17, 2010 Jan NEWA

VALACYCLOVIR HYDROCHLORIDE

TABLET; ORAL

VALACYCLOVIR HYDROCHLORIDE

>A> AB AUROBINDO PHARMA EQ 500MG BASE A090682 001 May 24, 2010 May NEWA

>A> AB EQ 1GM BASE A090682 002 May 24, 2010 May NEWA

>A> AB DR REDDYS LABS LTD EQ 500MG BASE A079012 001 May 24, 2010 May NEWA

>A> AB EQ 1GM BASE A079012 002 May 24, 2010 May NEWA

>A> AB MATRIX LABS LTD EQ 500MG BASE A078518 001 May 24, 2010 May NEWA

>A> AB EQ 1GM BASE A078518 002 May 24, 2010 May NEWA

>A> AB MYLAN EQ 500MG BASE A078070 001 May 24, 2010 May NEWA

>A> AB EQ 1GM BASE A078070 002 May 24, 2010 May NEWA

>A> AB ROXANE EQ 500MG BASE A078656 001 May 24, 2010 May NEWA

>A> AB EQ 1GM BASE A078656 002 May 24, 2010 May NEWA

>A> AB SANDOZ EQ 500MG BASE A077478 001 May 24, 2010 May NEWA

>A> AB EQ 1GM BASE A077478 002 May 24, 2010 May NEWA

>A> AB TEVA PHARMS EQ 500MG BASE A077655 001 May 24, 2010 May NEWA

>A> AB EQ 1GM BASE A077655 002 May 24, 2010 May NEWA

>A> AB WATSON LABS EQ 500MG BASE A077135 001 May 24, 2010 May NEWA

>A> AB EQ 1GM BASE A077135 002 May 24, 2010 May NEWA

>A> AB WOCKHARDT EQ 500MG BASE A090216 001 May 24, 2010 May NEWA

>A> AB EQ 1GM BASE A090216 002 May 24, 2010 May NEWA

VALPROATE SODIUM

INJECTABLE; INJECTION

VALPROATE SODIUM

AP HIKMA FARMACEUTICA EQ 100MG BASE/ML A078523 001 Feb 17, 2010 Jan NEWA

VALPROIC ACID

SYRUP; ORAL

VALPROIC ACID

>D> AA APOTEX INC 250MG/5ML A077105 001 Jul 29, 2005 May DISC

>A> @ 250MG/5ML A077105 001 Jul 29, 2005 May DISC

>A> AA SUN PHARM INDS INC 250MG/5ML A090517 001 May 28, 2010 May NEWA

VANCOMYCIN HYDROCHLORIDE

INJECTABLE; INJECTION

VANCOMYCIN HYDROCHLORIDE

AP BIONICHE PHARMA USA EQ 500MG BASE/VIAL A065401 001 Jun 30, 2008 Mar CAHN

AP EQ 1GM BASE/VIAL A065401 002 Jun 30, 2008 Mar CAHN

AP SANDOZ EQ 500MG BASE/VIAL A090250 001 Apr 27, 2010 Apr NEWA

INJECTABLE; INJECTION

VANCOMYCIN HYDROCHLORIDE

AP	SANDOZ	EQ 1GM BASE/VIAL	A090250 002	Apr 27, 2010	Apr	NEWA
----	--------	------------------	-------------	--------------	-----	------

VECURONIUM BROMIDE

INJECTABLE; INJECTION

VECURONIUM BROMIDE

>A>	AP	AKORN STRIDES	10MG/VIAL	A090243 001	May 11, 2010	May	NEWA
>A>	AP		20MG/VIAL	A090243 002	May 11, 2010	May	NEWA
	AP	MUSTAFA NEVZAT	10MG/VIAL	A078274 001	Dec 29, 2008	Mar	CAHN
	AP		20MG/VIAL	A078274 002	Dec 29, 2008	Mar	CAHN

VELAGLUCERASE ALFA

INJECTABLE; IV (INFUSION)

VPRIV

	SHIRE HUMAN GENETIC	400 UNITS/VIAL	N022575 001	Feb 26, 2010	Feb	NEWA
--	---------------------	----------------	-------------	--------------	-----	------

POWDER; IV (INFUSION)

VPRIV

+	SHIRE HUMAN GENETIC	200 UNITS/VIAL	N022575 002	Feb 26, 2010	Feb	NEWA
---	---------------------	----------------	-------------	--------------	-----	------

VENLAFAXINE HYDROCHLORIDE

TABLET; ORAL

VENLAFAXINE HYDROCHLORIDE

AB	AUROBINDO PHARMA	EQ 25MG BASE	A090555 001	Apr 07, 2010	Mar	NEWA
AB		EQ 37.5MG BASE	A090555 002	Apr 07, 2010	Mar	NEWA
AB		EQ 50MG BASE	A090555 003	Apr 07, 2010	Mar	NEWA
AB		EQ 75MG BASE	A090555 004	Apr 07, 2010	Mar	NEWA
AB		EQ 100MG BASE	A090555 005	Apr 07, 2010	Mar	NEWA
AB	INTERPHARM	EQ 25MG BASE	A079098 001	May 11, 2010	Apr	NEWA
AB		EQ 37.5MG BASE	A079098 002	May 11, 2010	Apr	NEWA
AB		EQ 50MG BASE	A079098 003	May 11, 2010	Apr	NEWA
AB		EQ 75MG BASE	A079098 004	May 11, 2010	Apr	NEWA
AB		EQ 100MG BASE	A079098 005	May 11, 2010	Apr	NEWA

VORICONAZOLE

TABLET; ORAL

VFEND

AB	PFIZER	50MG	N021266 001	May 24, 2002	Apr	CFTG
AB	+	200MG	N021266 002	May 24, 2002	Apr	CFTG

VORICONAZOLE

AB	MATRIX LABS LTD	50MG	A090547 001	Apr 22, 2010	Apr	NEWA
AB		200MG	A090547 002	Apr 22, 2010	Apr	NEWA

ZICONOTIDE

INJECTABLE; INTRATHECAL

PRIALT

>A>	+	AZUR PHARMA II	100MCG/1ML (100MCG/ML)	N021060 002	Dec 28, 2004	May	CAHN
>A>		@	200MCG/2ML (100MCG/ML)	N021060 003	Dec 28, 2004	May	CAHN
>A>	+		500MCG/5ML (100MCG/ML)	N021060 004	Dec 28, 2004	May	CAHN
>A>	+		500MCG/20ML (25MCG/ML)	N021060 001	Dec 28, 2004	May	CAHN
>D>	+	ELAN PHARMS	100MCG/1ML (100MCG/ML)	N021060 002	Dec 28, 2004	May	CAHN
>D>		@	200MCG/2ML (100MCG/ML)	N021060 003	Dec 28, 2004	May	CAHN
>D>	+		500MCG/20ML (25MCG/ML)	N021060 001	Dec 28, 2004	May	CAHN
>D>	+		500MCG/5ML (100MCG/ML)	N021060 004	Dec 28, 2004	May	CAHN

ZIDOVUDINE

INJECTABLE; INJECTION

RETROVIR

AP + VIIV HLTHCARE 10MG/ML N019951 001 Feb 02, 1990 Apr CFTG

ZIDOVUDINE

AP PHARMAFORCE 10MG/ML A091457 001 May 06, 2010 Apr NEWA

ZILEUTON

TABLET; ORAL

ZYFLO

>A> @ CORNERSTONE THERAP 300MG N020471 001 Dec 09, 1996 May CAHN

>A> + 600MG N020471 003 Dec 09, 1996 May CAHN

>D> @ CRITICAL 300MG N020471 001 Dec 09, 1996 May CAHN

>D> + 600MG N020471 003 Dec 09, 1996 May CAHN

TABLET, EXTENDED RELEASE; ORAL

ZYFLO CR

>A> + CORNERSTONE THERAP 600MG N022052 001 May 30, 2007 May CAHN

>D> + CRITICAL 600MG N022052 001 May 30, 2007 May CAHN

ZOLPIDEM TARTRATE

TABLET; ORAL

ZOLPIDEM TARTRATE

@ WORLD GEN 5MG A076062 001 Apr 23, 2007 Mar CAHN

@ 10MG A076062 002 Apr 23, 2007 Mar CAHN

OTC DRUG PRODUCT LIST - 30TH EDITION

OTC DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 5 - May 2010

2-1

ACETAMINOPHEN

SUPPOSITORY; RECTAL

ACETAMINOPHEN

>A>	PERRIGO NEW YORK	120MG	A070607 001	Apr 06, 1987	May	CAHN
>A>		650MG	A070608 001	Dec 01, 1986	May	CAHN
>D>	SUPPOSITORIA	120MG	A070607 001	Apr 06, 1987	May	CAHN
>D>		650MG	A070608 001	Dec 01, 1986	May	CAHN

CETIRIZINE HYDROCHLORIDE

SYRUP; ORAL

CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY

	AUROBINDO PHARMA	5MG/5ML	A090750 002	Feb 02, 2010	Jan	NEWA
--	------------------	---------	-------------	--------------	-----	------

CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF

	AUROBINDO PHARMA	5MG/5ML	A090750 001	Feb 02, 2010	Jan	NEWA
--	------------------	---------	-------------	--------------	-----	------

TABLET; ORAL

CETIRIZINE HYDROCHLORIDE ALLERGY

	AMNEAL PHARMS NY	5MG	A078780 001	Jan 21, 2010	Jan	NEWA
--	------------------	-----	-------------	--------------	-----	------

		10MG	A078780 004	Jan 21, 2010	Jan	NEWA
--	--	------	-------------	--------------	-----	------

>A>	CADISTA PHARMS	5MG	A078933 001	Jun 15, 2010	May	NEWA
-----	----------------	-----	-------------	--------------	-----	------

>A>		10MG	A078933 002	Jun 15, 2010	May	NEWA
-----	--	------	-------------	--------------	-----	------

	TORRENT PHARMS LLC	5MG	A079191 001	Apr 15, 2010	Mar	NEWA
--	--------------------	-----	-------------	--------------	-----	------

		10MG	A079191 004	Apr 15, 2010	Mar	NEWA
--	--	------	-------------	--------------	-----	------

CETIRIZINE HYDROCHLORIDE HIVES

>A>	CADISTA PHARMS	5MG	A078933 003	Jun 15, 2010	May	NEWA
-----	----------------	-----	-------------	--------------	-----	------

>A>		10MG	A078933 004	Jun 15, 2010	May	NEWA
-----	--	------	-------------	--------------	-----	------

CETIRIZINE HYDROCHLORIDE HIVES RELIEF

	AMNEAL PHARMS NY	5MG	A078780 003	Jan 21, 2010	Jan	NEWA
--	------------------	-----	-------------	--------------	-----	------

		10MG	A078780 002	Jan 21, 2010	Jan	NEWA
--	--	------	-------------	--------------	-----	------

	TORRENT PHARMS LLC	5MG	A079191 003	Apr 15, 2010	Mar	NEWA
--	--------------------	-----	-------------	--------------	-----	------

		10MG	A079191 002	Apr 15, 2010	Mar	NEWA
--	--	------	-------------	--------------	-----	------

CIMETIDINE

TABLET; ORAL

CIMETIDINE

	CONTRACT PHARMACAL	200MG	A074961 001	Jun 19, 1998	Jan	CAHN
--	--------------------	-------	-------------	--------------	-----	------

		200MG	A074963 001	Jun 19, 1998	Jan	CAHN
--	--	-------	-------------	--------------	-----	------

FAMOTIDINE

TABLET, CHEWABLE; ORAL

FAMOTIDINE

	PERRIGO	10MG	A075715 001	Aug 22, 2003	Apr	CRLD
--	---------	------	-------------	--------------	-----	------

PEPCID AC

+	MERCK	20MG	N020801 002	Dec 17, 2007	Apr	CRLD
---	-------	------	-------------	--------------	-----	------

IBUPROFEN

CAPSULE; ORAL

IBUPROFEN

+	CONTRACT PHARMACAL	200MG	A074782 001	Jul 06, 1998	Jan	CAHN
---	--------------------	-------	-------------	--------------	-----	------

TABLET; ORAL

IBUPROFEN

	CONTRACT PHARMACAL	200MG	A071732 001	Sep 10, 1987	Jan	CAHN
--	--------------------	-------	-------------	--------------	-----	------

		200MG	A071735 001	Sep 10, 1987	Jan	CAHN
--	--	-------	-------------	--------------	-----	------

		200MG	A072299 001	Jul 01, 1988	Jan	CAHN
--	--	-------	-------------	--------------	-----	------

TABLET; ORAL

IBUPROFEN

CONTRACT PHARMACAL 200MG

A073691 001 Feb 25, 1994 Jan CAHN

PROFEN

CONTRACT PHARMACAL 200MG

A071265 001 Oct 15, 1986 Jan CAHN

IBUPROFEN; PHENYLEPHRINE HYDROCHLORIDE

>A>

TABLET; ORAL

>A>

ADVIL CONGESTION RELIEF

>A>

+ WYETH CONS 200MG;10MG

N022565 001 May 27, 2010 May NEWA

IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET; ORAL

IBUPROFEN AND PSEUDOEPHEDRINE HYDROCHLORIDE

CONTRACT PHARMACAL 200MG;30MG

A075588 001 Apr 08, 2002 Jan CAHN

LEVONORGESTREL

TABLET; ORAL

LEVONORGESTREL

+ WATSON LABS 0.75MG

A078665 001 Aug 28, 2009 Apr CRLD

LOPERAMIDE HYDROCHLORIDE

TABLET; ORAL

LOPERAMIDE HYDROCHLORIDE

CONTRACT PHARMACAL 2MG

A073254 001 Jul 30, 1993 Jan CAHN

LORATADINE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE; ORAL

CLARITIN-D

+ SCHERING PLOUGH 5MG;120MG

N019670 002 Nov 27, 2002 Mar CMFD

LORATADINE AND PSEUDOEPHEDRINE SULFATE

IMPAX LABS 5MG;120MG

A076050 001 Jan 30, 2003 Mar CRLD

MICONAZOLE NITRATE

CREAM; SUPPOSITORY; TOPICAL, VAGINAL

>A>

MICONAZOLE NITRATE

>A>

PERRIGO R AND D 2%,1.2GM

A079114 001 Jun 02, 2010 May NEWA

CREAM; VAGINAL

MICONAZOLE NITRATE

PERRIGO R AND D 4%

A091366 001 Jan 15, 2010 Jan NEWA

NAPHAZOLINE HYDROCHLORIDE; PHENIRAMINE MALEATE

SOLUTION/DROPS; OPHTHALMIC

VISINE-A

+ JOHNSON AND JOHNSON 0.025%;0.3%

N020485 001 Jan 31, 1996 Jan CRLD

NONOXYNOL-9

SPONGE; VAGINAL

TODAY

>A>

+ AZTIQ PHARMA 1GM

N018683 001 Apr 01, 1983 May CAHN

>D>

+ PAV NOVA 1GM

N018683 001 Apr 01, 1983 May CAHN

PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL
SUDAFED 24 HOUR

+ MCNEIL CONS 240MG

N020021 002 Dec 15, 1992 Feb CAHN

RANITIDINE HYDROCHLORIDE

TABLET; ORAL

RANITIDINE HYDROCHLORIDE

CONTRACT PHARMACAL EQ 75MG BASE

A075094 001 Jun 21, 1999 Jan CAHN

**DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT
ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST**

CUMULATIVE SUPPLEMENT NUMBER 05 MAY 2010

NO MAY 2010 APPROVALS

ORPHAN PRODUCT DESIGNATIONS AND APPROVALS LIST

The list of List of Orphan Designations and Approvals is available at:

<http://www.fda.gov/orphan/designat/list.htm>

**DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY
ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION**

NO MAY 2010 ADDITIONS

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 5 - May 2010

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ADAPALENE - DIFFERIN</u>						
N022502 001					NDF	Mar 17, 2013
<u>ALENDRONATE SODIUM - FOSAMAX</u>						
N021575 001	5994329	Jul 17, 2018		Y		
	6015801	Jul 17, 2018		Y		
	6225294	Jul 17, 2018		Y		
<u>ALISKIREN HEMIFUMARATE; VALSARTAN - VALTURNA</u>						
N022217 001					NCE	Mar 05, 2012
<u>ALISKIREN HEMIFUMARATE; VALSARTAN - VALTURNA</u>						
N022217 002					NCE	Mar 05, 2012
<u>AMINOLEVULINIC ACID HYDROCHLORIDE - LEVULAN</u>						
N020965 001	>A> 7723910	Jun 17, 2019		U-289	M-82	Mar 12, 2013
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL XR 10</u>						
N021303 001	RE41148	Oct 21, 2018	DP			
	RE41148*PED	Apr 21, 2019				
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL XR 15</u>						
N021303 006	RE41148	Oct 21, 2018	DP			
	RE41148*PED	Apr 21, 2019				
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL XR 20</u>						
N021303 002	RE41148	Oct 21, 2018	DP			
	RE41148*PED	Apr 21, 2019				
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL XR 25</u>						
N021303 004	RE41148	Oct 21, 2018	DP			
	RE41148*PED	Apr 21, 2019				
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL XR 30</u>						
N021303 003	RE41148	Oct 21, 2018	DP			
	RE41148*PED	Apr 21, 2019				
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL XR 5</u>						
N021303 005	RE41148	Oct 21, 2018	DP			
	RE41148*PED	Apr 21, 2019				
<u>ANIDULAFUNGIN - ERAXIS</u>						
N021632 001	>A> 7709444	Apr 12, 2021	DP U-540			
<u>ANIDULAFUNGIN - ERAXIS</u>						
N021632 002	>A> 7709444	Apr 12, 2021	DP U-540			
<u>APREPITANT - EMEND</u>						
N021549 001					M-82	Mar 19, 2013
<u>APREPITANT - EMEND</u>						
N021549 002	>A> 5719147	Apr 17, 2015	DS DP U-853		M-82	Mar 19, 2013
<u>APREPITANT - EMEND</u>						
N021549 003	>A> 5719147	Apr 17, 2015	DS DP U-853		M-82	Mar 19, 2013

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 5 - May 2010

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ASCORBIC ACID; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM ASCORBATE; SODIUM CHLORIDE; SODIUM SULFATE - MOVIPREP</u>						
N021881 001	7658914	Sep 01, 2024	DS DP			
<u>AZTREONAM - CAYSTON</u>						
N050814 001	7208141	Dec 20, 2021	DP U-1031			
	7214364	Dec 20, 2021	DP			
	7427633	Dec 20, 2021	DP U-1031			
<u>BALSALAZIDE DISODIUM - COLAZAL</u>						
N020610 001	7452872	Aug 24, 2026	U-141			
	7452872*PED	Feb 24, 2027				
	7625884	Aug 24, 2026	U-141			
	7625884*PED	Feb 24, 2027				
<u>BEPOTASTINE BESILATE - BEPREVE</u>						
N022288 001	>A> 6780877	Dec 25, 2017	DS DP			
<u>BEXAROTENE - TARGRETIN</u>						
N021055 001	7655699	Apr 22, 2012	DS DP U-509			
<u>BEXAROTENE - TARGRETIN</u>						
N021056 001	7655699	Apr 22, 2012	DS DP U-510			
<u>BIVALIRUDIN - ANGIOMAX</u>						
N020873 001	5196404	May 23, 2010	DS DP U-1040			
	5196404*PED	Nov 23, 2010				
<u>BUDESONIDE - RHINOCORT</u>						
N020746 001	6686346	Apr 29, 2017	DP U-557	Y		
	6686346*PED	Oct 29, 2017				
	6986904	Apr 29, 2017	DP U-699	Y		
	6986904*PED	Oct 29, 2017				
<u>BUDESONIDE - RHINOCORT</u>						
N020746 002	6686346	Apr 29, 2017	DP U-557			
	6686346*PED	Oct 29, 2017				
	6986904	Apr 29, 2017	DP U-699			
	6986904*PED	Oct 29, 2017				
<u>BUPROPION HYDROBROMIDE - APLENZIN</u>						
N022108 001	7645802	Jun 27, 2026	DP			
	7649019	Jun 27, 2026	DP			
	7662407	Jun 27, 2026	DP			
	7671094	Jun 27, 2026	DP			
<u>BUPROPION HYDROBROMIDE - APLENZIN</u>						
N022108 002	7645802	Jun 27, 2026	DP			
	7649019	Jun 27, 2026	DP			
	7662407	Jun 27, 2026	DP			
	7671094	Jun 27, 2026	DP			
<u>BUPROPION HYDROBROMIDE - APLENZIN</u>						
N022108 003	7645802	Jun 27, 2026	DP			
	7649019	Jun 27, 2026	DP			
	7662407	Jun 27, 2026	DP			
	7671094	Jun 27, 2026	DP			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 5 - May 2010

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>CAPSAICIN - QUTENZA</u>						
N022395	001				ODE	Nov 16, 2016
<u>CARGLUMIC ACID - CARBAGLU</u>						
N022562	001				NCE	Mar 18, 2015
<u>CEFTIBUTEN DIHYDRATE - CEDAX</u>						
N050686	001	5599557	Feb 04, 2014	DP U-578		
		5599557	Feb 04, 2014	DP U-282		
<u>CEFTIBUTEN DIHYDRATE - CEDAX</u>						
N050686	002	5599557	Feb 04, 2014	DP U-578		
		5599557	Feb 04, 2014	DP U-282		
<u>CIPROFLOXACIN; CIPROFLOXACIN HYDROCHLORIDE - CIPRO XR</u>						
N021473	001	>A> 7709022	Jun 23, 2021	DP		
		>A> 7709022*PED	Dec 23, 2021			
<u>CIPROFLOXACIN; CIPROFLOXACIN HYDROCHLORIDE - CIPRO XR</u>						
N021473	002	>A> 7709022	Jun 23, 2021	DP		
		>A> 7709022*PED	Dec 23, 2021			
<u>CLINDAMYCIN PHOSPHATE - CLINDAMYCIN PHOSPHATE</u>						
A090785	001				PC	Sep 27, 2010
<u>CLINDAMYCIN PHOSPHATE; TRETINOIN - ZIANA</u>						
N050802	001	RE41134	Feb 24, 2015	DP U-1033		
<u>CLOBETASOL PROPIONATE - CLOBEX</u>						
N021644	001	7700081	Jan 03, 2022	U-1044		
<u>CLOFARABINE - CLOLAR</u>						
N021673	001	5661136	Jan 14, 2018	U-626		
		5661136*PED	Jul 14, 2018			
<u>CLONIDINE HYDROCHLORIDE - JENLOGA</u>						
N022331	001	5869100	Oct 13, 2013	DP		

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 5 - May 2010

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>COLESEVELAM HYDROCHLORIDE - WELCHOL</u>						
N022362 001	5607669	Jun 10, 2014	U-757			
	5607669*PED	Dec 10, 2014				
	5679717	Apr 29, 2014	U-757			
	5679717*PED	Oct 29, 2014				
	5693675	Dec 02, 2014	DS			
	5693675*PED	Jun 02, 2015				
	5917007	Apr 29, 2014	DS U-757			
	5917007*PED	Oct 29, 2014				
	5919832	Apr 29, 2014	DS			
	5919832*PED	Oct 29, 2014				
	6066678	Apr 29, 2014	DS U-757			
	6066678*PED	Oct 29, 2014				
	6433026	Apr 29, 2014	DS			
	6433026*PED	Oct 29, 2014				
	6784254	Apr 29, 2014	DS DP			
	6784254*PED	Oct 29, 2014				
	7101960	Apr 29, 2014	DS DP U-757			
	7101960*PED	Oct 29, 2014				
	7229613	Apr 17, 2022	U-493			
	7229613*PED	Oct 17, 2022				
<u>COLESEVELAM HYDROCHLORIDE - WELCHOL</u>						
N022362 002	5607669	Jun 10, 2014	U-757			
	5607669*PED	Dec 10, 2014				
	5679717	Apr 29, 2014	U-757			
	5679717*PED	Oct 29, 2014				
	5693675	Dec 02, 2014	DS			
	5693675*PED	Jun 02, 2015				
	5917007	Apr 29, 2014	DS U-757			
	5917007*PED	Oct 29, 2014				
	5919832	Apr 29, 2014	DS			
	5919832*PED	Oct 29, 2014				
	6066678	Apr 29, 2014	DS U-757			
	6066678*PED	Oct 29, 2014				
	6433026	Apr 29, 2014	DS			
	6433026*PED	Oct 29, 2014				
	6784254	Apr 29, 2014	DS DP			
	6784254*PED	Oct 29, 2014				
	7101960	Apr 29, 2014	DS DP U-757			
	7101960*PED	Oct 29, 2014				
	7229613	Apr 17, 2022	U-493			
	7229613*PED	Oct 17, 2022				
<u>DALFAMPRIDINE - AMPYRA</u>						
N022250 001	5370879	Dec 06, 2011	DP		NCE	Jan 22, 2015
	5540938	Jul 30, 2013	U-1030		ODE	Jan 22, 2017
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N021976 001	>A> 6037157	Jun 26, 2016	U-935			
	>A> 6703403	Jun 26, 2016	U-935			
	>A> 7470506	Jun 23, 2019	U-935			
	>A> 7700645	Dec 26, 2026	DS DP			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 5 - May 2010

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N021976 002	>A> 6037157	Jun 26, 2016	U-935			
	>A> 6703403	Jun 26, 2016	U-935			
	>A> 7470506	Jun 23, 2019	U-935			
	>A> 7700645	Dec 26, 2026	DS DP			
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N021976 003	>A> 6037157	Jun 26, 2016	U-935			
	>A> 6703403	Jun 26, 2016	U-935			
	>A> 7470506	Jun 23, 2019	U-935			
	>A> 7700645	Dec 26, 2026	DS DP			
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N021976 004	>A> 6037157	Jun 26, 2016	U-935			
	>A> 6703403	Jun 26, 2016	U-935			
	>A> 7470506	Jun 23, 2019	U-935			
	>A> 7700645	Dec 26, 2026	DS DP			
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N021976 005	>A> 6037157	Jun 26, 2016	U-935			
	>A> 6703403	Jun 26, 2016	U-935			
	>A> 7470506	Jun 23, 2019	U-935			
	>A> 7700645	Dec 26, 2026	DS DP			
<u>DECITABINE - DACOGEN</u>						
N021790 001					D-123	Mar 11, 2013
<u>DICLOFENAC POTASSIUM - CAMBIA</u>						
N022165 001	7482377	May 15, 2017	DS DP U-436		NDF	Jun 17, 2012
<u>DICLOFENAC POTASSIUM - ZIPSOR</u>						
N022202 001	6365180	Jul 15, 2019	DP U-980			
	7662858	Feb 24, 2029	U-1035			
<u>DIENOGEST; ESTRADIOL VALERATE - NATAZIA</u>						
N022252 001					>A> NP	May 06, 2013
<u>DOCETAXEL - TAXOTERE</u>						
N020449 001	4814470	May 14, 2010	DS DP		I-543	Sep 28, 2010
	4814470*PED	Nov 14, 2010			I-542	Sep 28, 2010
	5438072	Nov 22, 2013	DP		>A> M-61	May 13, 2013
	5438072*PED	May 22, 2014			>A> PED	Nov 13, 2013
	5698582	Jul 03, 2012	DP		PED	Mar 28, 2011
	5698582*PED	Jan 03, 2013				
	5714512	Jul 03, 2012	DP			
	5714512*PED	Jan 03, 2013				
	5750561	Jul 03, 2012	DP			
	5750561*PED	Jan 03, 2013				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 5 - May 2010

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DOXEPIN HYDROCHLORIDE - SILENOR</u>						
N022036 001	>A> 5502047	Mar 26, 2013	U-620		NP	Mar 17, 2013
	5585115	Jan 09, 2015	DP			
	>A> 5725884	Jan 09, 2015	DP			
	>A> 5866166	Jan 09, 2015	DP			
	>A> 5948438	Jan 09, 2015	DP			
	>A> 6103219	Jan 09, 2015	DP			
	6211229	Feb 17, 2020	U-620			
	>A> 6217909	Jan 09, 2015	DP			
<u>DOXEPIN HYDROCHLORIDE - SILENOR</u>						
N022036 002	>A> 5502047	Mar 26, 2013	U-620		NP	Mar 17, 2013
	5585115	Jan 09, 2015	DP			
	>A> 5725884	Jan 09, 2015	DP			
	>A> 5866166	Jan 09, 2015	DP			
	>A> 5948438	Jan 09, 2015	DP			
	>A> 6103219	Jan 09, 2015	DP			
	6211229	Feb 17, 2020	U-620			
	>A> 6217909	Jan 09, 2015	DP			
<u>DULOXETINE HYDROCHLORIDE - CYMBALTA</u>						
N021427 003	5023269	Jun 11, 2013	DS DP U-799			
	5023269	Jun 11, 2013	DS DP U-797			
	5023269	Jun 11, 2013	DS DP U-795			
	5508276	Jul 18, 2014	DP			
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N022291 003	6280959	Oct 30, 2018	DS DP U-930		NCE	Nov 20, 2013
	7160870	Dec 08, 2021	DS DP U-930		ODE	Nov 20, 2015
	7332481	May 24, 2021	U-930			
	7452874	May 24, 2021	DS DP			
	7473686	May 24, 2021	DS DP U-930			
	7547719	Mar 04, 2024	DS DP U-930			
<u>EPINEPHRINE - ADRENALIN</u>						
N020800 003	5665071	May 27, 2013	DP			
<u>EPINEPHRINE - ADRENALIN</u>						
N020800 004	5665071	May 27, 2013	DP			
<u>ERLOTINIB HYDROCHLORIDE - TARCEVA</u>						
N021743 001	>A> 6900221	Nov 09, 2020	DS DP U-875		I-624	Apr 16, 2013
	>A> 6900221	Nov 09, 2020	DS DP U-659			
	>A> 6900221	Nov 09, 2020	DS DP U-1046			
	>A> 7087613	Nov 09, 2020	U-659			
	>A> 7087613	Nov 09, 2020	U-1045			
<u>ERLOTINIB HYDROCHLORIDE - TARCEVA</u>						
N021743 002	>A> 6900221	Nov 09, 2020	DS DP U-875		I-624	Apr 16, 2013
	>A> 6900221	Nov 09, 2020	DS DP U-659			
	>A> 6900221	Nov 09, 2020	DS DP U-1046			
	>A> 7087613	Nov 09, 2020	U-659			
	>A> 7087613	Nov 09, 2020	U-1045			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 5 - May 2010

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ERLOTINIB HYDROCHLORIDE - TARCEVA</u>						
N021743 003	>A> 6900221	Nov 09, 2020	DS DP U-875		I-624	Apr 16, 2013
	>A> 6900221	Nov 09, 2020	DS DP U-659			
	>A> 6900221	Nov 09, 2020	DS DP U-1046			
	>A> 7087613	Nov 09, 2020	U-659			
	>A> 7087613	Nov 09, 2020	U-1045			
<u>ESOMEPRAZOLE MAGNESIUM; NAPROXEN - VIMOVO</u>						
N022511 001	>A> 5714504	Feb 03, 2015	DP U-1053		NC	Apr 30, 2013
	>A> 5900424	May 04, 2016	DS U-1053			
	>A> 6369085	May 25, 2018	DS DP U-1053			
	>A> 6875872	May 27, 2014	DS			
	>A> 6926907	Feb 28, 2023	DP U-1052			
	>A> 7411070	May 25, 2018	DS U-1053			
<u>ESOMEPRAZOLE MAGNESIUM; NAPROXEN - VIMOVO</u>						
N022511 002	>A> 5714504	Feb 03, 2015	DP U-1053		NC	Apr 30, 2013
	>A> 5900424	May 04, 2016	DS U-1053			
	>A> 6369085	May 25, 2018	DS DP U-1053			
	>A> 6875872	May 27, 2014	DS			
	>A> 6926907	Feb 28, 2023	DP U-1052			
	>A> 7411070	May 25, 2018	DS U-1053			
<u>ESTRADIOL ACETATE - FEMTRACE</u>						
N021633 001	7572779	Mar 02, 2024	U-904			
<u>ESTRADIOL ACETATE - FEMTRACE</u>						
N021633 002	7572779	Mar 02, 2024	U-904			
<u>ESTRADIOL ACETATE - FEMTRACE</u>						
N021633 003	7572779	Mar 02, 2024	U-904			
<u>ESZOPICLONE - LUNESTA</u>						
N021476 001	>A> 6444673	Feb 14, 2014	DS DP			
<u>ESZOPICLONE - LUNESTA</u>						
N021476 002	>A> 6444673	Feb 14, 2014	DS DP			
<u>ESZOPICLONE - LUNESTA</u>						
N021476 003	>A> 6444673	Feb 14, 2014	DS DP			
<u>ETHINYL ESTRADIOL; LEVONORGESTREL - SEASONIQUE</u>						
N021840 001	7615545	Jun 15, 2023	U-1			
<u>EVEROLIMUS - ZORTRESS</u>						
N021560 001	>A> 5665772	Sep 09, 2014	DS DP U-1049		>A> NP	Apr 20, 2013
	>A> 6004973	Jul 12, 2016	DP U-1049		NCE	Mar 30, 2014
	>A> 6239124	Aug 11, 2017	U-1049			
	>A> 6440990	Sep 24, 2013	DP U-1049			
	>A> 6445518	Jul 29, 2017	U-1049			
<u>EVEROLIMUS - ZORTRESS</u>						
N021560 002	>A> 5665772	Sep 09, 2014	DS DP U-1049		>A> NP	Apr 20, 2013
	>A> 6004973	Jul 12, 2016	DP U-1049		NCE	Mar 30, 2014
	>A> 6239124	Aug 11, 2017	U-1049			
	>A> 6440990	Sep 24, 2013	DP U-1049			
	>A> 6445518	Jul 29, 2017	U-1049			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 5 - May 2010

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EVEROLIMUS - ZORTRESS</u>						
N021560 003	>A> 5665772	Sep 09, 2014	DS DP U-1049		>A> NP	Apr 20, 2013
	>A> 6004973	Jul 12, 2016	DP U-1049		NCE	Mar 30, 2014
	>A> 6239124	Aug 11, 2017	U-1049			
	>A> 6440990	Sep 24, 2013	DP U-1049			
	>A> 6445518	Jul 29, 2017	U-1049			
<u>EZETIMIBE - ZETIA</u>						
N021445 001	7612058	Jan 25, 2022	U-1027			
	7612058*PED	Jul 25, 2022				
<u>FENOFIBRATE - FENOGLIDE</u>						
N022118 001	7658944	Dec 09, 2024	DP			
<u>FENOFIBRATE - FENOGLIDE</u>						
N022118 002	7658944	Dec 09, 2024	DP			
<u>FEXOFENADINE HYDROCHLORIDE - ALLEGRA</u>						
N020872 001	7662835	May 18, 2014	U-139			
	7662835*PED	Nov 18, 2014				
	7666881	May 18, 2014	U-139			
	7666881*PED	Nov 18, 2014				
<u>FEXOFENADINE HYDROCHLORIDE - ALLEGRA</u>						
N020872 002	7662835	May 18, 2014	U-139			
	7662835*PED	Nov 18, 2014				
	7666881	May 18, 2014	U-139			
	7666881*PED	Nov 18, 2014				
<u>FEXOFENADINE HYDROCHLORIDE - ALLEGRA</u>						
N020872 004	7662835	May 18, 2014	U-139			
	7662835*PED	Nov 18, 2014				
	7666881	May 18, 2014	U-139			
	7666881*PED	Nov 18, 2014				
<u>FEXOFENADINE HYDROCHLORIDE - ALLEGRA</u>						
N021909 001	7662835	May 18, 2014	U-139			
	7662835*PED	Nov 18, 2014				
<u>FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE - ALLEGRA D 24 HOUR</u>						
N021704 001	7662835	May 18, 2014	U-139			
	7662835*PED	Nov 18, 2014				
<u>FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE - ALLEGRA-D 12 HOUR</u>						
N020786 001	7662835	May 18, 2014	U-139			
	7662835*PED	Nov 18, 2014				
	7666881	May 18, 2014	U-139			
	7666881*PED	Nov 18, 2014				
<u>GADOBENATE DIMEGLUMINE - MULTIHANCE</u>						
N021357 001					NPP	Mar 17, 2013
<u>GADOBENATE DIMEGLUMINE - MULTIHANCE</u>						
N021357 002					NPP	Mar 17, 2013
<u>GADOBENATE DIMEGLUMINE - MULTIHANCE</u>						
N021357 003					NPP	Mar 17, 2013

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 5 - May 2010

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>GADOBENATE DIMEGLUMINE - MULTIHANCE</u>						
N021357	004				NPP	Mar 17, 2013
<u>GATIFLOXACIN - ZYMAXID</u>						
N022548	001	>A> 5880283	Dec 05, 2015	DS	>A> NP	May 18, 2013
		>A> 5880283*PED	Jun 05, 2016			
		>A> 6333045	Aug 20, 2019	DS DP		
		>A> 6333045*PED	Feb 20, 2020			
<u>GLIMEPIRIDE; PIOGLITAZONE HYDROCHLORIDE - DUETACT</u>						
N021925	001	>A> 7700128	Oct 02, 2026	DP		
<u>GLIMEPIRIDE; PIOGLITAZONE HYDROCHLORIDE - DUETACT</u>						
N021925	002	>A> 7700128	Oct 02, 2026	DP		
<u>HYDROCHLOROTHIAZIDE; LOSARTAN POTASSIUM - HYZAAR</u>						
N020387	001	5608075****	Mar 04, 2009		Y	
		5608075*PED	Sep 04, 2009			
<u>HYDROCHLOROTHIAZIDE; LOSARTAN POTASSIUM - HYZAAR</u>						
N020387	002	5608075****	Mar 04, 2009		Y	
		5608075*PED	Sep 04, 2009			
<u>HYDROCHLOROTHIAZIDE; LOSARTAN POTASSIUM - LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE</u>						
A077157	001				PC	Oct 03, 2010
<u>HYDROCHLOROTHIAZIDE; LOSARTAN POTASSIUM - LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE</u>						
A077157	003				PC	Oct 03, 2010
<u>HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL - BENICAR HCT</u>						
N021532	002	6878703	Nov 19, 2021	U-3	Y	
<u>HYDROMORPHONE HYDROCHLORIDE - EXALGO</u>						
N021217	001	5702725	Jul 07, 2014	DP U-1043	NDF	Mar 01, 2013
		5914131	Jul 07, 2014	DP U-1043		
<u>HYDROMORPHONE HYDROCHLORIDE - EXALGO</u>						
N021217	002	5702725	Jul 07, 2014	DP U-1043	NDF	Mar 01, 2013
		5914131	Jul 07, 2014	DP U-1043		
<u>HYDROMORPHONE HYDROCHLORIDE - EXALGO</u>						
N021217	003	5702725	Jul 07, 2014	DP U-1043	NDF	Mar 01, 2013
		5914131	Jul 07, 2014	DP U-1043		
<u>IBANDRONATE SODIUM - BONIVA</u>						
N021455	002	>A> 7718634	May 06, 2023	U-642		
<u>IMIQUIMOD - ALDARA</u>						
N020723	001	>A> 7696159	Apr 01, 2024	DS	U-1048	
		>A> 7696159	Apr 01, 2024	DS	U-1047	
		>A> 7696159*PED	Oct 01, 2024			
<u>IMIQUIMOD - IMIQUIMOD</u>						
A078548	001				PC	Aug 24, 2010
<u>IMIQUIMOD - ZYCLARA</u>						
N022483	001				NP	Mar 25, 2013

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 5 - May 2010

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>INSULIN ASPART PROTAMINE RECOMBINANT; INSULIN ASPART RECOMBINANT - NOVOLOG MIX 70/30</u>						
N021172 001	>A> 5547930	Sep 28, 2013	DS DP			
	>A> 5834422	Sep 28, 2013	DP U-471			
	>A> 5840680	Sep 28, 2013	DS DP U-471			
<u>INSULIN GLARGINE RECOMBINANT - LANTUS</u>						
N021081 001	>A> 7713930	Jun 13, 2023	DP			
	>A> 7713930*PED	Dec 13, 2023				
<u>INSULIN GLULISINE RECOMBINANT - APIDRA</u>						
N021629 001	7696162	Mar 22, 2022	DP U-471			
<u>INSULIN GLULISINE RECOMBINANT - APIDRA</u>						
N021629 002	7696162	Mar 22, 2022	DP U-471			
<u>INSULIN GLULISINE RECOMBINANT - APIDRA SOLOSTAR</u>						
N021629 003	6221633	Jun 18, 2018	DS DP U-471			
	6960561	Jan 25, 2023	DP U-471			
	7452860	Mar 22, 2022	DP			
	7696162	Mar 22, 2022	DP U-471			
<u>ITRACONAZOLE - ITRACONAZOLE</u>						
N022484 001	>A> 6509038	May 12, 2017	DP U-1054		NP	Apr 29, 2013
	>A> 7081255	May 12, 2017	DP U-1054			
<u>KETOROLAC TROMETHAMINE - SPRIX</u>						
N022382 001	>A> 6333044	Dec 25, 2018	DP U-1057			
	>A> 7476689	Oct 11, 2012	DP U-1056			
<u>LACOSAMIDE - VIMPAT</u>						
N022255 001	>A> 5654301	Aug 05, 2014	DS DP U-914		NCE	Oct 28, 2013
	>A> RE38551	Mar 17, 2017	DS DP U-914			
<u>LAMOTRIGINE - LAMICTAL XR</u>						
N022115 001					I-622 NDF PED	Jan 29, 2013 May 29, 2012 Nov 29, 2012
<u>LAMOTRIGINE - LAMICTAL XR</u>						
N022115 002					I-622 NDF PED	Jan 29, 2013 May 29, 2012 Nov 29, 2012
<u>LAMOTRIGINE - LAMICTAL XR</u>						
N022115 003					I-622 NDF PED	Jan 29, 2013 May 29, 2012 Nov 29, 2012
<u>LAMOTRIGINE - LAMICTAL XR</u>						
N022115 004					I-622 NDF PED	Jan 29, 2013 May 29, 2012 Nov 29, 2012
<u>LAMOTRIGINE - LAMICTAL XR</u>						
N022115 005					I-622 NDF PED	Jan 29, 2013 May 29, 2012 Nov 29, 2012
<u>LAPATINIB DITOSYLATE - TYKERB</u>						
N022059 001	6713485	Sep 29, 2020	DS DP U-800		I-620	Jan 29, 2013

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 5 - May 2010

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LEVETIRACETAM - KEPRA</u>						
N021872 001					I-563 PED	Mar 19, 2010 Sep 19, 2010
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N021924 002	>A> 7723390	Mar 14, 2024	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N021924 003	>A> 7723390	Mar 14, 2024	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N021924 004	>A> 7723390	Mar 14, 2024	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N021924 005	>A> 7723390	Mar 14, 2024	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N021924 006	>A> 7723390	Mar 14, 2024	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N021924 007	>A> 7723390	Mar 14, 2024	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N021924 008	>A> 7723390	Mar 14, 2024	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N021924 009	>A> 7723390	Mar 14, 2024	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N021924 010	>A> 7723390	Mar 14, 2024	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N022121 001	>A> 7723390	Mar 14, 2024	DP			
<u>LIRAGLUTIDE RECOMBINANT - VICTOZA</u>						
N022341 001	6268343	Aug 22, 2017	DS DP U-968		NCE	Jan 25, 2015
	6458924	Aug 22, 2017	DS DP U-968			
	7235627	Aug 22, 2017	DS DP			
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N021977 001	7655630	Feb 24, 2023	DS		M-82	Apr 05, 2013
	7659253	Feb 24, 2023	DS DP U-727			
	7659254	Feb 24, 2023				U-1034
	7662787	Feb 24, 2023	DS			
	7671030	Feb 24, 2023				DP U-727
	7671031	Feb 28, 2023				U-727
	7674774	Mar 18, 2023				DP U-842
	7678770	Mar 25, 2023				U-842
	7678771	Mar 25, 2023				DP U-842
	7687466	Feb 24, 2023				DP
	7687467	Apr 08, 2023				DP U-842
	>A> 7700561	Jun 29, 2023				DP
	>A> 7718619	Feb 24, 2023				DP U-842
	>A> 7723305	Feb 24, 2023				DP U-842

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 5 - May 2010

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N021977 002	7655630	Feb 24, 2023	DS		M-82	Apr 05, 2013
	7659253	Feb 24, 2023	DS DP U-727			
	7659254	Feb 24, 2023	U-1034			
	7662787	Feb 24, 2023	DS			
	7671030	Feb 24, 2023	DP U-727			
	7671031	Feb 28, 2023	U-727			
	7674774	Mar 18, 2023	DP U-842			
	7678770	Mar 25, 2023	U-842			
	7678771	Mar 25, 2023	DP U-842			
	7687466	Feb 24, 2023	DP			
	7687467	Apr 08, 2023	DP U-842			
	>A> 7700561	Jun 29, 2023	DP			
	>A> 7718619	Feb 24, 2023	DP U-842			
	>A> 7723305	Feb 24, 2023	DP U-842			
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N021977 003	7655630	Feb 24, 2023	DS		M-82	Apr 05, 2013
	7659253	Feb 24, 2023	DS DP U-727			
	7659254	Feb 24, 2023	U-1034			
	7662787	Feb 24, 2023	DS			
	7671030	Feb 24, 2023	DP U-727			
	7671031	Feb 28, 2023	U-727			
	7674774	Mar 18, 2023	DP U-842			
	7678770	Mar 25, 2023	U-842			
	7678771	Mar 25, 2023	DP U-842			
	7687466	Feb 24, 2023	DP			
	7687467	Apr 08, 2023	DP U-842			
	>A> 7700561	Jun 29, 2023	DP			
	>A> 7718619	Feb 24, 2023	DP U-842			
	>A> 7723305	Feb 24, 2023	DP U-842			
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N021977 004	7655630	Feb 24, 2023	DS		M-82	Apr 05, 2013
	7659253	Feb 24, 2023	DS DP U-727			
	7659254	Feb 24, 2023	U-1034			
	7662787	Feb 24, 2023	DS			
	7671031	Feb 28, 2023	U-727			
	7678770	Mar 25, 2023	U-842			
	7687466	Feb 24, 2023	DP			
	>A> 7700561	Jun 29, 2023	DP			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 5 - May 2010

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N021977 005	7655630	Feb 24, 2023	DS		M-82	Apr 05, 2013
	7659253	Feb 24, 2023	DS DP U-727			
	7659254	Feb 24, 2023	U-1034			
	7662787	Feb 24, 2023	DS			
	7671030	Feb 24, 2023	DP U-727			
	7671031	Feb 28, 2023	U-727			
	7674774	Mar 18, 2023	DP U-842			
	7678770	Mar 25, 2023	U-842			
	7678771	Mar 25, 2023	DP U-842			
	7687466	Feb 24, 2023	DP			
	7687467	Apr 08, 2023	DP U-842			
	>A> 7700561	Jun 29, 2023	DP			
	>A> 7718619	Feb 24, 2023	DP U-842			
	>A> 7723305	Feb 24, 2023	DP U-842			
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N021977 006	7655630	Feb 24, 2023	DS		M-82	Apr 05, 2013
	7659253	Feb 24, 2023	DS DP U-727			
	7659254	Feb 24, 2023	U-1034			
	7662787	Feb 24, 2023	DS			
	7671030	Feb 24, 2023	DP U-727			
	7671031	Feb 28, 2023	U-727			
	7674774	Mar 18, 2023	DP U-842			
	7678770	Mar 25, 2023	U-842			
	7678771	Mar 25, 2023	DP U-842			
	7687466	Feb 24, 2023	DP			
	7687467	Apr 08, 2023	DP U-842			
	>A> 7700561	Jun 29, 2023	DP			
	>A> 7718619	Feb 24, 2023	DP U-842			
	>A> 7723305	Feb 24, 2023	DP U-842			
<u>LOPINAVIR; RITONAVIR - KALETRA</u>						
N021251 001	>A> 5541206	Jul 30, 2013	DS DP U-895		D-124	Apr 27, 2013
	>A> 5541206	Jul 30, 2013	DS DP U-348			
	>A> 5635523	Jun 03, 2014	U-895			
	>A> 5635523	Jun 03, 2014	U-352			
	>A> 5886036	Nov 19, 2013	DS DP U-895			
	>A> 6037157	Jun 26, 2016	U-895			
	>A> 6037157	Jun 26, 2016	U-346			
	>A> 6703403	Jun 26, 2016	U-895			
	>A> 6703403	Jun 26, 2016	U-257			
	>A> 6911214	Nov 28, 2021	DP U-895			
<u>LOPINAVIR; RITONAVIR - KALETRA</u>						
N021906 001	>A> 5886036	Nov 19, 2013	DS DP U-895		D-124	Apr 27, 2013
<u>LOPINAVIR; RITONAVIR - KALETRA</u>						
N021906 002	>A> 5886036	Nov 19, 2013	DS DP U-895		D-124	Apr 27, 2013
<u>LOSARTAN POTASSIUM - COZAAR</u>						
N020386 001	5608075****	Mar 04, 2009		Y		
	5608075*PED	Sep 04, 2009				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 5 - May 2010

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LOSARTAN POTASSIUM - COZAAR</u>						
N020386 002	5608075****	Mar 04, 2009		Y		
	5608075*PED	Sep 04, 2009				
<u>LOSARTAN POTASSIUM - COZAAR</u>						
N020386 003	5608075****	Mar 04, 2009		Y		
	5608075*PED	Sep 04, 2009				
<u>LOSARTAN POTASSIUM - LOSARTAN POTASSIUM</u>						
A076958 001					PC	Oct 03, 2010
<u>LOSARTAN POTASSIUM - LOSARTAN POTASSIUM</u>						
A076958 002					>A> PC	Oct 03, 2010
<u>LOSARTAN POTASSIUM - LOSARTAN POTASSIUM</u>						
A076958 003					PC	Oct 03, 2010
<u>MARAVIROC - SELZENTRY</u>						
N022128 001					>A> NPP	May 28, 2013
<u>MARAVIROC - SELZENTRY</u>						
N022128 002					>A> NPP	May 28, 2013
<u>MESALAMINE - SFROWASA</u>						
N019618 002	7645801	Jul 24, 2027	DS DP			
<u>METAXALONE - SKELAXIN</u>						
N013217 003	>A> 7714006	Dec 03, 2021		U-1050		
<u>METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - ACTOPLUS MET</u>						
N021842 001	>A> 5965584	Jun 19, 2016	DP	U-1055		
<u>METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - ACTOPLUS MET</u>						
N021842 002	>A> 5965584	Jun 19, 2016	DP	U-1055		
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET</u>						
N022044 001	6890898	Feb 02, 2019		U-803		
	6890898	Feb 02, 2019		U-1038		
	6890898	Feb 02, 2019		U-1036		
	7078381	Feb 02, 2019		U-803		
	7078381	Feb 02, 2019		U-1038		
	7078381	Feb 02, 2019		U-1036		
	7125873	Jul 26, 2022	DP	U-803		
	7125873	Jul 26, 2022	DP	U-1038		
	7125873	Jul 26, 2022	DP	U-1036		
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET</u>						
N022044 002	6890898	Feb 02, 2019		U-803		
	6890898	Feb 02, 2019		U-1038		
	6890898	Feb 02, 2019		U-1036		
	7078381	Feb 02, 2019		U-803		
	7078381	Feb 02, 2019		U-1038		
	7078381	Feb 02, 2019		U-1036		
	7125873	Jul 26, 2022	DP	U-803		
	7125873	Jul 26, 2022	DP	U-1038		
	7125873	Jul 26, 2022	DP	U-1036		
<u>METHYLPHENIDATE HYDROCHLORIDE - METHYLIN</u>						
N021419 001	7691880	Oct 07, 2024	DP			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 5 - May 2010

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>METHYLPHENIDATE HYDROCHLORIDE - METHYLIN</u>						
N021419 002	7691880	Oct 07, 2024	DP			
<u>MICONAZOLE - ORAVIG</u>						
N022404 001	>A> 6916485	Sep 11, 2022	DP U-1051		NDF	Apr 16, 2013
	>A> 7651698	Jan 08, 2026	U-1051			
<u>MOMETASONE FUROATE MONOHYDRATE - NASONEX</u>						
N020762 001					>A> I-626	May 26, 2013
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N022321 001	7682633	Jun 19, 2027	U-443			
	7682634	Jun 19, 2027	DP			
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N022321 002	7682633	Jun 19, 2027	U-443			
	7682634	Jun 19, 2027	DP			
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N022321 003	7682633	Jun 19, 2027	U-443			
	7682634	Jun 19, 2027	DP			
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N022321 004	7682633	Jun 19, 2027	U-443			
	7682634	Jun 19, 2027	DP			
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N022321 005	7682633	Jun 19, 2027	U-443			
	7682634	Jun 19, 2027	DP			
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N022321 006	7682633	Jun 19, 2027	U-443			
	7682634	Jun 19, 2027	DP			
<u>MOXIFLOXACIN HYDROCHLORIDE - VIGAMOX</u>						
N021598 001	7671070	Sep 29, 2019	U-709			
	7671070*PED	Mar 29, 2020				
<u>NICARDIPINE HYDROCHLORIDE - CARDENE IN 0.83% SODIUM CHLORIDE IN PLASTIC CONTAINER</u>						
N019734 004	7659291	Apr 18, 2027	U-1029			
<u>NICARDIPINE HYDROCHLORIDE - CARDENE IN 0.86% SODIUM CHLORIDE IN PLASTIC CONTAINER</u>						
N019734 003	7659291	Apr 18, 2027	U-1029			
<u>NICARDIPINE HYDROCHLORIDE - CARDENE IN 4.8% DEXTROSE IN PLASTIC CONTAINER</u>						
N019734 002	7659291	Apr 18, 2027	U-1029			
<u>NICARDIPINE HYDROCHLORIDE - CARDENE IN 5.0% DEXTROSE IN PLASTIC CONTAINER</u>						
N019734 005	7659291	Apr 18, 2027	U-1029			
<u>OLMESARTAN MEDOXOMIL - BENICAR</u>						
N021286 001					NPP PED	Feb 04, 2013 Aug 04, 2010
<u>OLMESARTAN MEDOXOMIL - BENICAR</u>						
N021286 003					NPP PED	Feb 04, 2013 Aug 04, 2010
<u>OLMESARTAN MEDOXOMIL - BENICAR</u>						
N021286 004					NPP PED	Feb 04, 2013 Aug 04, 2010

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 5 - May 2010

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OSELTAMIVIR PHOSPHATE - TAMIFLU</u>						
N021087	001				M-90	Feb 22, 2013
<u>OSELTAMIVIR PHOSPHATE - TAMIFLU</u>						
N021087	002				M-90	Feb 22, 2013
<u>OSELTAMIVIR PHOSPHATE - TAMIFLU</u>						
N021087	003				M-90	Feb 22, 2010
<u>OSELTAMIVIR PHOSPHATE - TAMIFLU</u>						
N021246	001				M-90	Feb 22, 2013
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N020553	001	7674799	Mar 30, 2025	DS		
		7674800	Mar 30, 2025	DS		
		7683072	Mar 30, 2025	DS		
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N020553	002	7674799	Mar 30, 2025	DS		
		7674800	Mar 30, 2025	DS		
		7683072	Mar 30, 2025	DS		
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N020553	003	7674799	Mar 30, 2025	DS		
		7674800	Mar 30, 2025	DS		
		7683072	Mar 30, 2025	DS		
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N020553	004	7674799	Mar 30, 2025	DS		
		7674800	Mar 30, 2025	DS		
		7683072	Mar 30, 2025	DS		
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N020553	005	>A> 7674799	Mar 30, 2025	DS		
		7674800	Mar 30, 2025	DS		
		7683072	Mar 30, 2025	DS		
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N020553	006	7674799	Mar 30, 2025	DS		
		7674800	Mar 30, 2025	DS		
		7683072	Mar 30, 2025	DS		
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N020553	007	7674799	Mar 30, 2025	DS		
		7674800	Mar 30, 2025	DS		
		7683072	Mar 30, 2025	DS		
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N020553	008	7674799	Mar 30, 2025	DS		
		7674800	Mar 30, 2025	DS		
		7683072	Mar 30, 2025	DS		
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N021610	001	7276250	Feb 04, 2023		DP U-826	
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N021610	002	7276250	Feb 04, 2023		DP U-826	

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 5 - May 2010

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N021610 003	7276250	Feb 04, 2023	DP U-826			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N021610 004	7276250	Feb 04, 2023	DP U-826			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N021610 005	7276250	Feb 04, 2023	DP U-826			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N021610 006	7276250	Feb 04, 2023	DP U-826			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N021610 007	7276250	Feb 04, 2023	DP U-826			
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - CREON</u>						
N020725 001					I-625	Apr 30, 2013
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - CREON</u>						
N020725 002					I-625	Apr 30, 2013
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - CREON</u>						
N020725 003					I-625	Apr 30, 2013
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - PANCREAZE</u>						
N022523 001					NCE	Apr 12, 2015
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - PANCREAZE</u>						
N022523 002					NCE	Apr 12, 2015
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - PANCREAZE</u>						
N022523 003					NCE	Apr 12, 2015
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - PANCREAZE</u>						
N022523 004					NCE	Apr 12, 2015
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ZENPEP</u>						
N022210 001	7658918	Feb 20, 2028	DP			
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ZENPEP</u>						
N022210 002	7658918	Feb 20, 2028	DP			
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ZENPEP</u>						
N022210 003	7658918	Feb 20, 2028	DP			
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ZENPEP</u>						
N022210 004	7658918	Feb 20, 2028	DP			
<u>PANTOPRAZOLE SODIUM - PROTONIX</u>						
N022020 001	7544370	Jun 07, 2026	DP			
	7544370*PED	Dec 07, 2026				
<u>PENCICLOVIR SODIUM - DENAVIR</u>						
N020629 001	5866581	Oct 04, 2014	U-501			
	6124304	Oct 04, 2014	U-501			
<u>POLIDOCANOL - ASCLERA</u>						
N021201 001					NCE	Mar 30, 2015
<u>POLIDOCANOL - ASCLERA</u>						
N021201 002					NCE	Mar 30, 2015

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 5 - May 2010

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX ER</u>						
N022421 001	4886812	Oct 08, 2010	DS DP		I-623	Mar 19, 2013
	7695734	Apr 26, 2028	DP		NDF	Feb 19, 2013
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX ER</u>						
N022421 002	4886812	Oct 08, 2010	DS DP		I-623	Mar 19, 2013
	7695734	Apr 26, 2028	DP		NDF	Feb 19, 2013
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX ER</u>						
N022421 003	4886812	Oct 08, 2010	DS DP		I-623	Mar 19, 2013
	7695734	Apr 26, 2028	DP		NDF	Feb 19, 2013
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX ER</u>						
N022421 004	4886812	Oct 08, 2010	DS DP		I-623	Mar 19, 2013
	7695734	Apr 26, 2028	DP		NDF	Feb 19, 2013
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX ER</u>						
N022421 005	4886812	Oct 08, 2010	DS DP		I-623	Mar 19, 2013
	7695734	Apr 26, 2028	DP		NDF	Feb 19, 2013
<u>PRAMIPEXOLE DIHYDROCHLORIDE - PRAMIPEXOLE DIHYDROCHLORIDE</u>						
A077724 001					PC	Jul 03, 2010
<u>PRAMIPEXOLE DIHYDROCHLORIDE - PRAMIPEXOLE DIHYDROCHLORIDE</u>						
A077724 002					PC	Jul 03, 2010
<u>PRAMIPEXOLE DIHYDROCHLORIDE - PRAMIPEXOLE DIHYDROCHLORIDE</u>						
A077724 003					PC	Jul 03, 2010
<u>PRAMIPEXOLE DIHYDROCHLORIDE - PRAMIPEXOLE DIHYDROCHLORIDE</u>						
A077724 004					PC	Jul 03, 2010
<u>PRAMIPEXOLE DIHYDROCHLORIDE - PRAMIPEXOLE DIHYDROCHLORIDE</u>						
A077724 005					PC	Jul 03, 2010
<u>PREDNISOLONE SODIUM PHOSPHATE - ORAPRED ODT</u>						
N021959 001	>A> 6740341	Nov 24, 2019	DP			
<u>PREDNISOLONE SODIUM PHOSPHATE - ORAPRED ODT</u>						
N021959 002	>A> 6740341	Nov 24, 2019	DP			
<u>PREDNISOLONE SODIUM PHOSPHATE - ORAPRED ODT</u>						
N021959 003	>A> 6740341	Nov 24, 2019	DP			
<u>PREGABALIN - LYRICA</u>						
N022488 001	5563175	Oct 08, 2013		U-661	I-535	Jun 21, 2010
	6001876	Dec 30, 2018		U-819		
	6001876	Dec 30, 2018		U-55		
	6197819	Dec 30, 2018	DS DP			
<u>REGADENOSON - LEXISCAN</u>						
N022161 001	7655636	Jun 22, 2019		U-869		
	7655637	Jun 22, 2019	DS DP	U-869		
	7683037	Jun 22, 2019		U-1042		
<u>RIFAXIMIN - XIFAXAN</u>						
N021361 002	7045620	Jun 19, 2024	DS		NP >A> ODE	Mar 24, 2013 Mar 24, 2017

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 5 - May 2010

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>RISEDRONATE SODIUM - ACTONEL</u>						
N020835 005	>A> 7718634	May 06, 2023	U-662			
	>A> 7718634*PED	Nov 06, 2023				
<u>RITONAVIR - NORVIR</u>						
N022417 001	5541206	Jul 30, 2013	DS DP U-688			
	5541206*PED	Jan 30, 2014				
	5635523	Jun 03, 2014	U-688			
	5635523*PED	Dec 03, 2014				
	5648497	Jul 15, 2014	DS			
	5648497*PED	Jan 15, 2015				
	5674882	Oct 07, 2014	U-688			
	5674882*PED	Apr 07, 2015				
	6037157	Jun 26, 2016	U-688			
	6037157*PED	Dec 26, 2016				
	6703403	Jun 26, 2016	U-688			
	6703403*PED	Dec 26, 2016				
	7148359	Jul 19, 2019	DP			
	7148359*PED	Jan 19, 2020				
	7364752	Nov 10, 2020	DP U-688			
	7364752*PED	May 10, 2021				
<u>ROMIDEPSIN - ISTODAX</u>						
N022393 001					ODE	Nov 05, 2016
<u>ROSUVASTATIN CALCIUM - CRESTOR</u>						
N021366 002	7030152	Apr 02, 2018	U-1032		I-621	Feb 08, 2013
<u>ROSUVASTATIN CALCIUM - CRESTOR</u>						
N021366 003	7030152	Apr 02, 2018	U-1032		I-621	Feb 08, 2013
<u>ROSUVASTATIN CALCIUM - CRESTOR</u>						
N021366 004	7030152	Apr 02, 2018	U-1032		I-621	Feb 08, 2013
<u>ROSUVASTATIN CALCIUM - CRESTOR</u>						
N021366 005	7030152	Apr 02, 2018	U-1032		I-621	Feb 08, 2013
<u>RUFINAMIDE - BANZEL</u>						
N021911 001	>A> 6740669	Aug 17, 2020	DS DP			
<u>RUFINAMIDE - BANZEL</u>						
N021911 002	>A> 6740669	Aug 17, 2020	DS DP			
<u>RUFINAMIDE - BANZEL</u>						
N021911 003	>A> 6740669	Aug 17, 2020	DS DP			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 5 - May 2010

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>SITAGLIPTIN PHOSPHATE - JANUVIA</u>						
N021995 001	6890898	Feb 02, 2019	U-775			
	6890898	Feb 02, 2019	U-1039			
	6890898	Feb 02, 2019	U-1036			
	7078381	Feb 02, 2019	U-775			
	7078381	Feb 02, 2019	U-1038			
	7078381	Feb 02, 2019	U-1037			
	7078381	Feb 02, 2019	U-1036			
	7125873	Jul 26, 2022	U-775			
	7125873	Jul 26, 2022	U-1038			
	7125873	Jul 26, 2022	U-1037			
	7125873	Jul 26, 2022	U-1036			
<u>SITAGLIPTIN PHOSPHATE - JANUVIA</u>						
N021995 002	6890898	Feb 02, 2019	U-775			
	6890898	Feb 02, 2019	U-1039			
	6890898	Feb 02, 2019	U-1036			
	7078381	Feb 02, 2019	U-775			
	7078381	Feb 02, 2019	U-1038			
	7078381	Feb 02, 2019	U-1037			
	7078381	Feb 02, 2019	U-1036			
	7125873	Jul 26, 2022	U-775			
	7125873	Jul 26, 2022	U-1038			
	7125873	Jul 26, 2022	U-1037			
	7125873	Jul 26, 2022	U-1036			
<u>SITAGLIPTIN PHOSPHATE - JANUVIA</u>						
N021995 003	6890898	Feb 02, 2019	U-775			
	6890898	Feb 02, 2019	U-1039			
	6890898	Feb 02, 2019	U-1036			
	7078381	Feb 02, 2019	U-775			
	7078381	Feb 02, 2019	U-1038			
	7078381	Feb 02, 2019	U-1037			
	7078381	Feb 02, 2019	U-1036			
	7125873	Jul 26, 2022	U-775			
	7125873	Jul 26, 2022	U-1038			
	7125873	Jul 26, 2022	U-1037			
	7125873	Jul 26, 2022	U-1036			
<u>SODIUM OXYBATE - XYREM</u>						
N021196 001	7668730	Mar 07, 2024	U-1028			
<u>SODIUM PHOSPHATE, DIBASIC ANHYDROUS; SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE - OSMOPREP</u>						
N021892 001	7687075	Jun 22, 2028	DS DP			
<u>SOMATROPIN RECOMBINANT - NORDITROPIN FLEXPRO</u>						
N021148 008	5849700	Dec 15, 2015	U-1041		I-572	Oct 31, 2011
	5849704	Dec 15, 2015	DP U-1041		I-551	Sep 20, 2010
					I-536	May 31, 2010
					ODE	May 31, 2014
<u>SOMATROPIN RECOMBINANT - NORDITROPIN FLEXPRO</u>						
N021148 009	5849700	Dec 15, 2015	U-1041		I-572	Oct 31, 2011
	5849704	Dec 15, 2015	DP U-1041		I-551	Sep 20, 2010
					I-536	May 31, 2010
					ODE	May 31, 2014

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 5 - May 2010

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SOMATROPIN RECOMBINANT - NORDITROPIN FLEXPRO</u>						
N021148 010	5849700	Dec 15, 2015	U-1041		I-572	Oct 31, 2011
	5849704	Dec 15, 2015	DP U-1041		I-551 I-536 ODE	Sep 20, 2010 May 31, 2010 May 31, 2014
<u>TELAVANCIN HYDROCHLORIDE - VIBATIV</u>						
N022110 001	>A> 7531623	Jan 01, 2027	DS			
	7700550	May 01, 2021	U-282			
<u>TELAVANCIN HYDROCHLORIDE - VIBATIV</u>						
N022110 002	>A> 7531623	Jan 01, 2027	DS			
	7700550	May 01, 2021	U-282			
<u>TEMSIROLIMUS - TORISEL</u>						
N022088 001					M-91	Apr 26, 2013
<u>TENOFOVIR DISOPROXIL FUMARATE - VIREAD</u>						
N021356 001					NPP	Mar 24, 2013
<u>TERBINAFINE - LAMISIL AT</u>						
N021958 001	5681849	Oct 28, 2014	DP			
	5681849*PED	Apr 28, 2015				
	5856355	May 18, 2012	DP U-540			
	5856355	May 18, 2012	DP U-504			
	5856355*PED	Nov 18, 2012				
<u>TIOTROPIUM BROMIDE MONOHYDRATE - SPIRIVA</u>						
N021395 001	7642268	Sep 24, 2021	DS DP			
<u>TOLTERODINE TARTRATE - DETROL</u>						
N020771 001	5559269	Nov 05, 2013	U-318	Y		
	5559269*PED	May 05, 2014				
<u>TOLTERODINE TARTRATE - DETROL</u>						
N020771 002	5559269	Nov 05, 2013	U-318	Y		
	5559269*PED	May 05, 2014				
<u>TRANDOLAPRIL; VERAPAMIL HYDROCHLORIDE - TRANDOLAPRIL AND VERAPAMIL HYDROCHLORIDE</u>						
A079135 001					>A> PC	Dec 05, 2010
<u>TRANDOLAPRIL; VERAPAMIL HYDROCHLORIDE - TRANDOLAPRIL AND VERAPAMIL HYDROCHLORIDE</u>						
A079135 002					>A> PC	Dec 05, 2010
<u>TRANDOLAPRIL; VERAPAMIL HYDROCHLORIDE - TRANDOLAPRIL AND VERAPAMIL HYDROCHLORIDE</u>						
A079135 003					>A> PC	Dec 05, 2010
<u>TRAZODONE HYDROCHLORIDE - OLEPTRO</u>						
N022411 001	6607748	Jun 29, 2020	DP		NDF	Feb 02, 2013
<u>TRAZODONE HYDROCHLORIDE - OLEPTRO</u>						
N022411 002	6607748	Jun 29, 2020	DP		NDF	Feb 02, 2013
<u>TRIPTORELIN PAMOATE - TRELSTAR</u>						
N022437 001	5776885	Jul 07, 2015	DP		NP	Mar 10, 2013
<u>VARDENAFIL HYDROCHLORIDE - LEVITRA</u>						
N021400 001	7696206	Oct 31, 2018	DS DP U-533			
<u>VARDENAFIL HYDROCHLORIDE - LEVITRA</u>						
N021400 002	7696206	Oct 31, 2018	DS DP U-533			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 5 - May 2010

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>VARDENAFIL HYDROCHLORIDE - LEVITRA</u>						
N021400 003	7696206	Oct 31, 2018	DS DP U-533			
<u>VARDENAFIL HYDROCHLORIDE - LEVITRA</u>						
N021400 004	7696206	Oct 31, 2018	DS DP U-533			
<u>VARENICLINE TARTRATE - CHANTIX</u>						
N021928 001	7265119	Aug 03, 2022	DS DP U-56			
<u>VARENICLINE TARTRATE - CHANTIX</u>						
N021928 002	7265119	Aug 03, 2022	DS DP U-56			
<u>VELAGLUCERASE ALFA - VPRIV</u>						
N022575 001					NCE	Feb 26, 2015
<u>VELAGLUCERASE ALFA - VPRIV</u>						
N022575 002					NCE	Feb 26, 2015
<u>VORINOSTAT - ZOLINZA</u>						
N021991 001	7652069	Mar 04, 2023	DS			

Footnote:

1. Patents are published upon receipt by the Orange Book Staff and may not reflect the official receipt date as described in 21 CFR 314.53(d)(5).
2. Patents listed prior to August 18, 2003 are flagged with method of use claims only as applicable and submitted by the sponsor. They may not be flagged with respect to other claims which may apply.
3. **** The expiration date for U.S. Patent No. 5,608,075 is March 4, 2009.

PATENT AND EXCLUSIVITY TERMS

Due to space limitations in the patent and exclusivity columns, abbreviations and references have been developed. Refer to the APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 29th Edition for a full listing of patent and exclusivity terms (Abbreviations, Dosing Schedule, Indications, and Patent Use Codes).

The current complete list of patent terms is available at <http://www.accessdata.fda.gov/scripts/cder/ob/docs/pattermsall.cfm>